Selective Protein Functionalisation at Methionine by Nelson, Jennifer Emily
Selective Protein Functionalisation at 
Methionine 
 
Jennifer E. Nelson 
Murray Edwards College 
University of Cambridge 
 
 
This dissertation is submitted for the degree of Doctor of Philosophy 
 
Department of Chemistry 




















This thesis is submitted in partial fulfilment of the requirements for the degree of Doctor of 
Philosophy. It describes the work carried out in the Department of Chemistry from October 
2015 to March 2019. This dissertation is the result of my own work and includes nothing which 





11th April 2019  
 
Statement of Length 
This dissertation does not exceed the word limit of 60 000 as set by the Degree Committee for 









Firstly, I would like to thank Professor Matthew Gaunt; I feel that I have developed personally 
and achieved so much more than I could have imagined during my PhD and that is due to the 
opportunities and support I have received in this group. I am so grateful to have worked on such 
an interesting project and for the platform this experience has given me for my future career. 
Thank you also to Mike, who I had the privilege of working with during the first two years of 
my PhD. I appreciate your patience and guidance, you taught me so much, and it was a pleasure 
to work together. 
To Patrick W., I doubt that I would have survived my first year were it not for your friendship. 
You have been an important part of my time in Cambridge and I thank you for that. I’d like to 
thank Patrick D., Antonio and Henry for the craic, for bringing so much fun to the lab and for 
always being keen for boffice. Thank you also to the rest of the Gaunt group, I have been so 
lucky to have been able to work with some of my best friends every day, and it has made this 
experience so much more enjoyable.  
To Patrick D. and Patrick W., thank you for your tireless efforts in proof reading this thesis, I 
am extremely grateful. Thank you also to Henry and Antonio for taking the time to proof read 
this work. 
I would like to acknowledge the technical staff, Nic, Naomi and Carlos for their support, the 
NMR service, Duncan, Andrew and Peter, and the mass spectrometry service, Dijana and Asha, 
for their help and advice. Thank you also to AstraZeneca and the EPSRC for their generous 
financial support. I am grateful to Professor Jason Chin, Dr Nicolas Huguenin and Dr Mark 
Skehel (MRC Laboratory of Molecular Biology) for their assistance with FPLC purification 
and Dr Hilary Lewis and Dr Matthew Edgeworth (AstraZeneca/MedImmune) for carrying out 
MS/MS analysis. 
Finally, thank you to my family, and to Henry, for their unwavering love and support, and their 





The development of novel bioconjugation strategies for the functionalisation of polypeptides 
and proteins has been of great benefit to the fields of chemical biology and medicine. Selective 
protein functionalisation has enabled the development of technologies such as targeted drug 
delivery, enzyme activity profiling and imaging of cells in vivo. Many strategies for 
bioconjugation target the nucleophilic side chains of the amino acids cysteine and lysine. 
However, many strategies remain sequence specific and some require pre-installation of 
recognition units to achieve high selectivity. 
Due to the low natural abundance and ancillary protein function of methionine, selective 
functionalisation of this amino acid presents an opportunity to develop a strategy 
complementary to current technologies. Strategies targeting methionine remain under-explored, 
with few truly biocompatible methods reported to date. This thesis describes the development 
of a novel bioconjugation method employing hypervalent iodine reagents for the selective 
functionalisation of methionine residues. The broad scope and excellent biocompatibility of the 
reaction is demonstrated, with a number of different polypeptide and protein substrates 
tolerated. Additionally, through the synthesis of different hypervalent iodine reagents, varying 
the ester group of the iodonium salt (R), a number of different payloads can be transferred to 
polypeptides and proteins. 
 
The highly reactive diazo group which is introduced using this methodology can be exploited 
in subsequent bioorthogonal transformations. Firstly, phosphine reagents can be employed for 
the cleavage of the methionine label, in a stimuli-responsive reversal of the conjugation. 































products which exhibited improved stability. Finally, a C-benzylation has been developed using 
photoredox catalysis to enable functionalisation of this diazo moiety.  
The methionine bioconjugation strategy has also been used in tandem with a literature 
procedure for the functionalisation of tryptophan residues. Through the combination of two 
bioconjugation techniques, a simultaneous dual functionalisation of polypeptides has been 
developed, forming dually- or triply-functionalised scaffolds in a single step from native 
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1.1 Introduction to protein modification 
Methods for the modification of peptides and proteins have proven integral to the advancement 
of chemical biology and medicine. Novel strategies to introduce exogenous functionality in a 
selective fashion have enabled the investigation of biomacromolecules and have provided 
insights into cellular mechanisms.1,2 The resulting functionalised species can exhibit control 
over chemical and biological behaviour, providing a platform for the development of targeted 
therapeutics and cellular imaging agents.3  
The development of selective chemical modification strategies for proteins must overcome 
challenges unique to biological systems, including the abundance of competing, reactive 
functionality capable of unwanted side reactions and the need for aqueous conditions.4 In order 
for reactions to be considered biocompatible they must strive to fulfil several criteria. Namely, 
they should proceed with almost perfect conversion, yielding homogeneous, stable products 
under biologically ambient conditions (aqueous solvent, pH 6-8, < 37 °C).4,5,6 Additionally, it 
is important that reactions should not perturb the protein architecture so as to preserve the 
integrity of the biomolecule’s structure and function.7 For reactions carried out in vivo, it is 
desirable for the kinetics to be comparable to that of an enzymatic timescale (k = 104 – 105 M-
1s-1)8 to ensure that the reactions can occur at low concentrations and can compete with, or be 
used to investigate, cellular processes. Many existing methodologies for the synthetic 
modification of small molecules prove incompatible with polypeptide and protein systems. 
Therefore, the development of new, biocompatible reactions are required. 
Despite the stringent demands of biological systems, a large number of reactions that meet 
many or all of these criteria have been developed.2 The native chemical functionality of peptides 
and proteins can be targeted using a set of techniques termed ‘bioconjugation’ (Scheme 1). 
These approaches typically exploit the reactivity of the side-chains of canonical, proteinogenic 





Scheme 1 Bioconjugation to introduce a functional payload to a protein 
In contrast, bioorthogonal chemistry exploits the reactivity of non-native functionality 
previously introduced into a biomolecule. Defined as reactions in which both starting materials 
and products do not interfere with biological processes,4 bioorthogonal transformations are 
generally achieved in two steps.9 Incorporation of a non-native functional group is followed by 
treatment of the system with a probe molecule bearing functionality which is complementary 
to the introduced moiety. These two coupling partners can undergo a secondary, chemoselective 
reaction to form the desired product (Scheme 2).4,9 Incorporation of the non-native group is 
most commonly achieved through genetic encoding10,11 or metabolic labelling,12 but may also 
be accomplished via an initial bioconjugation reaction at a native residue. 
 
Scheme 2 Two step bioorthogonal functionalisation of a protein; 1. Incorporation of non-native functionality through 
metabolic labelling, genetic encoding or bioconjugation reaction, 2. Chemoselective labelling of non-native functional group  
Progress in the field of protein modification has enabled both the in vitro and in vivo 
functionalisation of biomolecules.2,6,13 These advances have greatly benefited chemical biology 
and medicine; enabling targeted drug delivery using antibody-drug conjugates,14 enzyme 
activity profiling15,16 and imaging of cells in vivo17 (Figure 1). The aim of this introduction is 
to inform the reader of key approaches to bioconjugation, focusing on important seminal work 
and recent developments for the targeting of the most-commonly modified residues, 
demonstrating the need for novel and distinct bioconjugation strategies. For a more detailed 

















Figure 1 Potential biological applications of modified polypeptides and proteins 
 
1.2 Traditional bioconjugation strategies 
The most common bioconjugation methods target the ionisable and nucleophilic amino acids 
cysteine and lysine through reaction with a range of electrophiles (Scheme 3).20  
 
Scheme 3 Two of the most common strategies for bioconjugation: modification of cysteine and lysine through nucleophilic 
addition or substitution reaction with electrophiles 
 
1.2.1 Established bioconjugation reactions of cysteine 
Owing to the strongly nucleophilic nature of its sulfhydryl side chain,21 cysteine is the most 
explored residue for bioconjugation. With initial reports as early as 1935,22 strategies targeting 
cysteine are now routinely practised, with some widely acknowledged as the benchmark of 
protein bioconjugation. Possessing a pKa of approximately 8.5, at physiological pH the 

























surpasses the reactivity of any other nucleophilic function in proteins.21 Bioconjugation is 
usually achieved through nucleophilic addition or substitution with the thiolate anion.2 
Furthermore, as a relatively rare amino acid (natural abundance ~3% in vertebrates),23 cysteine 
can often be used to carry out single-site modifications. This is important as it facilitates the 
formation of homogeneous, well-defined products which are particularly vital for use as 
targeted therapeutics.24 
Cysteine residues serve a unique and important structural role in proteins through the formation 
of disulfide bonds between the thiol groups of two side chains (Scheme 4).25 The secondary and 
tertiary structure of many proteins can be influenced by these stabilising interactions.26 As 
cysteine residues are generally present in the oxidised disulfide form, solvent-exposed free 
cysteine residues required for many bioconjugation strategies are rarely found in proteins.27 
This can be overcome through the generation of free cysteine via the reduction of disulfide 
bonds with reagents such as tris[2-carboxyethyl]phosphine (TCEP),28,29 or through the 
incorporation of free cysteine via recombinant expression.30 However, considering their 
important structural role, reduction and functionalisation of disulfide bonds can cause structural 
perturbation in proteins, which may prove detrimental to protein function.31 Nevertheless, 
cysteine-selective modification strategies remain the most widely exploited in the field of 
bioconjugation. 
 
Scheme 4 Oxidation of cysteine within biological systems forms disulfide bonds which are pivotal to protein structure and 
function. Reduction with TCEP regenerates the free thiol group 
Illustrated in Scheme 5 is a brief overview of established transformations targeting cysteine for 
polypeptide and protein functionalisation. The most widely used strategies involve Michael 
addition to maleimide reagents32–36 due to the very fast kinetics (second order rate constant = 
734 M-1s-1)37 and high selectivity of these reactions (Scheme 5b).3,5,18 The prevalence of this 
approach has led to the commercialisation of a number of maleimide-derived reagents, and 
some antibody-drug conjugates made through cysteine-maleimide conjugation are now 


























reagents (Scheme 5a),22,39,40 aminoethylation (Scheme 5c),41–44 Michael-type addition with 
vinyl sulfones45–47 or carbonylacrylic reagents (Scheme 5d),48 radical-based thiol-ene (Scheme 
5g)49–52 and thiol-yne chemistry (Scheme 5h)52–56 and oxidative functionalisation to form mixed 
disulfides (Scheme 5f).57–62  
Cysteine bioconjugation can also be achieved via disulfide rebridging (Scheme 5e). This 
involves reduction of a disulfide bond to form two free cysteine residues, followed by reaction 
with dielectrophilic reagents such as dibromomaleimide, which can reconnect the two cysteine 
residues.63–67 One aim of the rebridging strategy is to avoid structural perturbation, which may 
be caused by breaking and functionalising the native disulfide bonds, through reforming 
unnaturally linked cysteine residues with exogenous functionality appended. 
 
















































































































Despite its frequent use within chemical biology for cysteine bioconjugation, Michael addition 
to maleimides still faces some inherent limitations. The resulting conjugates tend to decompose 
in the presence of thiol nucleophiles or an external base via elimination of the maleimide 
through retro-Michael addition (Scheme 6).68 This has prompted developments for the 
improved stability of maleimide-based conjugates via hydrolysis of the succinimide ring 
(Scheme 6),69,70 but has also driven the expansion of the cysteine bioconjugation field with 
alternative reagents. 
 
Scheme 6 Cysteine bioconjugation with maleimide reagents. Products undergo facile decomposition via retro-Michael 
addition of external thiol nucleophiles or an external base. Hydrolysis of the maleimide ring can lead to conjugates 
possessing improved stability. 
 
1.2.2 Recent developments in cysteine functionalisation 
A powerful protein functionalisation method pioneered by Davis and co-workers used cysteine 
residues to form the non-canonical amino acid dehydroalanine (Dha) which could provide a 
platform for further functionalisation (Scheme 7a).71 Dha is a naturally occurring amino acid, 
although it is not encoded by DNA and instead arises through post-transcriptional 
modifications.72 While the synthesis of Dha was reported as early as 1963 from serine,73 its 
formation could also be carried out with the use of non-native alkylated selenocysteine74 among 
other methods (Scheme 7a).75–79 These earlier techniques could be applied to both peptides77 
and proteins,78 but applications were limited to hydrolysis as a method of peptide digestion. 
While valuable, this did not constitute a bioconjugation method. However, advancements 












































naturally occurring cysteine residues (Scheme 7a).71 Subsequent Michael addition of Dha with 
varied thiols could install numerous functionalities, providing a novel bioconjugation approach 
used to mimic post-translational mutagenesis (Scheme 7b). However, the reaction proceeded 
with low diastereoselectivity,80 and high concentrations of thiol-containing reagents were 
required which could potentially perturb native disulfide bonds forming mixed disulfides.81 
While technically a bioorthogonal transformation, this distinct ‘umpolung’ approach allows the 
typically nucleophilic cysteine residues to instead react with external nucleophiles in a two-step 
sequence. 
 
Scheme 7 a) Strategies for the formation of dehydroalanine b) Dehydroalanine can react with a variety of thiols to form 
functionalised cysteine analogues which can mimic post-translational modifications71 
Further work on Dha, reported by Davis, showed the chemical editing of amino acid residues 
via selective reaction at cysteine, mimicking posttranslational mutagenesis.82 The authors 
























































biocompatible due to the tolerance of radicals to aqueous conditions and the unreactive nature 
of radicals to functionality present in biomolecules. Therefore, a remarkable radical-based 
strategy for the two-step bioorthogonal transformation of cysteine into alternative natural and 
non-natural amino acids was presented. Various alkyl halides could be used for the generation 
of primary, secondary and tertiary radicals (R•), which could react with Dha in peptides and 
proteins with excellent site- and regioselectivity (Scheme 8). However, the reaction displayed 
high sensitivity to oxygen, resulting in oxidative degradation through cleavage of the peptide 
backbone when not carried out under an inert atmosphere. Nonetheless, the method has since 
been applied to the a-deuteration of protein backbones as a potential tool for probing protein 
mechanisms.83  
 
Scheme 8 Posttranslational mutagenesis through C(sp3)–C(sp3) bond forming radical reactions; DTT = dithiothreitol; 
DBHDA = 2,5-dibromohexanediamide; Orn = ornithine; Cit = citrulline 
Owing to the fact that transition metal-catalysed reactions can be optimised to proceed with 
high chemoselectivity, mild conditions and excellent functional group tolerance,84 there have 
been several reports of protein functionalisation using organometallic reagents.84 These 
methods often require the use of functional handles85 or non-natural amino acids (e.g. 4-iodo 
phenylalanine or aldehyde/alkyne containing amino acids),84,86,87 providing a bioorthogonal 
approach. Additionally, high concentrations of reagents are generally required which could 







































In light of these challenges, Buchwald, Pentelute and co-workers presented an elegant method 
for the bioconjugation of cysteine using organometallic palladium reagents (Scheme 9).88 Using 
an aryl-palladium complex 1 with 2-dicyclohexylphosphino-2’,6’-diisopropoxybiphenyl 
(RuPhos) as the ligand, quantitative conversion of cysteine was observed, yielding S-arylated 
products stable to acids, bases and external thiol nucleophiles. The arylation technique could 
be used to transfer a variety of biologically relevant aryl groups and was applied to the synthesis 
of antibody-drug conjugates. In contrast to other organometallic bioconjugation strategies 
targeting tryptophan and tyrosine, which require longer reaction times and achieve lower 
conversions,84 the rate of the reaction was comparable to that of cysteine-maleimide 
conjugation even at low micromolar concentrations.  
This cysteine arylation method was also applied to the synthesis of macrocyclic peptides, to 
11CN radiolabelling of unprotected peptides for in vivo imaging,89 and to peptide and protein 
cross-linking.90 Further developments additionally demonstrated the development of water 
soluble organometallic reagents, improving the biocompatibility of this approach.91  
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Davis and co-workers also reported a palladium-mediated cysteine arylation (Scheme 10).92 A 
three amino acid recognition sequence (Asp-Ala-Asp) had previously been found to act as a 
natural metal binding motif and was exploited by Davis to direct a M(II)-aryl species, generated 
in situ, to the active site of a protein. Once in this active site, the M(II)-aryl species could react 
selectively with a proximal cysteine thiolate allowing high site-selectivity for cysteine 
arylation. Through mimicking the metal binding capabilities of natural protein systems and 
exploiting endogenous features to direct functionalisation, this proof-of-principle method 
represents a distinct strategy for selective bioconjugation. It could also be used for labelling, 
detection and identification of metal-dependent proteins in cell lysates.  
 
Scheme 10 Cysteine arylation using organometallic palladium reagents exploiting an inhert binding motif within proteins a) 
General reaction scheme for cysteine arylation b) Schematic of metal binding to recognition unit within the protein 
mannosylglycerate synthase (visualisation created using Pymol, PDB = 2BO6) with Asp-Ala-Asp binding motif highlighted 
in red, naturally bound metal ion (here Mn2+) highlighted in green and proximal Cys233 residue highlighted in pink 
Through a similar exploitation of a recognition motif, Pentelute and coworkers reported the 
selective perfluoroarylation of single cysteine residues within proteins using nucleophilic 
aromatic substitution (Scheme 11).93 The serendipitously discovered “p-clamp”, a four amino 
acid sequence (Phe-Cys-Pro-Phe), was reported to adjust the microenvironment of the clamp’s 
cysteine residue within a complex peptide or protein. Structural and computational mechanistic 
studies confirmed that the role of the proline was to position the residues into a conformation 
which promoted the reaction, highlighting the significance of the trans conformation prolyl 
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electrophile 2 and the phenylalanine side chain were observed, with the phenylalanine residues 
also thought to be activating the cysteine thiol.94 In contrast to the work from Davis (Scheme 
10) which could exploit a recognition unit inherent to the biological system, incorporation of 
the p-clamp motif into the biomolecule of interest was required prior to cysteine bioconjugation.  
 
Scheme 11 Selective cysteine conjugation using a 4 amino acid p-clamp sequence (Phe-Cys-Pro-Phe) for selective 
perfluoroarylation 
The authors have since shown that the concept could be applied to a longer, 29 amino acid 
abiotic peptide.95 Although this strategy requires the pre-installation of the p-clamp, its utility 
was demonstrated through the covalent attachment of the p-clamp sequence to an enzyme, 
allowing regiospecific, single-site perfluoroarylation. Most importantly, regioselective 
perfluoroarylation was achieved whilst leaving the enzyme’s active-site cysteine residue 
unchanged.95  
Recently, Pentelute et al. have also applied a similar concept to thiol-yne chemistry for cysteine-
cyclooctyne bioconjugation, developing a peptide recognition unit which could react in a 
sequence-selective fashion with aza-dibenzocyclooctyne (DBCO) reagents 3 (Scheme 12a).96 
Named a “DBCO-tag”, this seven amino acid sequence facilitates the use of commercially 
available DBCO reagents for regioselective modification of single cysteine residues on proteins 
which contain multiple endogenous cysteines. While the exact structural and mechanistic role 
of this recently developed DBCO-tag is currently not well understood, it has enabled the 
transfer of multiple functional payloads to proteins and has been used for the site-selective 







































unprecedented site-selective labelling of three unprotected cysteine-containing peptides in a 
single solution using three different reagents (Scheme 12b).96 This exploited the p-clamp 
sequence, the DBCO-tag and Michael addition to maleimide reagents to sequentially and 
selectively label three cysteine residues with unique microenvironments within a complex 
mixture. 
 
Scheme 12 a) Site-selective cysteine-cyclooctyne conjugation b) One-pot sequential labelling of three unprotected cysteine-
containing peptides combining DBCO-tag, p-clamp and maleimide conjugation methodologies 
The radiolabelling of peptides has received considerable attention owing to its application in 
positron emission tomography (PET) for the visualisation of biochemical processes in vivo. 
PET techniques involve the introduction of a positron-emitting radioisotope such as 11C or 18F. 
However, strategies for the radiolabelling of peptides commonly rely on bioorthogonal 
techniques, requiring pre-functionalisation of the peptide.97 In 2018, Davis and Gouverneur 
described the first protocol enabling direct 18F-labelling of cysteine residues in unmodified 
peptides. They use a newly developed 18F-Umemoto reagent 4 to introduce a trifluoromethyl 
group (Scheme 13).98 Biodistribution studies revealed the [18F]-SCF3 moiety was viable for in 
vivo imaging, however mixed DMSO/water solvent systems were used in the reaction, 












































































Scheme 13 18F labelling of unmodified peptides with a CF3 group; RCY, radiochemical yield 
Bernardes and co-workers reported approaches to enable the introduction of an electrophilic 
handle at cysteine residues (Scheme 14).99,100 This approach was similar to the work of Davis 
for the conversion of cysteine to Dha and its subsequent reaction with external nucleophiles, 
providing an analogous ‘umpolung’ strategy. The site-selective reaction with homobifunctional 
electrophilic reagents 5 or 6 could install an electrophilic handle at cysteine residues. Now, the 
inherently nucleophilic cysteine residue could instead undergo subsequent reaction with various 
external nucleophilic groups, providing a complementary strategy for bioorthogonal 
transformations at cysteine. However, the requirement for basic pH presented a limitation of 
the method when translating to biological systems. 
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1.2.3 Bioconjugation of lysine 
In addition to cysteine, lysine is also an important target for bioconjugation. Lysine residues 
are often exploited due to their well-established reactivity and the abundance of methods for 
the modification of primary amines. In contrast to cysteine (natural abundance ~3% in 
vertebrates), lysine is one of the most common amino acids (~7% in vertebrates),23 with 20 or 
more lysine residues frequently present on the surface of a protein.3 Owing to its high natural 
abundance, bioconjugation at lysine residues often results in heterogeneous mixtures of 
products with varying degrees of conjugation, meaning strategies are seldom regioselective. 
However, when multiple conjugations are desired, or when selectivity is less important, lysine 
bioconjugation has found broad utility.3 
With a pKa of approximately 10,2 lysine residues are protonated under biological conditions. 
In this state, lysine possesses no significant nucleophilicity and most amine-reactive reagents 
will instead modify any accessible cysteine residues due to the superior nucleophilicity of the 
sulfhydryl side chain. To circumvent this, it is important to maintain basic conditions (pH > 8) 
to obtain optimal yields and selectivity for bioconjugation.81 
Scheme 15 provides an overview of strategies for the functionalisation of lysine. Strategies 
involving activated esters (N-hydroxysuccinimide (NHS)101 and sulfo-NHS,102 Scheme 15b) 
and imido esters103–105 (Scheme 15g) have proven the most applicable, and many of these 
compounds have been developed into commercially available reagents for bioconjugation.20 
However, depletion of these highly reactive reagents can occur in water via hydrolysis.2 
Alternative methods have employed isocyanates106 or isothiocyanates (Scheme 15a),107–109 
sulfonyl halides (Scheme 15d),110–113 squaric acid diesters (Scheme 15f),114,115 activated lactams 
(Scheme 15h),116–118 fluorobenzenes (Scheme 15e)119–121 or reductive amination with aldehydes 
(Scheme 15c).122–125 These will not be discussed in detail and the reader is directed to a number 





Scheme 15 Overview of established methods for the bioconjugation of lysine involving the reaction of lysine with various 
electrophilic reagents 
Following on from their work on palladium-mediated cysteine arylation,88 a recent example 
from Buchwald and Pentelute aimed to expand their strategy for the arylation of lysine. They 
reported a general lysine arylation method, to form stable N-aryl conjugates using preformed 
or in situ generated [LPd(Ar)X] complexes (Scheme 16a,b).129 The biaryl phosphine ligand, in 
combination with mildly basic sodium phenoxide, enabled the functionalisation of complex 
peptide substrates and found application in the synthesis of macrocyclic peptides (Scheme 16c). 
While the protocol was shown to be completely selective in the presence of most other 








































































































dehydroalanine formation. Undesirable diarylation was observed in the case of the guanidinium 
side chain of the amino acid arginine. 
 
Scheme 16 a) Palladium-mediated arylation of lysine in unprotected peptides b) Most effective [LPd(Ar)X] complex, using 
ligand t-BuBrettPhos c) Macrocyclic peptide formed using polymetalated Pd complex 
In light of the challenges associated with more traditional lysine bioconjugation strategies, 
namely low regioselectivity and instability of reagents,2 recent approaches have sought to 
circumvent these issues. Despite the abundance of methods for the functionalisation of lysine, 
a strategy which could label a single lysine residue in a protein containing multiple lysines has 
remained elusive. It is understood that variations in the local microenvironment of amino acids 
can induce innate and subtle reactivity differences between different amino acids bearing the 
same side chain within a protein.130 In the case of lysine, the pKa of the amine side chain can 
vary by up to 5 units depending on the polarity of its microenvironment, its solvent accessibility, 
protein folding and the nature of the surrounding residues.131 This difference in pKa can incite 
distinct reactivity, with some residues proving ‘hyper-reactive’ towards certain electrophiles. 
Strategies attempting to exploit hyper-reactive lysine residues have been reported, although 
they remain poorly understood and largely substrate dependent.132–134  
In 2017, Bernardes et al. pioneered the use of computer-aided design to exploit the varying pKa 
of lysine residues within proteins for both chemo- and regioselective modification of a single, 
specific lysine (Scheme 17).130 At slightly basic pH, the lysine residue with the lowest pKa was 
kinetically favoured for reaction with sulfonyl acrylate reagents 7. Upon lysine labelling, 














































undergo subsequent aza-Michael addition with an external amine reagent. The authors proposed 
computational evidence that the sulfonyl acrylate reagents were selective for lysine over other 
nucleophilic groups as a result of a transient hydrogen bond between the sulfonyl group and the 
e-amino group of lysine which stabilised the intermediate formed. This method highlights the 
power of precise prediction of a residue’s microenvironment within a protein, facilitating 
rational design of a selective bioconjugation approach.  
 
Scheme 17 Chemo- and regio-selective lysine modification on a native protein using computer-designed sulfonyl acrylate 
reagents 
Cysteine and lysine residues remain the most widely explored amino acids and provide 
platforms for state-of-the-art bioconjugation techniques. However, approaches targeting these 
amino acids still present some inherent limitations. Many strategies remain sequence specific 
and, in the case of cysteine, require pre-installation of recognition units or incorporation of free 
cysteine residues to achieve high selectivity. In order to address these limitations, attention has 
focused on the targeting of alternative native functionality within proteins. Through the 
development of distinct bioconjugation strategies, it may be possible to not only overcome 
issues fundamental to cysteine and lysine bioconjugation, but may also provide a 
complementary strategy to enable the formation of multi-functionalised protein scaffolds.19 
Formation of multi-functionalised conjugates through mutually orthogonal reactions used in 
tandem are desirable due to the potential application of the resulting products in simultaneous 
metabolic imaging of two different processes or in monitoring protein dynamics.19 
To this end, strategies for the selective functionalisation of several other native functional 
groups have been reported, including the bioconjugation of tryptophan,135–139 histidine,140–142 
tyrosine143–147 and the N-terminus148–151 and C-terminus152 (Figure 2). These methods have been 
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available for targeting these alternative native motifs for bioconjugation reactions of 
polypeptides and proteins.  
One particular amino acid of interest for the development of a novel bioconjugation strategy is 
methionine (Figure 2). Possessing relatively low natural abundance (~2% in vertebrates)23 and 
simple ancillary protein function,81 targeting of this amino acid presents a potential opportunity 
for addressing the limitations inherent to cysteine and lysine bioconjugation. 
 
Figure 2 Figure highlighting the alternative amino acid side chains and the C- and N-terminus which have been targeted for 
distinct bioconjugation strategies. Methionine is highlighted as a potentially favourable target for bioconjugation 
 
1.3 Methionine bioconjugation  
Methionine is encoded by the AUG start codon at the beginning of protein synthesis, but is 
often post-translationally excised, resulting in low natural abundance (~2%).23 Bearing a 
hydrophobic thioether side chain which is commonly buried within a protein’s hydrophobic 
core, solvent exposed methionine residues are rarely found on the surface of proteins.81 
Therefore, it may be possible to target single methionine residues to provide an effective 
strategy for the formation of homogeneous, well-defined protein conjugates. The polar, non-
ionisable side chain is the only amino acid residue which remains nucleophilic at low pH, 
thereby offering complementary reactivity to other polar, ionisable amino acids.126  
Additionally, within most proteins, methionine plays a simple structural role, with a third of all 
proteins found to be stabilised by S/p interactions between the sulfur atom and other aromatic 
amino acids. Methionine residues involved in these stabilising interactions are generally found 





















bioconjugation.153 The replacement of methionine with norleucine, an amino acid with a 
straight hydrocarbon chain, showed no detrimental effect on protein structure or function, 
demonstrating methionine’s ancillary role.154  
Methionine is the key component of the cofactor S-adenosyl methionine 8 (SAM). As the main 
cellular carrier of methyl groups within the body, SAM plays an important role alongside a 
SAM-dependent methyl transferase enzyme to transfer methyl groups to various biomolecules 
including DNA.155,156 However, SAM is naturally biosynthesised from L-methionine in living 
cells and is not a target for bioconjugation reactions. 
The relatively high oxidation potential of the methyl thioether side chain of methionine157 lends 
itself to reversible, biochemical oxidation processes which can be exploited by biological 
systems to protect against oxidative stress by reactive oxygen species.158 Proteins that are 
damaged by oxidative stress are often targeted for proteolysis, or other protein degradation 
pathways, to prevent cellular damage.159 To avoid this degradation an antioxidant enzyme, 
methionine sulfoxide reductase, can catalyse the reduction of methionine-S-sulfoxide 9 back to 
methionine (Scheme 18), which is no longer targeted for proteolysis.159 Therefore, methionine 
plays a regulatory role in endogenous antioxidant enzymes and key metabolic processes and in 
some proteins methionine can also function as a redox sensor.160 
As oxidative stress has been linked to pathological diseases such as cancer, harnessing the redox 
properties of methionine may assist in reducing the prevalence of cancer.161,162 The inhibition 
of cancer cell growth has been demonstrated through the metabolism of methionine to 
homocysteine 10,163 while methionine has also been shown to chelate lead and remove it from 
tissues, decreasing oxidative stress.164 Methionine can also directly influence the functioning 
of the immune system through the production of the low molecular weight antioxidant 
glutathione 11.158  
The oxidation and reduction of methionine is a reversible process, repeatedly modifying and 
regenerating the thioether side chain in response to external stimuli. This redox process means 
that the thioether of methionine may still be available for bioconjugation even after being 




Scheme 18 Methionine and the synthesis/metabolism of its derivatives within biological systems 
The low natural abundance and ancillary function of methionine presents the opportunity to 
functionalise proteins without perturbing protein structure and function. Additionally, selective 
labelling could also allow the investigation into the unique biological roles of methionine within 
more specific systems. Therefore, a strategy to selectively target this amino acid could prove 
invaluable. Previously reported strategies for the selective functionalisation of methionine are 
comparable to its biochemical roles, with the methyl thioether providing a platform for 
oxidation to the sulfoxide, or for alkylation to sulfonium salts. 
Inspired by the redox properties of the thioether of methionine, Scoffone demonstrated the 
selective, dye-sensitised photooxidation of methionine in ribonuclease A165 (Scheme 19a) and 
lysozyme166 (Scheme 19b). Using the photosensitisers rose bengal or methylene blue (Scheme 
19c), quantitative conversion to methionine sulfoxide was observed, causing an 87% decrease 
in enzymatic activity in the case of ribonuclease A, due to the resulting change in conformation. 
In both cases, oxidation was found to be reversible, using either thioglycolic acid 12 or 2-
mercaptoethanol 13 as a reductant, restoring full enzymatic activity on regeneration of the 










































































Scheme 19 Reversible, dye-sensitised photooxidation of a) Ribonuclease A and b) Lysozyme. c) photo-sensitisers 
In a similar oxidative strategy, Whitehead and Bentley reported that the thioether of methionine 
could be converted to a sulfoximine using sodium azide or hydrazoic acid (Scheme 20).167,168 
This technique was applied to the functionalisation and inhibition of the enzyme horseradish 
peroxidase and provided evidence for the presence of a methionine residue in its active site.169 
However, while both of these oxidative strategies probe enzymatic function, they employ 
strongly acidic conditions which are largely incompatible with most biological systems. 
 
Scheme 20 Oxidative functionalisation of methionine with azide reagents 
Arguably, compared to these oxidative approaches, more impactful discoveries in the field of 
protein functionalisation have resulted from the development of alkylative strategies targeting 
methionine, as these strategies have presented the opportunity to incorporate a functional handle 
or payload. As early as 1940, Toennies reported pioneering work for the functionalisation of 
methionine using methyl iodide to form the corresponding S-methyl sulfonium species 14 
(Scheme 21a).170 This could be applied to the enzyme ribonuclease A as a method for the 
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strategies emerged from 1945,172 reported on simple systems by Toennies and subsequently by 
Gundlach in 1959.173 Both described the reaction of methionine with a-halo acids forming 
carboxymethyl sulfonium salts 15 (Scheme 21b). While a-halo acids have been previously 
shown to react with free cysteine residues, in the absence of cysteine and under acidic 
conditions these reagents can selectively react with methionine. Exposing the resulting 
sulfonium salt to acidic conditions led to decomposition, yielding homoserine 16 and the 
corresponding homoserine lactone 17 through loss of a neutral sulfide (HO2CCH2SMe). 
Alternative degradation pathways yielded S-carboxymethyl homocysteine 18 and regenerated 
methionine through dealkylation.173  
 
Scheme 21 Early work for the alkylation of methionine using methyl iodide and a-halo acids 
Aside from the ancillary biological role and redox properties, there are specific examples in 
which methionine plays a more important role within proteins, namely it can be found as the 
key residue in the active site of many kinases.174 In these situations the functionalisation of 
methionine may be a valuable tool to allow investigation into its more complex biological roles. 
To this end, Gundlach applied the use of a-halo acids to the inhibition of the enzyme 
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through detection of degradation products resulting from functionalisation of the thioether side 
chain. Additionally, depending on the reaction conditions, the modification of other amino acids 
such as lysine and histidine was observed. The use of a-halo acids was also applied to the 
functionalisation of the enzyme fumarase in 1969 using iodoacetate,176 however again the 
process lacked selectivity, yielding a mixture of products resulting from reaction with histidine 
residues in addition to methionine. 
Lawson and Schramm demonstrated that more complex a-halo carbonyl derivatives could be 
used to label a methionine residue adjacent to the active site of the enzyme chymotrypsin 
(Scheme 22).177,178 Through the use of p-nitrophenyl bromoacetyl-a-aminobutyrate 19 at pH 5, 
a serine residue in the active site of the enzyme was acylated. A subsequent, proximity-driven 
alkylation of a neighbouring methionine residue could occur, followed by cleavage of the acyl-
enzyme bond. While modification of the serine residue caused full deactivation of the enzyme, 
alkylation of methionine partially restored the enzymatic activity (20-30% activity of standard 
chymotrypsin). Restoration of the enzymatic activity was largely due to regeneration of the free 
serine residue, however the reduced activity of the trialkyl sulfonium enzyme 20 indicated that 
methionine may play a role within the active site. The authors propose that this bioconjugation 
strategy could prove a useful tool for the mapping of enzyme active sites. 
 
Scheme 22 Inhibition of chymotrypsin through alkylation of methionine; labelling of an active site serine residue using a 
bifunctional reagent allowed proximity-driven alkylation of a methionine residue followed by cleavage of the acyl-enzyme 
bond  




























































Developments from Hysert et al. expanded the scope of reagents for the direct alkylation of 
methionine.179 They employed allyl bromide 22, 1-bromo-2-butyne 23 or 2-
bromoacetophenone 24 with N-acetyl-DL-methionine 21 at pH 3–8 to form the corresponding 
sulfonium species 25 (Scheme 23). Importantly, no decomposition of the sulfonium products 
was observed, indicating the potential stability of these sulfonium motifs. A drawback of this 
method was the requirement for organic solvent in order to facilitate methionine modification. 
Additionally, the reaction was only able to achieve full conversion after 24 hours. 
 
Scheme 23 Broader scope of alkylating reagents for alkylation of methionine 
Following the alkylation of methionine residues with a-halo carbonyl reagents, it was reported 
that dealkylation of the resulting sulfonium species could also be achieved, in many cases 
restoring enzymatic activity. Naider showed that sulfur nucleophiles could regenerate 
methionine residues from their sulfonium salts on simple peptidic systems (Scheme 24a).180 
Although reaction times were long and required elevated temperatures, this reversible 
alkylation of methionine was applied to a methionine residue close to the active site of the 
enzyme b-galactosidase (Scheme 24b).181 It was hypothesised that the active site could bind the 
alkylating agent, bringing this into close proximity to methionine for selective functionalisation. 
Using kinetic studies, it was concluded that the inactivation of b-galactosidase using N-
bromoacetyl-b-D-galactosylamine 26 did proceed via the formation of a reversible enzyme-
substrate complex prior to covalent bond formation, with bond formation suggested to be 
directed by the enzyme’s active site. This proved distinct to alkylation with iodoacetamide 
which obeyed a second-order rate law, indicating a simple bimolecular reaction. 
A reversible alkylation procedure was also described by Luehr in which p-methoxybenzyl 
chloride 27 and silver tetrafluoroborate in acetonitrile could afford the S-benzyl sulfonium 
species 28 in just 30 minutes from protected methionine amino acid residues (Scheme 24c).182 
The use of silver tetrafluoroborate allowed alkylation using unactivated alkyl halides. Heating 






























quantitatively, however complete hydrolysis of the methyl ester protecting group was observed. 
In this example, the forcing conditions required for dealkylation would likely prove 
incompatible with larger biomolecules. 
While a number of reports for the dealkylation of S-alkyl sulfonium residues have been 
demonstrated, showing the reversible nature of these transformations, conflicting reports have 
indicated that these groups are either inert or prone to decomposition under similar 
conditions.173,183–185 
 
Scheme 24 Examples of the reversible alkylation of methionine 
Deming and co-workers sought to expand the scope of methionine alkylation for the synthesis 
of polypeptides containing diverse and reactive functionality.186 They aimed to develop a 
superior alkylative strategy using a polypeptide formed only of methionine residues, known as 
poly(Met). Despite the poor solubility of poly(Met) in many solvents, facile alkylation was 
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easily isolable products (Scheme 25a). Improving on previous strategies which generally 
employed only activated alkyl bromides and iodides, Deming demonstrated that, in a similar 
fashion to Luehr (Scheme 24c), the addition of silver tetrafluoroborate could promote the 
complete conversion of methionine alkylation with unactivated alkyl halides. Alternatively, to 
avoid the use of silver salts, functional alkyl triflates could be used in organic solvents for 
efficient alkylation of poly(Met). To exemplify the selectivity of the methionine alkylation 
procedure a polymer of methionine and lysine residues was synthesised and selectively 
alkylated at methionine. This was achieved through complete protonation of lysine residues 
under pH control (Scheme 25b). Interestingly, the alkyne groups introduced into the polymer 
could be quantitatively reacted with azide-terminated PEG chains in a subsequent 
bioorthogonal reaction. Importantly, this ‘secondary click’ strategy established the stability of 
these trialkyl sulfonium species and their compatibility with existing ‘click’ conjugation 
methods. Although the reaction displayed a broad scope of alkylating reagents, modification of 
methionine required the incorporation of organic solvents and long reaction times.  
 
Scheme 25 a) Alkylation of poly(methionine) with a range of alkylating reagents b) Selective methionine functionalisation of 
synthetic copolymer; reagents i. propargyl bromide, 0.2M formic acid, pH 2.4 (94%) ii) a-methoxy-w-azidoethyl-
poly(ethyleneglycol), CuSO4, ascorbic acid, PMDETA, H2O (95%) 
In further work, Deming described a more general platform for reversible, chemoselective 
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This advancement proved distinct to previous methionine labelling strategies as it encompassed 
the general, triggered reversal of the alkylation. In contrast, earlier studies found that alkylating 
agents and nucleophilic cleavage reagents were substrate and functional group dependent, 
sometimes generating other products aside from regenerated methionine. Deming detailed an 
optimised alkylation strategy for the formation of stable sulfonium conjugates, enabling the 
introduction of bioorthogonal tags for subsequent modification and cleavage (Scheme 26a).187 
This was applied to a synthetic peptide which incorporated competing nucleophilic residues 
(Scheme 26b), demonstrating the selective nature of this reversible alkylation under pH control 
and alluding to its potential application in the controlled release of therapeutic peptides.  
 
Scheme 26 a) Schematic for the alkylation, subsequent bioorthogonal modification and release of methionine b) Reversible 






















































































Recently, Deming also revealed that alkylated methionine residues could be selectively 
demethylated using ammonium pyrrolidinedithiocarbamate (APDC) resulting in a neutral 
thioether with increased stability (Scheme 27).188 In addition, through the use of substituted 
epoxides as alkylating reagents, demethylation could form homocysteine analogues. The 
process tolerates a number of different functional groups including azides, monosaccharides 
and zwitterionic groups, and can even selectively distinguish methyl from ethyl substituents. 
However, the reaction is highly dependent on the solvent, requiring less polar, ethanol-rich 
solvent mixtures to achieve good conversion over 24 hours. 
 
Scheme 27 Selective demethylation of alkylated methionine residues with APDC (competing pathways of dealkylation and 
nucleophilic subsitition are shown) 
In contrast to the alkylative strategies reported thus far, which form stable sulfonium products 
and aim to evade decomposition, a distinct methionine functionalisation strategy set out to form 
unstable sulfonium intermediates for the selective cleavage of methionyl peptide bonds. 
Products resulting from the alkylation of methionine with iodoacetamide require elevated 
temperatures for decomposition to the corresponding homoserine lactone. Gross and Witkop 
deduced that an alternative reagent would be required to form a sulfonium species which would 
be sufficiently unstable in order to undergo intramolecular displacement at room temperature 
under physiological pH in aqueous solution. They showed that the reagent cyanogen bromide 
(CNBr, 30) could react efficiently with methionine residues under acidic conditions at room 
temperature to form an unstable cyanosulfonium salt 31, which could undergo facile 
intramolecular cyclisation and loss of methyl thiocyanate 32 to form the corresponding 
iminolactone 33. This unstable iminolactone is rapidly hydrolysed to two peptidic fragments; 

















































Scheme 28 Site-selective cleavage of methionyl peptide bonds using cyanogen bromide 30 
Although this degradative process is not truly a bioconjugation reaction, CNBr-mediated site-
selective peptidic cleavage efficiently produces well-defined, smaller peptide fragments which 
can be analysed to give important insight into the composition of the larger initial protein 
scaffold. Cyanogen bromide cleavage of methionine-containing peptides and proteins has been 
invaluable in protein sequence determination and is used routinely in biological research.191 
The instability of the resulting cyanosulfonium salts demonstrate the importance of the high 
product stability which must be achieved in related bioconjugation reactions to avoid unwanted 
decomposition. 
The strategies for selective modification of methionine residues reported thus far largely use 
conditions incompatible with biological systems.  Methods often require elevated temperatures, 
proceed over long reaction times and form products with varying levels of stability. As such, 
many current techniques for methionine labelling represent chemical modification methods as 
opposed to true bioconjugation strategies. As an interesting target for bioconjugation, with low 
natural abundance and ancillary function, strategies for the selective functionalisation of 
methionine residues using biocompatible conditions remain highly sought after. 
A recent advance was published in 2017 by Toste and Chang for the modification of methionine 
residues, representing a truly biocompatible strategy for methionine bioconjugation. The 
authors refer to the method as redox-activated chemical tagging (ReACT).192 In contrast to the 
more traditional alkylative approaches, this oxidative sulfur imidation strategy uses oxaziridine 
reagents 36 to achieve highly selective, robust labelling in just 1-2 minutes, with a rate constant 
comparable to that of bioorthogonal reactions (18 M-1s-1)8,192 (Scheme 29). This oxidative 
strategy exhibits high functional group tolerance in the presence of other nucleophilic residues, 
however cysteine residues are oxidised to the corresponding disulfide. The sulfimide products 
exhibit remarkable stability at varying pH, in the presence of disulfide reducing agents and also 





















































methionine residues in both proteins and antibodies, allowing the facile synthesis of 
homogeneous antibody-drug conjugates (ADCs) and has also simplified proteomic profiling 
through identification of hyper-reactive methionine residues in whole proteomes.  
 
 



















1.4 Conclusion and outlook 
Considering the pioneering work of Chang and Toste, it is evident that methionine is a valuable 
target for bioconjugation. Yet, while alkylative strategies remain the predominant method for 
chemical modification, inherent flaws such as long reaction times, stringent pH control and 
variable stability of sulfonium products preclude the applicability of current strategies to 
bioconjugation. A truly biocompatible, selective and efficient bioconjugation strategy is highly 
sought after, and many valuable techniques continue to be reported in the hope of achieving 
this goal. 
The oxidative bioconjugation strategy published by Chang and Toste represents an excellent 
advance for methionine labelling. Although, with few strategies currently reported for 
methionine bioconjugation, there is chemical and biological need for further complementary 
techniques. Alkylative strategies forming cationic sulfonium moieties have been shown to be 
useful in the formation of cell-penetrating peptides as transporters for intracellular therapeutic 
delivery.193 As such, the development of a biocompatible strategy of this nature would expand 
the repertoire of methods for bioconjugation and could prove invaluable in the advancement of 
biological applications.  
A serendipitously discovered methionine alkylation strategy was reported concurrently to the 
publication of the work detailed in this thesis. As a novel, transition metal-catalysed methionine 
alkylation method, this strategy employed water soluble metalloporphyrins for selective 
bioconjugation under biocompatible conditions (Scheme 30).194 While only reported on a single 
polypeptide system, this method provided a complementary strategy for methionine alkylation. 
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2 Development of a methionine-selective bioconjugation strategy 
2.1 Hypervalent iodonium salts for bioconjugation  
A number of strategies for bioconjugation have exploited hypervalent iodonium salts (l3-
iodanes) for the selective and efficient introduction of exogenous functionality into peptides 
and proteins. Iodonium salts (Ar(R)I+X-) are a class of l3-iodane electrophiles in which two 
carbon based ligands (R, Ar) and a counter-anion (X) are bound to a central iodine(III) atom 
(Scheme 31a).195 Despite being classed as ‘salts’, X-ray structural data for the majority of 
iodonium salts show secondary bonding between the iodine atom and the counter-anion (bond 
distance = 2.3-2.7 Å), resulting in a ‘T-shaped’ pseudo-trigonal bipyramidal geometry.195 As 
such, the electrophilic iodine centre shares a hypervalent three-centre, four-electron bond with 
two axial ligands, which is longer and weaker than regular covalent bonds.195 It is this 
‘hypervalent’ bond that is responsible for the high electrophilic reactivity of l3-iodane species.  
Synthesis of these reagents is usually achieved via initial oxidation of an aryl iodide to an 
iodine(III) species. Subsequent ligand exchange with an arene, organometallic reagent or other 
suitable nucleophile can occur in the presence of an acid to yield the l3-iodane (Scheme 31b). 
The anion (X) usually originates from the acid used in the ligand exchange, such as boron 
trifluoride diethyl etherate (X = BF4) or trifluoromethanesulfonic acid (X = OTf).196 
 
Scheme 31 a) General structure of hypervalent iodine reagents (R = carbon-based ligand, X = counter-anion). Considered 10-
I-3 species under Martin-Arduengo designation [N-X-L] (where N = number of valence electrons on central atom, X = 
central atom, L = number of ligands on central atom)197 b) General synthetic strategy for formation of diaryl iodonium salts 
l3-iodanes react readily with nucleophiles to form a Nu–I bond upon displacement of a ligand. 
Reactions with unsymmetrical l3-iodanes give two T-shaped intermediates, which are in fast 
equilibrium through Berry pseudorotation.198 The prevailing mechanism involves subsequent 
reductive ligand coupling of the nucleophile and the equatorial group to afford the product, Nu–
L, releasing Ar–I (Scheme 32). Other mechanisms for the reactivity of hypervalent iodonium 
salts are possible and are discussed at length in a number of reviews.195,196,199–201 The high 




















Scheme 32 General reactivity of l3-iodanes with nucleophiles  
Iodonium salts are highly useful reagents for the electrophilic transfer of the ligand (R) to 
electron-rich organic substrates, and have been employed in the arylation of phenols (Scheme 
33a),203,204 fluoride anions (Scheme 33b)205,206 sodium tetraphenylborate (Scheme 33c),207–209 
anilines (Scheme 33d),210 and sulfur/selenium nucleophiles (Scheme 33e).211–213 Diaryl 
iodonium salts, in which R = Ar, are one of the most common classes of l3-iodanes.  
 
Scheme 33 Reactivity of iodonium salts with nucleophiles 
Most iodonium salts are air and moisture stable compounds which, depending on the nature of 
the counter-anion, possess some aqueous solubility.196 They are generally mild and non-toxic 
and can react with certain nucleophiles with high selectivity. A number of protein 
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Togni, Hilvert and Beier were able to achieve the perfluoroalkylation of protected cysteine 
residues through the use of an iodine(III) heterocycle 38, a five-membered ring variant of an 
l3-iodane reagent, in which iodine and oxygen are incorporated into the ring (Scheme 34).214,215 
The perfluoroalkylation proceeded at -40 °C in 2 hours, with the products shown to be stable 
and unreactive to external thiol nucleophiles. This strategy was applied to the labelling of 
exposed cysteine residues in a synthetic retro-aldolase enzyme.215 The use of established 
maleimide based bioconjugation methods resulted in not only cysteine labelling, but also non-
specific labelling of a lysine residue essential for enzymatic activity. In contrast, selective 
cysteine modification was achieved using 38, leaving the lysine residue unmodified, 
highlighting the high selectivity which can be achieved using hypervalent iodine reagents.  
 
Scheme 34 Selective bioconjugation of cysteine residues using iodine (III) heterocycle 
Waser and Adibekian also employed benziodoxole reagents for the alkynylation of cysteine 
residues (Scheme 35). Alkynylation was initially achieved on protected dipeptide substrates,216 
but could subsequently be applied to complex proteomes and even living cells.217 The labelling 
was complete in just 30 seconds at room temperature and, through variation of the carbon-based 
ligand on the l3-iodane reagent 39, could introduce a pendant azide moiety. A subsequent 
copper catalysed azide-alkyne cycloaddition reaction with an external alkyne reagent allowed 
the introduction of a functional payload to enable proteomic profiling in complex protein 
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Scheme 35 Selective bioconjugation of cysteine residues within proteomes and living cells using iodine (III) heterocycle 
(CuAAC – Copper catalysed azide alkyne cycloaddition) 
A similar benziodoxole reagent, 40, was used for the alkynylation of the C2 position of 
tryptophan residues. Waser et al. described the gold-catalysed alkynylation of protected 
dipeptide substrates using 40 (Scheme 36a).218 The reaction proceeded in good conversion over 
24 hours and was selective for tryptophan over other aromatic amino acids. However, lower 
conversion was observed on peptides which were not protected at the C- and N-terminus. 
Hansen and co-workers detailed a similar gold-catalysed alkynylation strategy which could be 
applied to several polypeptides and proteins (Scheme 36b).219 They employed the same 
benziodoxole reagent 40 for the modification of tryptophan at the C2 position, producing a 
single regioisomer which was confirmed using NMR and MS/MS analysis. No 
functionalisation was observed under strictly aqueous conditions, presenting a drawback of this 
strategy due to the requirement for organic solvent.  
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Diaryl iodonium salts, whose use in the arylation of small molecules is well established, have 
also been used as reagents for peptide functionalisation. Gaunt and co-workers reported the use 
of diaryliodonium salt 41 for the O-arylation of a tyrosine residue in a protected tripeptide 
(Scheme 37).204 Although the reaction proceeded in 2 hours, organic solvents and relatively 
high concentrations (> 1 mM) were required, factors which would likely prove incompatible 
with biological systems.  
 
Scheme 37 Functionalisation of a tyrosine residue in a model tripeptide using a diaryliodonium salt 
It has been shown that cyclic hypervalent iodine reagents can be valuable tools for selective 
bioconjugation, with a limited number of methods detailing the functionalisation of different 
amino acid residues. Due to the desirable properties of these l3-iodanes, including stability, 
partial water solubility and high selectivity, their application as reagents for bioconjugation has 
been explored. Thus far, there has been no report of the use of hypervalent iodine reagents for 
bioconjugation at methionine. 
 
2.1.1 An a-aryliodonio diazo compound as a reagent for methionine bioconjugation 
In 1994, Weiss et al. reported the synthesis and reactivity of a structurally remarkable iodonium 
salt 43 bearing an a-diazoacetate ligand (Scheme 38).220 This was the first reported example of 
an a-aryliodonio diazo compound, and its synthesis was achieved in a single step from 
(diacetoxyiodo)benzene 42 and ethyldiazoacetate 37. This novel iodonium salt displayed 
umpolung reactivity at the a-carbon of the diazoester motif due to the electrophilic nature of 
the iodine centre. As a result, 43 could react with a variety of neutral nucleophiles to afford 
stable a-substituted diazo products 44.  
Notably, iodonium salt 43 could react with dimethyl sulfide 45 resulting in the formation of a 
cationic sulfonium species. Due to the structural similarity of dimethyl sulfide to the methyl 
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hypervalent iodine reagent 43 could present an opportunity for the development of a novel 
bioconjugation reaction at methionine. This would not only represent a distinct alkylative 
bioconjugation strategy, it would facilitate the introduction of reactive, non-native functionality 
into the biomolecule of interest. The newly introduced diazo moiety could also serve as a 
potential platform for further bioorthogonal transformations. 
 
Scheme 38 Synthesis and reactivity of novel a-aryliodonio diazo compound 43 
 
2.2 Previous work  
Employing the original conditions reported by Weiss,220 Dr M. G. Suero discovered that the 
reaction of a simple, protected methionine amino acid 46 with iodonium salt 43 afforded the 
sulfonium product 47 in 85% yield, determined by 1H NMR (Scheme 39a). In order to gain an 
insight into the selectivity of the functionalisation, a control reaction on the amino acid cysteine 
was carried out (Scheme 39b). No sulfur alkylation occurred, with exclusive formation of the 
oxidised disulfide species 48 observed by LCMS analysis. Remarkably, the unprotected amine 
of the amino acid also remained untouched, demonstrating the selectivity of the iodonium salt 
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Scheme 39 a) Initial reaction of methionine with Weiss iodonium salt 43 (a 1H NMR yield); b) Exposure of cysteine to 
reaction conditions saw exclusive oxidation to disulfide 48. Reactions carried out by Dr M. G. Suero 
Dr M. G. Suero and Dr M. T. Taylor found that on switching the reaction solvent from CH2Cl2 
to water, a complex mixture was observed for the reaction of methionine 46 with iodonium salt 
43. Early efforts towards the optimisation of the methionine functionalisation involved the 
alteration of the aryl group of the iodonium salt. Through the use of iodonium salt 50 with an 
o-tolyl aryl group, Dr M. T. Taylor found that a complex mixture was observed for the reaction 
with methionine 49 (Scheme 40a). Interestingly, homoserine lactone 17 could be isolated from 
the mixture, indicating that product formation had likely occurred but had proven unstable and 
undergone subsequent cyclisation with loss of a neutral thioether. A model dipeptide system 
(MetGly, 51) proved more stable under the reaction conditions, forming the sulfonium product 
52 in 30% yield (Scheme 40b). However, in this case the reaction was slow and did not go to 
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Scheme 40 Optimisation of methionine labelling in water; a) Degradation side-product 17 isolated via reverse phase HPLC 
b) Optimisation on model dipeptide substrate 51 (a 1H NMR yield). Reactions carried out by Dr M. T. Taylor. 
Further optimisation of the reaction identified that iodonium salts bearing an o-tolyl or 2,4-
difluorophenyl moiety facilitated the highest yield of sulfonium product 52 (Table 1, Entries 2-
5). Improvements to the yield could also be made through the addition of an aqueous solution 
of the iodonium salt as opposed to the solid reagent (Table 1, Entry 5). Various counterions 
were screened in the reaction (Ts2N–, TsO–, OSO3H–, BF4–) and it was found that the salt with 
a BF4– counterion provided optimal results, increasing the yield to 95% (Table 1, entries 4-5) 
as well as improving the water solubility of the iodonium salt reagent. The optimal conditions 
(Entries 4 & 5, Table 1) afforded MetGly conjugate 52 in 95% yield over 1 hour. Due to the 
ease of purification and the stability of iodonium salt 54, bearing a 2,4-difluorophenyl moiety 
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Table 1 Key results from the optimisation of methionine functionalisation through variation of the aryl group and counterion 
of the iodonium salt. Yields were calculated using 1H NMR. Reactions carried out by Dr M. T. Taylor 
 
In order for the reaction to be applicable to larger protein or enzymatic systems, it must operate 
successfully at low micromolar concentrations. Dr M. T. Taylor discovered that decreasing the 
concentration of peptide in the reaction (from 50 mM to 5 mM) led to an increase in an oxidised 
side-product, sulfoxide 55 (Table 2). This side-product was likely formed due to reaction of 
methionine with reactive oxygen species (ROS) produced from molecular oxygen such as the 
superoxide anion (O2-•), hydroxyl radical (•OH) or hydrogen peroxide (H2O2).162 To reduce 
such side reactions, Dr. M. T. Taylor screened a number of additives that were known to be 
ROS-scavengers (Table 2).162,221,222  
While all of the ROS-scavengers tested reduced the amount of sulfoxide formed, the use of 
thiourea resulted in the highest yield, achieving >95% conversion to the desired sulfonium 
product 52. Remarkably, it was observed that thiourea facilitated conversion to the desired 
product through both quenching of reactive oxygen species, and a rate acceleration effect. 
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aYield determined using 1H NMR, with DMF as an internal standard.
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untouched during the reaction, reinforcing the unreactive nature of the iodonium salt towards 
other nucleophiles. 
Table 2 Screening of scavengers of ROS to reduce formation of oxidation side-product 55. Yields calculated using 1H NMR. 
Reactions carried out by Dr. M. T. Taylor 
 
Further optimisation was carried out by Dr M. T. Taylor in order to translate the methionine 
functionalisation from a small molecule system to a polypeptide, exenatide (Scheme 41). 
Exenatide (ByettaTM) is a 39-amino acid synthetic peptide drug, of molecular weight 4186.6 
Da, and is approved for the treatment of patients with type 2 diabetes mellitus.223 It contains 
one methionine residue, alongside multiple different nucleophilic residues including lysine, 
serine and glutamic acid and has an a-helical secondary structural element. The selective 
functionalisation of the methionine residue of exenatide could be achieved in >95% conversion 
through treatment with 54 in combination with a selection of additives. As polypeptide 
architectures contain more readily oxidised functional groups than small molecule systems, an 
additional additive was required to prevent undesired oxidation of the polypeptide. Therefore, 
TEMPO was added to the reaction to act as a scavenger of ROS. Formic acid could aid in the 
prevention of any non-specific labelling through protonation of other nucleophilic residues such 
as lysine. Finally, thiourea was used and, although its role was not well-understood, appeared 
to accelerate the rate of the reaction dramatically. In the presence of thiourea the reaction 
reached completion in <2 minutes, compared to 30-60 minutes for the control reaction in the 
absence of thiourea.  






























































aYield determined using 1H NMR, using DMF as an internal standard.
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Pleasingly, the reaction could be carried out at micromolar concentrations without competing 
levels of oxidation and could form a single product 56 in excellent conversion. The high 
selectivity achieved was significant considering the myriad other nucleophilic residues present 
in the polypeptide and indicated the exquisite selectivity of the iodonium salt 54 for the 
thioether group of methionine. 
 
 
Scheme 41 Optimised conditions for the functionalisation of methionine within model polypeptide exenatide. Conversion 
determined by LCMS total ion count (TIC). Reaction carried out by Dr M. T. Taylor. 
Overall, the initial results demonstrated the excellent selectivity of the reaction, implied fast 
kinetics and operated at low concentrations and under aqueous conditions. As a result, 
development of this methionine-selective strategy could provide a biocompatible method for 
the alkylative functionalisation of methionine residues within polypeptides and proteins. 
 
2.3 Project aims 
As discussed in Section 1.3, methionine presents an interesting target for bioconjugation due to 
its low natural abundance and ancillary protein function. Currently, there are no alkylative 
strategies for the bioconjugation of methionine which can operate under biocompatible 
conditions. 
The goal of this project was to further optimise and develop a general platform for the alkylation 
of methionine using hypervalent iodine reagents. Building on the discovery and optimisation 
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of this reaction to a variety of polypeptide and protein substrates. Additionally, the aim was to 
synthesise a number of iodonium salts, varying the ester moiety (R), in order to transfer a range 
of functional payloads to the biomolecules of interest. 
 
Scheme 42 Schematic representation of methionine-selective bioconjugation using hypervalent iodine reagents.  
The introduction of a non-native diazo moiety using this technique also presented an 
opportunity for the development of subsequent bioorthogonal transformations at methionine 
residues. Hence, a final aim of this project was to explore the chemistry surrounding the b-
sulfonium a-diazoester motif, aiming to exploit its high reactivity to introduce additional 
exogenous functionality. The goal was to combine bioconjugation reactions and bioorthogonal 
transformations for the development of a general methionine-selective protein functionalisation 
platform. 
This project was carried out in collaboration with Dr M. T. Taylor, therefore due to the 
collaborative nature of this project, for clarity, all work undertaken is attributed by name in both 
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2.4 Results and discussion 
2.4.1 Optimisation of methionine bioconjugation and isolation of sulfonium products 
With initial optimised conditions in hand, attention was focused towards expanding the scope 
of polypeptide and protein substrates which could be efficiently and selectively labelled at 
methionine residues. While some polypeptide substrates showed promise for selective 
methionine labelling in mixed organic/aqueous solvent mixtures, successful reaction in fully 
aqueous conditions would be required to demonstrate a biocompatible approach.  
It was found that under completely aqueous conditions a number of polypeptide substrates 
could be functionalised in almost quantitative conversion (Scheme 43). These polypeptides 
represented small helical or unstructured polypeptides of molecular weight ranging from ~1.6-
4.2 kDa. In most of these cases, the use of formic acid, previously used to reduce non-specific 
labelling, was not required. Avoiding the use of acid was advantageous as it provided conditions 
which would prove more biocompatible with protein systems. 
Aviptadil, a 28-amino acid synthetic peptide, exerts anti-inflammatory and immunomodulatory 
effects and is used in the treatment of pulmonary hypertension and erectile disfunction.224 
Selective labelling of aviptadil could be achieved despite the presence of several nucleophilic 
residues within its structure, including lysine, histidine and serine. Selectivity over the 
nucleophilic residue tyrosine, not present in exenatide, was also demonstrated on this substrate. 
Tetracosactide, a 24-amino acid synthetic peptide approved for medical use, was also tolerated 
well in the reaction.225 
Teriparatide is the 34-amino acid, bioactive, N-terminal domain of parathyroid hormone and is 
used in the treatment of some forms of osteoporosis.226 The sequence contains two methionine 
residues and the secondary structure includes two alpha helices. Interestingly, excellent 
conversion to the doubly-functionalised product 59 could be achieved with high selectivity. No 
singly-modified product was observed, confirming that all surface exposed methionine residues 
could be labelled using this technique.  
The substrate GTP binding protein fragment Ga contains one methionine residue and one free 
cysteine residue. When subjected to the optimised reaction conditions by Dr M. T. Taylor, 
complete formation of the dimer was observed through disulfide bond formation at cysteine, 
with complete labelling of methionine residues. This represents an interesting example of 
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functionalisation in the presence of free cysteine residues, demonstrating complete selectivity 
for alkylation at methionine, with concomitant oxidation at cysteine. 
 
Scheme 43 Substrate scope of polypeptides for methionine-selective bioconjugation. Conversion determined via LCMS total 
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Attention was next focused on the optimisation of protein substrates in order to demonstrate 
further applicability of this methodology. Dr M. T. Taylor was able to establish that methionine 
could be functionalised selectively in three protein systems of molecular weight ranging from 
~6.6-14.2 kDa (Scheme 44). However, reactions for the formation of lactalbumin conjugate 61 
and ubiquitin conjugate 63 required mixed organic/aqueous solvent systems of 1:1 CH3CN:H2O 
and achieved a lower conversion to product of 84%. The labelling of these substrates in 100% 
H2O was attempted, varying reaction time and temperature, although unfortunately delivered 
significantly lower conversions to the desired products. Nevertheless, successful 
functionalisation of these protein substrates demonstrated the increased complexity which 
could be tolerated by the methionine bioconjugation reaction, including secondary structural 
elements such as b-strands and b-sheets. Additionally, both aprotinin and lactalbumin contain 
multiple disulfide bonds which were unreactive to the iodonium salt 54, demonstrating the high 
selectivity of this reagent for methionine. 
In the case of protein RNA-ase B, in which all methionine residues are buried within the folded 
protein structure, bioconjugation was unsuccessful. This lack of reactivity highlighted the 
inherent selectivity of the process for exposed methionine residues. The selectivity for exposed 
residues was also evident in the case of ubiquitin, in which the methionine residue is partially 
buried. The limited solvent exposure caused the rate of functionalisation to be retarded to the 
point that oxidation to the methionine sulfoxide became competitive. As a result, the labelling 
required deoxygenated conditions to achieve efficient conversion to sulfonium conjugate 63. 
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Scheme 44 Substrate scope of proteins for methionine-selective bioconjugation. Conversion determined via LCMS total ion 
count. Reactions conducted by Dr M. T. Taylor. a 0 °C. b 1:1 CH3CN:H2O. c 10 mM HCl. d 5 mM Formic acid. e H2O.          
f 20 °C. g Reaction carried out under N2, using N2-degassed solvent. 
 
2.4.2 Structural analysis of b-sulfonium a-diazoester conjugates 
It was envisaged that the selectivity of the methionine labelling could be probed through 
characterisation using tandem mass spectrometry (MS/MS). Purification of polypeptide 
sulfonium conjugates was required in order to carry out MS/MS analysis. Therefore, 
polypeptide-sulfonium conjugates 56-59 were isolated on a larger scale (~ 2 mg) using reverse 
phase semi-preparative HPLC. In the case of these substrates, the reaction proceeded in almost 
quantitative conversion. Therefore, isolation required only the separation of the sulfonium 
conjugate from by-products resulting from the consumption of the iodonium salt reagent and 
the additives such as thiourea. Yields of isolated products were determined by UV concentration 
analysis using A280 absorbance of chromophoric residues tyrosine and tryptophan. Polypeptides 
56-59 were isolated in yields ranging from 56-92% (Scheme 45). Isolation of these 
functionalised peptide scaffolds in synthetically useful yields demonstrates the stability of the 
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Scheme 45 Isolated yields for larger scale reactions with polypeptides 56-59. Yield determined by concentration analysis 
using A280 absorbance. 
MS/MS is a technique frequently used for sequence determination of peptides and proteins and 
for the identification of post-translational modifications.227 Charge-directed cleavages of 
peptidic bonds generate ions, described using Roepstorff nomenclature, which can be used to 
assign the sequence of a peptide or protein. Fragment ions retaining the positive charge on the 
N-terminus are termed a-, b- or c-type, while ions retaining the positive charge on the C-
terminus are termed x-, y- or z-type. These ions occur with differing probabilities, with b- and/or 
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Figure 3 Roepstorff nomenclature for the fragmentation ions formed through backbone cleavage of protonated peptides. 
Fragment ions retaining the positive charge on the N-terminus are termed a-, b- or c-type, ions retaining the positive charge 
on the C-terminus are termed x-, y- or z-type.228 
Purified sulfonium conjugates 56-59 were subjected to MS/MS analysis, carried out by Dr H. 
J. Lewis and Dr M. J. Edgeworth (AstraZeneca/MedImmune). Due to the relatively small size 
of the polypeptides, MS/MS analysis could be carried out on the intact modified polypeptide 
and did not require tryptic digestion. The MS/MS data for tetracosactide conjugate 57 is 
presented in Scheme 46. 
Diagnostic fragment ions c32+ and c42+ were observed, the difference of which was equal to the 
sum of the methionine residue plus the desired modification (Scheme 46). Therefore, 
methionine was confirmed as the site of labelling. In the case of all polypeptides 56-59, MS/MS 
data concluded that modification had taken place exclusively at methionine. Additional MS/MS 
























Scheme 46 MSMS analysis of tetracosactide conjugate 57. ETD and HCD fragmentation spectrum show the spectra resulting 
from two different ionisation techniques. The highlighted boxes in the table and the corresponding highlighted peaks in the 
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The secondary structure of peptides and proteins is often crucial to their biological function and 
activity. Therefore, circular dichroism (CD) spectra were obtained for purified polypeptide 
conjugates 56-59 to determine whether the secondary structure and folding had been perturbed 
by the modification. For aviptadil and tetracosactide conjugates 58 and 57, the secondary 
structure was less well-defined and changes in CD spectra were less apparent (see Section 
5.3.1). However, the retention of secondary structure was evident in the case of teriparatide 
conjugate 59 (Figure 4). Clear overlap of the spectra resulting from the modified and 
unmodified polypeptides provided evidence that the secondary structure was not significantly 
affected by modification at methionine residues. Pleasingly, negative bands could be observed 
for the two a-helices in the characteristic regions of 222 nm and 208 nm,229 confirming that the 
distinctive structure had been retained. This highlights the suitability of methionine as a target 
for bioconjugation. 
 
Figure 4 Circular dichroism spectra of teriparatide and modified teriparatide 59 in 5 mM pH 7.4 buffer  
Isolation of the protein sulfonium conjugate of ubiquitin 63 was attempted. However, in 
contrast to the isolation of the polypeptide substrates, reactions on a larger scale, did not go to 
completion, with significant quantities of starting protein ubiquitin remaining. Nevertheless, 
isolation of the crude reaction mixture was pursued. The small difference in mass between the 
modified and the unmodified protein was reflected in poor separation between species during 
HPLC purification. As such, separation proved extremely difficult. A cationic sulfonium 
moiety is formed through this alkylative strategy, hence it was envisaged that separation of 
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technique which separates compounds based on their differing affinity to an ionic stationary 
phase.  With the assistance of Dr N. Huguenin, Fast Protein Liquid Chromatography (FPLC) 
purification was carried out on the crude reaction mixture of ubiquitin conjugate 63. Isolation 
of pure material was achieved, with good separation from the ubiquitin protein using an ion 
exchange (IEX) column for FPLC (Section 5.3.1, Figure 39). As sodium chloride and 
ammonium acetate buffers were used for product elution, salts remained present in the isolated 
product sample and prevented CD analysis. Desalting of the sample was attempted but resulted 
in degradation of the conjugate. 
In contrast to the polypeptide sulfonium conjugates, MS/MS analysis could not be obtained for 
the larger protein substrates 61-63, despite continued efforts. Nonetheless, selectivity could be 
inferred from the previous polypeptide examples. 
 
2.4.3 Scope of iodonium salt transferring reagents 
Following the successful bioconjugation of several polypeptides and proteins, efforts focused 
on varying the functional payload which could be transferred to the biomolecule of interest. It 
was hypothesised that this could be achieved through variation of the ester group of the 
iodonium salt reagent. Starting from commercially available alcohols, reaction with 
bromoacetyl bromide 64 afforded the corresponding a-bromoacetates 65-69 in 56-98% yield 
(Scheme 47a). Reaction of 65-69 with N,N’-ditosylhydrazine 70 provided various a-
diazoacetates in 48-74% yield. Subsequent reaction with (2,4-difluorophenyl)-l3-iodanediyl 
acetate 76, in the presence of a Lewis acid furnished the desired iodonium salts 77-85 in 60-
87% yield. 
Iodonium salts were synthesised incorporating a number of different functional groups 
including alkenes (78, 79), alkynes (80, 82) or norbornene moieties (84) which provided the 
opportunity for subsequent bioorthogonal transformations8 (Scheme 47b). An iodonium salt 
was synthesised incorporating a myristyl chain (81) which, when introduced into proteins, 
could mimic a post-translational modification.4 Additionally, a fluorescein-derived iodonium 
salt (85) was synthesised by Dr M. T. Taylor which could potentially be used as a valuable 
reagent in cellular imaging.5 
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These iodonium salts demonstrated limited stability over prolonged periods at room 
temperature, however were stable for >3 months when stored as a solid, under air at -20 °C. All 
iodonium salts required minimal purification, requiring only trituration and washing of the 
desired product, providing a facile isolation procedure. Iodonium salts 54 and 77 could be 
isolated in the solid state, yielding a yellow solid which could subsequently be handled with 
ease. All other iodonium salts resulting from modification of the ester moiety were isolated as 
a gum but could be readily used without complex purification. The straightforward synthesis 
and purification of these iodonium salts, alongside their desirable stability, provides a strategy 
for polypeptide and protein modification which may easily be tailored to incorporate numerous 
functional groups. 
 
Scheme 47 a) General scheme outlining the synthesis of iodonium salt derivatives altering the ester group, R. b) Scope of 
iodonium salts. c Synthesised directly from a-diazoacetophenone. Synthesised by Dr M. T. Taylor. 
The synthesised iodonium salt reagents were tested in the methionine-selective labelling of 
exenatide using the previously optimised reaction conditions (Scheme 48). Many functional 
groups were tolerated well by the reaction, achieving quantitative conversion for the synthesis 
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cleanly, although the reaction did not reach completion, with 10% of starting material exenatide 
remaining. Phenyl ketone conjugate 92 and fluorescein conjugate 94 could also be formed, 
albeit with lower conversion.  
 
Scheme 48 Reaction of exenatide with various iodonium salts to form exenatide-sulfonium conjugates bearing a range of 
functional payloads. Conversion determined via LCMS total ion count. Reaction carried out by Dr M. T. Taylor. a H2O. b 
1:1 CH3CN:H2O. c 5 mM Formic acid. 
 
2.4.4 Stability studies of methionine sulfonium conjugates 
While sulfonium species reported by Deming demonstrated excellent stability,187 analogous 
sulfonium species formed through the reaction of CNBr with methionine are known to undergo 
backbone cleavage (see Section 1.3). It was therefore important to carry out stability studies of 
novel b-sulfonium a-diazoesters to determine the half-life of these species. 
Initially, the stability of the exenatide conjugate bearing an ethyl ester, 56, was investigated 
over multiple hours at room temperature, in H2O (Figure 5). Pleasingly, the sulfonium conjugate 
exhibited a half-life of approximately 96 hours, similar to that of maleimide-cysteine conjugates 
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Figure 5 Stability study of exenatide conjugate 56 in H2O at room temperature. t = 0 hours begins after storage of 56 for 24 
hours. Degradation occurs predominantly via backbone hydrolysis. 
Degradation of the sulfonium conjugate was predominantly through a ‘cyanogen bromide-type’ 
cleavage of the peptide backbone, via displacement of neutral thioether by the proximal 
carbonyl group and subsequent hydrolysis to form homoserine lactone and a corresponding 
amine peptide fragment (Scheme 49).  
 
Scheme 49 Degradation of exenatide conjugate 56 over time, in H2O at room temperature, predominantly occurs via 
backbone hydrolysis 
An analogous stability study was carried out on the exenatide sulfonium conjugate 86 bearing 
a cyclohexyl ester (Figure 6). Interestingly, this species showed an improved stability profile, 
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approximately 140 hours. This suggests that tailoring the structure of the ester payload may 
enable the stability of resulting conjugates to be modulated.  
 
 
Figure 6 Stability study of exenatide conjugate 86 in H2O at room temperature 
Additional stability studies were carried out by Dr M. T. Taylor in order to examine the 
behaviour of the diazo sulfonium conjugates in a variety of aqueous media. A solution of 
propargyl conjugate 91 was monitored at room temperature in H2O, pH 3 formic acid or pH 7.4 
phosphate buffer over a number of hours (Figure 7). In the case of the propargyl ester species, 
the stability was evidently poorer than the cyclohexyl or ethyl ester analogues, with a half-life 
of <50 hours at room temperature. The nature of the aqueous media had a dramatic effect on 
sulfonium stability, with the conjugate proving significantly less stable in basic phosphate 
buffer compared to water or acidic conditions. In the same way as 56 and 86, 91 degraded 
through peptide backbone hydrolysis. However, an additional degradation pathway was 
observed for 91; cleavage of the sulfonium label to yield the initial exenatide polypeptide with 
unmodified methionine residue.  
Dr M. T. Taylor also observed partial stability of sulfonium conjugate 91 over 8 hours in the 
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occurred was the reduction of the diazo moiety to the hydrazone. Although technically a 
degradative pathway, the label remained intact, and no cleavage was observed. While this study 
does indicate the instability of the sulfonium species to glutathione, it is notable that the payload 
is not cleaved from the substrate, an important factor for functionalised protein products. 
 
 
Figure 7 Stability profile of 91.  For each experiment, 91 (100 µM) was allowed to stand in solution at room temperature 
(21°C) over the time course and analyzed by LCMS.  91 degrades via a mixture of peptide backbone hydrolysis and label 
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2.4.5 Mass spectral characteristics of b-sulfonium a-diazoester-containing peptide and 
protein conjugates 
A well-established phenomenon within mass spectrometry is that upon ionisation, alkylated 
methionine residues can fragment at the Cg-SR2 bond to produce an [M-(SR2-H)+H]+ ion, in 
addition to the formation of the parent molecular ion [M]+ (Scheme 50).188,232,233 This 
fragmentation pattern is unique to methionine and, therefore, it may be used as a key diagnostic 
tool to confirm functionalisation at methionine residues.  
 
Scheme 50 Diagnostic fragmentation of alkylated methionine derivatives upon ionisation during mass spectrometry 
Iminolactone 95 is an intermediate in the cyanogen bromide-mediated backbone cleavage of 
alkylated methionine derivatives (Scheme 51).189,190 This iminolactone is identical in mass to 
the diagnostic fragment ion observed in the mass spectrum of alkylated methionine derivatives. 
These iminolactone species are readily hydrolysed under acidic conditions to form the 
corresponding homoserine lactone peptide and amino peptide. Therefore, it is not expected that 
this iminolactone species would be observed by mass spectrometry. However, in order to 
unambiguously assign the fragment ion observed to the diagnostic fragmentation and not the 
iminolactone degradation product, the origin of this molecular ion was further explored.  
 
Scheme 51 Cyanogen bromide-mediated peptide backbone cleavage. The intermediate iminolactone species has an identical 
mass to the fragment ion observed upon mass spectral ionisation. 
In order to confirm that the b-sulfonium a-diazoester species synthesised displayed the 
diagnostic fragmentation pattern, isolation and characterisation of dipeptide model system 51 
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isolated as a single pure product in >90% purity. 52 clearly displayed the diagnostic fragment 
ion, [M-(MeSR)+H]+ (m/z 159.0760) in addition to the molecular ion, [M]+ (m/z 319.1061). 
This demonstrated that the fragment was created upon ionisation in the mass spectrometer and 
was not the result of CNBr-type degradation of the isolated sample (Figure 8). 
 
Figure 8 Mass spectrum of MetGly sulfonium conjugate 52, clearly showing both the molecular ion [M]+ and the diagnostic 
fragment ion [M-(160)+H]+.  
Next, the mass traces of two different exenatide sulfonium species, 56 and 90, were considered, 
bearing an ethyl diazoester and a myristyl diazoester respectively (Figure 9). Due to the non-
polar, aliphatic chain, 90 eluted at a much later retention time (~3.2 min) compared to 56 (~2.2 
min). However, an identical fragment mass was observed (e.g. M = 1035.5) in both mass 
chromatograms. Were these ions a result of cyanogen bromide-type degradation, the 
iminolactone side-product would be identical and would appear at the same retention time for 
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Figure 9 Comparison between the mass spectra of exenatide conjugates 56 and 90 bearing differing ester groups. As a result 
of the ester groups, the two sulfonium conjugates elute from the LCMS at different retention times. However, both display 
identical fragmentation patterns. 
In an attempt to observe an authentic spectrum of the putative iminolactone intermediate 95, 
the polypeptide aviptadil was stirred with cyanogen bromide under acidic conditions. The 
iminolactone was not observed, with only the corresponding hydrolysed peptidic fragments 96 
and 97 detected clearly by LCMS at different retention times (homoserine lactone 96 and amine 
fragment 97, Scheme 52). The absence of the iminolactone indicated the instability of this 
intermediate to hydrolysis and hence provided further evidence that the iminolactone was not 
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Scheme 52 Cyanogen bromide-mediated cleavage of polypeptide aviptadil, forming homoserine lactone peptide 96 and 
amine peptide 97. No iminolactone intermediate could be observed. 
 
2.4.6 Exploiting the reactivity of the diazo motif in b-sulfonium a-diazoester conjugates 
The novel alkylative bioconjugation reaction developed herein introduces a non-native, high 
energy diazo motif. This newly introduced, protein-bound bioorthogonal handle presents an 
opportunity for further exploitation of resulting conjugates in subsequent transformations. 
Diazo motifs are known to display a diverse reactivity manifold, with different reagents and 
catalysts able to induce distinct chemical transformations (Figure 10).  
Nucleophilic attack of phosphine reagents at the terminal nitrogen atom of diazo species is 
precedented, inducing Staudinger-like formation of a phosphine-imine bond (Figure 10a).234 
Additionally, thermal or photochemical generation of metal carbenoid species using transition 
metals has been extensively studied (Figure 10b).235 Photochemical reactions of diazo species 
are also well known, through photoinitiated formation of carbenes236 or carbon-centred radicals 
(Figure 10c)237,238 which are subsequently employed in various transformations. As such, it was 
envisaged that the b-sulfonium a-diazoester would display analogous reactivity to that of 
related diazo species, allowing further diversification of protein conjugates. 
Investigation into Staudinger-inspired reactivity of the b-sulfonium a-diazoester conjugates 
and the visible light-induced formation of carbon-centred radicals is described herein. However, 
efforts to explore the formation and reactivity of metal carbenoids derived from the b-sulfonium 
a-diazoester conjugate are ongoing within the group and are beyond the scope of this report. 
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Figure 10 Distinct modes of reactivity of diazo functional groups through the use of varied reagents and catalysts 
 
2.4.6.1 Phosphine-promoted cleavage of methionine label 
Reversible modification of polypeptides through triggered release of payloads is advantageous 
for many biological applications, for example the release of therapeutic peptides from a carrier 
or recovery of affinity purified peptides for proteomic analysis.239,240 As a potential tool for the 
triggered release of polypeptides, the reversibility of the methionine bioconjugation was 
investigated. As previously discussed, Deming reported the general, triggered reversal of their 
methionine alkylation strategy using 2-mercaptopyridine as a nucleophilic cleavage reagent187 
(Section 1.3). Inspired by this, we turned our attention to investigating whether successful 
cleavage of the diazoester moiety could be achieved.  
Dr M. T. Taylor screened a number of phosphine reagents under varying reaction conditions in 
the hope of achieving reversal of the labelling with Staudinger-inspired reactivity. It was 
discovered that nucleophilic phosphine reagents could attack the electrophilic nitrogen atom of 
the diazo motif in a similar fashion to the Staudinger reaction, forming a phosphine-imine bond. 
This could be followed by a second molecule of the phosphine reagent displacing the sulfonium 
species, regenerating the neutral thioether of exenatide and releasing cationic phosphorus 
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methionine label were found to be triphenyl phosphine or tris(2-carboxyethyl)phosphine 
(TCEP), achieving quantitative conversion over 30 minutes. 
 
Scheme 53 Triggered cleavage of methionine diazoester label using phosphine reagents (e.g. PPh3 or TCEP), reforming the 
free polypeptide exenatide. Conditions developed by Dr M. T. Taylor. 
With optimised conditions in hand, the reversal of the labelling was investigated on the scope 
of polypeptide substrates. In all cases, >95% conversion to unmodified polypeptide was 
observed in 30 minutes (Scheme 54). For the teriparatide bis-sulfonium conjugate 59, cleavage 
of the label was achieved at both methionine residues, with no evidence of the singly-cleaved 
product. In order for the release of the label to occur cleanly, purified sulfonium polypeptide 
product must be used in the reaction. When the reaction was attempted on the crude sulfonium 
species, unmodified product was observed in much lower conversion and the reaction profile 
proved complex. However, Dr M. T. Taylor demonstrated that the label of unpurified protein 
sulfonium conjugate ubiquitin 63 could be cleaved. Upon treatment with TCEP, 63 was reverted 
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Scheme 54 Triggered reversal of polypeptide conjugates of tetracosactide, aviptadil and teriparatide, regenerating the parent 
polypeptide with free methionine residue 
Interestingly, on consideration of the mass spectrum of aviptadil conjugate 58, it was observed 
that, upon hydrolysis, the characteristic [M-(MeSR)+H]+ fragment ion disappeared completely 
from the mass spectrum (Scheme 55). This observation provided further evidence to 
corroborate the diagnostic fragmentation of the Cg-SR2 bond, discussed in Section 2.4.5. If the 
ion were a result of peptide backbone cleavage, the iminolactone would be irreversibly 
hydrolysed to form two smaller peptidic fragments which would remain unaffected by the 
reduction and would be visible in the mass spectrum. Instead, complete disappearance of the 
ion was observed, with reformation of the parent polypeptide, again confirming the nature of 
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Scheme 55 Mass traces of aviptadil conjugate 58, clearly showing the diagnostic fragment ions (M = 820.2, 1093.4, 1639.5), 
and the crude reaction of 58 with TCEP, cleaving the sulfonium label and regenerating free aviptadil. No evidence of the 
fragment ions could be observed after the reversal of the labelling. 
 
2.4.6.2 Photochemical reduction of a-sulfonium diazoesters 
Improved stability of the sulfonium conjugates was desired as it would enable more facile 
handling of resulting functionalised species and facilitate the use of these conjugates in 
subsequent bioorthogonal transformations and its use in biological applications. Therefore, 
efforts focused on improving the stability of b-sulfonium a-diazoester conjugates. 
The reduction of the diazo moiety in the sulfonium products, to a methylene unit, would form 
the corresponding trialkylsulfonium species. It was hypothesised that trialkyl sulfonium 
derivatives of methionine would likely exhibit improved stability, analogous to those reported 
in previous methionine alkylation strategies (see Section 1.3). 
A screen of reductive conditions was carried out by Dr M. T. Taylor (Scheme 56). Hantzsch 
ester, 102,241 triaryl phosphine 103242 and glutathione 104243 were screened on a small molecule 
diazosulfonium species 99 in DMF, at room temperature. While in the case of Hantzsch ester 
102 an appreciable amount of the reduced product 101 was observed, under all the other 
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Scheme 56 a) Scheme for the screening of reduction conditions for diazosulfonium species 99. b) Table for the screening of 
different reducing agents. c) Reducing agents used in the screening. Reactions carried out by Dr M. T. Taylor. 
It was proposed that instead of a 2-electron reduction procedure, a single-electron reduction 
could provide a mild and selective method for formation of 101. Radical reactions of a-diazo 
compounds have been reported, resulting in the elimination of nitrogen and the formation of 
carbon-centred radicals.237,238 Horner and co-workers demonstrated that hydroxyalkyl radicals 
105 can react with a-diazoketones 106, causing overall hydrogen atom transfer and loss of 
dinitrogen, forming carbon-centred radicals 107 (Scheme 57a).238 They proposed that initial 
homolytic addition took place at the terminal nitrogen atom of the a-diazo moiety. It was 
therefore postulated that an analogous single electron reduction could be developed at the 
terminal nitrogen of the diazo moiety. Through a similar hydrogen atom transfer and nitrogen 
extrusion pathway, a putative carbon-centred radical may be formed 108 (Scheme 57b). 
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Scheme 57 a) Reaction of a-diazoketones with hydroxylalkyl radicals to form carbon-centred radicals. b) Schematic of the 
proposed reactivity of diazosulfonium species under single-electron reduction conditions 
It was envisaged that this single electron reduction could be achieved using a photocatalytic 
approach. Photocatalysis relies on the use of visible light to excite a photocatalyst, typically a 
metal complex or organic species. In its excited state, the photocatalyst has an increased 
propensity to act as both an electron donor and acceptor, through either a reductive or oxidative 
quenching cycle (Scheme 58). Therefore, visible light photocatalysis offers access to both a 
powerfully oxidising and reducing species under mild conditions.  
 
Scheme 58 Oxidative and reductive quenching cycle of Ru(bpy)3. Upon excitation with visible light, the excited 
photocatalyst can proceed by either oxidative or reductive quenching. In the oxidative quenching cycle, the excited 
photocatalyst acts as a single electron reductant of an electron acceptor, A. In the reductive quenching cycle, the excited 
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Screening of various photocatalytic conditions was carried out by Dr M. T. Taylor under visible 
light irradiation (Table 3). A hydrogen atom transfer donor (HAT donor) would be required in 
order to trap the proposed radical forming as a result of single-electron reduction. 1,4-
cyclohexadiene 109 and Hantzsch ester 102 are both known HAT sources245,246 and were the 
two HAT sources used for all of the screening reactions.  A range of photocatalysts were 
screened by Dr M. T. Taylor, with reduction potentials in the range -0.81 to -1.73 eV.244 
Conversion to the reduced sulfonium product 101 correlated with the reduction potentials of 
the photocatalysts screened (Table 3, Entries 1-4), with the most strongly reducing 
photocatalyst, Ir(ppy)3, achieving the highest conversion to product (Table 3, Entry 4). 
Additional screening was carried out by Dr M. T. Taylor and it was found that >95% conversion 
to reduction product 101 could be achieved using Hantzsch ester 102 as the HAT source (Entry 
5, Table 3). Pleasingly, using 1:1 CH3CN:H2O as the solvent provided a more biocompatible 
reaction media, without decreasing the conversion to the desired product. 
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Table 3 Optimisation of reduction procedure for diazosulfonium species using various photocatalysts. All reactions carried 
out by Dr M. T. Taylor. 
 
With optimised conditions in hand for the model sulfonium system, the aim was to translate the 
photochemical reduction to polypeptide and protein systems. It was found that the optimised 
conditions were applicable to exenatide sulfonium conjugate 86, with >95% conversion 
achieved in 45 minutes (Scheme 59). The reduction was carried out on crude sulfonium 
conjugate 86 and did not require purification of the diazosulfonium species prior to reduction. 
As a result, the labelling and photoreduction could be carried out in a two-step one-pot 
procedure to rapidly furnish the desired trialkylsulfonium derivative 110 from the native 
polypeptide. Remarkably, no other functionality present in exenatide was reduced using this 
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Scheme 59 Optimised conditions for the photochemical reduction of sulfonium diazoesters 
Following the reduction of the diazo sulfonium species, investigation into the stability of the 
reduced trialkylsulfonium species was carried out. The aim was to observe the effect of the 
reduction on the stability of the resulting products in comparison to the diazosulfonium 
analogues. Exenatide trialkylsulfonium conjugate 110 proved indefinitely stable towards 




Figure 11 Stability study of exenatide trialkylsulfonium species 110 towards glutathione. 110 showed no signs of 
degradation over multiple hours. 
Additional stability studies were carried out by Dr M. T. Taylor for glucagon trialkylsulfonium 
conjugate 111 in a variety of aqueous media (Figure 12). In all cases, degradation occurred 




















































Stability of 110 in GSH (1 mM)
Development of selective methionine bioconjugation 
 71 




Figure 12 Stability profile of 111. In all instances, degradation of 111 occurs via the hydrolysis of the ester moiety to yield a 
free carboxylate. Studies carried out by Dr M. T. Taylor. 
Dr M. T. Taylor was also able to observe the stabilities of trialkylsulfonium conjugates of the 
polypeptide glucagon with two different ester moieties 111 and 113 (Figure 13). The cyclohexyl 
ester exhibited a significantly higher stability than the corresponding hexynyl ester, with a half-
life of approximately 90 hours compared to only 10 hours for the hexynyl conjugate. In both 
cases decomposition occurred via ester hydrolysis, to yield the carboxylate. It was hypothesised 
that the increased steric hindrance of the cyclohexyl ester could disfavour ester hydrolysis, 
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Figure 13 Comparative stability studies of glucagon trialkylsulfonium conjugates 111 and 113 observing the effect of the 
ester group on the stability of the species in pH 7.4 buffer. Reactions carried out by Dr M. T. Taylor. 
 
2.4.6.3 A photoredox-mediated bioorthogonal transformation at b-sulfonium a-diazoesters 
Following the development of a mild and selective photochemical reduction of the b-sulfonium 
a-diazoester moiety, it was hoped that this highly reactive diazo motif could be exploited as a 
platform for subsequent bioorthogonal transformations to introduce additional functionality of 
biological relevance. It had been demonstrated previously that Hantzsch esters could be used 
as hydrogen atom donors247 in the photoredox-mediated reduction of sulfonium diazoesters, 
proposed to be occurring via a putative radical intermediate 118 (Section 2.4.6.2). It was 
hypothesised that, by analogy, the use of a C4-substituted Hantzsch ester 119 (Scheme 60) and 
a photocatalyst would enable the generation of a benzyl radical 121 which may be formally 
transferred to the a-position of the diazoester 116 through coupling with putative carbon-
centred radical 118. If successful, modification of the diazo moiety could be achieved, 
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Scheme 60 Schematic design plan for secondary functionalisation of the diazosulfonium conjugate. Left; photocatalytic 
oxidation of Hantzsch ester to yield radical cation as a HAT source forming reduction product 117. Right; C-4 substituted 
Hantzsch esters as a source of a benzyl radical, a hypothesised radical-functionalisation to form 123. 
Similar transformations have been reported for the use of C4-substituted Hantzsch esters as 
alkyl donors248 using either a Lewis acid,249 or photoredox catalysis.250 Hantzsch esters 
substituted with a benzyl group have been shown to generate a benzyl radical, which can react 
through radical addition into imines or through coupling with other carbon-centred radicals to 
form benzyl-substituted products (Scheme 61a, b).248 Generation of the alkyl radical is reported 
to require a photocatalyst due to the substituted Hantzsch ester likely absorbing at a wavelength 
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Scheme 61 Literature precedence for substituted Hantzsch ester reagents acting as alkyl donors under Lewis acidic 
conditions or photoredox catalysis. 
Initial efforts for the development of this photoredox benzylation process were carried out by 
Dr M. T. Taylor on model polypeptide sulfonium conjugate exenatide 86, using 1-phenylethyl 
substituted Hanztsch ester 124. The highest conversion to product achieved from the initial 
screening was 38% (Entry 1, Table 4), through the use of a Ru(bpy)3Cl2 photocatalyst and a 
strong oxidant potassium persulfate. The main deleterious pathway was discovered to be the 
formation of the reduction product 110, assumed to be formed through abstraction of a 
hydrogen atom instead of the proposed radical-radical coupling. Cleavage of the methionine 
label, regenerating free exenatide was also observed, alongside an oxidative side-product 126, 
resulting from subsequent oxidation of free methionine to the sulfoxide. It was noted that a 
more powerful 40 W Kessil light bulb proved more efficient in the reaction compared to a 30 
W bulb, allowing a shorter reaction time. This initial hit provided a promising preliminary result 
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Table 4 Preliminary optimisation of photochemical benzylation. All reactions carried out by Dr M. T. Taylor. 
 
 
Following the identification of an initial hit using a Ru(bpy)3Cl2 photocatalyst and an oxidant 
K2S2O8, capable of single electron oxidation, it was proposed that modification of the Hantzsch 
ester reagents may allow modulation of the benzylation reaction. Therefore, the synthesis of 
alternative Hantzsch esters which would form more stabilised secondary or tertiary benzyl 
radical species was investigated. Incorporation of a diphenyl substituent proved successful, with 
Hantzsch ester 128 isolated in 37% yield from diphenylacetaldehyde and methyl-3-
aminocrotonate 127 (Scheme 62). Unfortunately, synthesis of a Hantzsch ester bearing a 
dimethylphenyl substituent 129 was unsuccessful. Using 2-methyl-2-phenylpropanal and 
methyl-3-aminocrotonate 127, the corresponding Hantzsch ester 129 could be formed under the 
reaction conditions but was unstable to purification. Facile dealkylation was observed to occur, 
forming the aromatised Hantzsch pyridine 133. After extensive efforts, only the Hantzsch 
pyridine 133 could be isolated as a result of oxidative aromatisation and dealkylation. The same 
fate was observed for Hantzsch ester 130, with a quaternary centre. Similarly, Hantzsch esters 
131 and 132, bearing tertiary carbon substituents, could not be synthesised, presumably due to 
similar instability of the products. Correlations could be drawn between the stability of the 
radical formed and the tendency for aromatisation to the Hantzsch pyridine 133. Additionally, 
C4-substituted Hantzsch esters are known to adopt a higher energy, ‘puckered’ flat boat 
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a)Light placed at 5 cm distance from reaction vessel. b)Reaction outcome determined by TIC.
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substituted Hantzsch esters, bearing quaternary substituted carbon centres, may be negatively 
affecting the stability through further destabilisation of the flat boat conformation. 
 
Scheme 62 Scheme for the synthesis of Hantzsch ester derivatives 128-132 
Benzhydryl Hantzsch ester 128 was screened extensively under various photoredox benzylation 
conditions, although no evidence of benzylation product was observed by LCMS analysis. The 
predominant product in every case was the reduced species 110 and, in many cases, conversion 
was low, with significant quantities of initial diazosulfonium conjugate 86 remaining. As a 
result, benzylation reaction using 128 was not pursued further. 
Another factor which was investigated during the development of the photoredox benzylation 
reaction was the solubility of the C4-substituted Hantzsch ester reagents. It was observed that 
the reaction mixture was heterogeneous, with the substituted Hantzsch ester seemingly 
insoluble in the reaction solvent. As a result, an analogous Hantzsch ester 136 was synthesised 
by Dr M. T. Taylor which incorporated glycol ether groups to aid aqueous solubility (Scheme 
63). 136 could be synthesised from the corresponding aldehyde, 2-phenylpropanal 134, 2-
methoxyethylacetoacetate 135 and ammonium acetate in 55% yield. 
 
Scheme 63 Synthesis of C4-substituted Hantzsch ester incoroporating glycol groups to improve aqueous solubility. Reaction 
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Pleasingly, Hantzsch ester 136 displayed improved aqueous solubility and was hence employed 
by Dr M. T. Taylor under the photoredox alkylation conditions. A number of different 
conditions were screened, altering the photocatalyst loading and the amount of oxidant, 
improving slightly on the previous result of 38% conversion (Entry 1, Table 4). The highest 
conversion achieved was through lowering the concentration of Hantzsch ester 136 to 20 mM 
and using 1 mM photocatalyst (Scheme 64). In this case, the main competing reaction pathway 
was now cleavage of the methionine label, regenerating free exenatide in 23% conversion. 
Reduction of the diazo moiety to the methylene unit was still observed as a competing pathway, 
forming reduction product 110 in 10% conversion, although no oxidised peptide 126 was 
observed.  
 
Scheme 64 Improved conditions for alkylation of exenatide conjugate using Hantzsch ester 136 with improved solubility 
Following this positive result, improving the solubility of the C4-substituted Hantzsch ester 
reagent, the nature of the benzyl radical was modified to investigate the effect of both steric and 
electronic parameters. Benzyl Hantzsch ester 137 was synthesised by Dr M. T. Taylor and was 
subjected to visible light irradiation with sulfonium conjugate 86 in the presence of a 
photocatalyst and oxidant. Pleasingly, 72% conversion to benzylated product 138 was achieved, 
with 28% of the reduced product 110 also observed (Scheme 65). With this promising hit, it 
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Scheme 65 Reaction of benzyl Hantzsch ester 137 under photoredox alkylation conditions, yielding C-benzylation product 
138 in a promising 72% conversion. Reaction carried out by Dr M. T. Taylor. 
To this end, a number of C4-substituted Hantzsch esters were synthesised, with systematic 
variance of the substituents on the benzyl group. Firstly, synthesis of the 2-phenylacetaldehyde 
derivatives was carried out from the corresponding carboxylic acid, through a two-step LiAlH4 
reduction to the alcohol and subsequent oxidation to the aldehyde using Dess-Martin 
Periodinane (DMP). For some substrates, the aldehyde could be synthesised directly from the 
commercially available alcohol, using DMP oxidation (Scheme 66). 
 
Scheme 66 Synthesis of a variety of aldehydes, precursors to benzyl substituted Hantzsch esters. aSynthesised directly from 
alcohol, bSynthesised from acid, cDue to lower purity aldehyde used directly in following step. 
With a number of aldehydes in hand, various Hantzsch esters could be synthesised, albeit in 
generally poor yields (145-150, 18-38%, Scheme 67). In a similar manner to the tertiary and 
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due to the instability of the products to dealkylation and aromatisation. As such, the oxidised 
Hantzsch pyridine was also isolated in significant quantities from the reactions. Unfortunately, 
iodo-substituted Hantzsch ester 151 could not be isolated as purification proved incredibly 
difficult and predominantly Hantzsch pyridine was isolated. 
 
Scheme 67 Synthesis of various benzyl substituted Hantzsch esters bearing glycol groups for improved aqueous solubility. 
With a range of benzyl substituted Hantzsch esters in hand, incorporating both electron 
withdrawing and electron donating substituents, photoredox conditions could be screened in 
the hope of improving the conversion to C-benzylation product. Each Hantzsch ester was 
screened under multiple reaction conditions, varying both the concentration of Hantzsch ester 
and photocatalyst loading. The aim of the screening was to reduce the amount of competing 
reduction product, 110, formed and hence gain a high ratio of benzylation:reduction. 
It was observed that para-substituted benzyl Hantzsch esters gave poor conversion to product 
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tolerated in the reaction. para-Bromo substituted Hantzsch ester 147 achieved up to 20% 
conversion to product, though undesired formation of the reduction product 110 was the 
predominant side reaction (Entries 4 & 5, Table 5). meta-Substituted Hantzsch esters, tested by 
Dr M. T. Taylor (Entries 7 & 8, Table 5), were not tolerated in the reaction, resulting in complete 
decomposition of the polypeptide scaffold. 
Table 5 Optimisation of photochemical alkylation of sulfonium diazo conjugate through systematic variance of the 
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ortho-Substituted Hantzsch esters were next investigated. An electron withdrawing 
trifluoromethyl substituent in Hantzsch ester 150 gave poor conversion to benzylation product, 
despite a reasonable ratio of benzylation to reduction of 3:1 (Entry 1, Table 6). Reaction with 
the ortho-fluoro-substituted Hantzsch ester 154 proved capricious, with results ranging from 
complete decomposition to 45% conversion to product (Entries 2 & 3, Table 6). ortho-bromo 
Hantzsch ester 149 gave poor conversion to benzylation product, with the reduction product 
110 predominating (Entry 4, Table 6). The ortho-methoxy substituted Hantzsch ester 156 gave 
reasonable conversion to product in the range of 51-54% (Entries 5 & 6, Table 6) but 
demonstrated a poor benzylation to reduction ratio of only 1.5:1. Given the increased reactivity 
observed for the ortho-methoxy and ortho-trifluoromethyl Hantzsch esters compared to their 
para-substituted analogues, it was deduced that steric effects were more strongly influencing 
over the benzylation reaction than electronic effects. 
ortho-Methyl and mesityl Hantzsch esters 155 and 148 were observed as the most effective for 
benzylation (Entries 7-10, Table 6). Through increasing the concentration of Hantzsch ester 
from 20 mM to 30 mM, mesityl Hantzsch ester 148 gave good conversion to benzylation 
product, with a benzylation to reduction ratio of 8:1 (Entry 8, Table 6). Under the same reaction 
conditions, ortho-methyl Hantzsch ester 155 gave an excellent 86% conversion to product, with 
a benzylation to reduction ratio of 12:1 (Entry 10, Table 6), providing the best result from this 
screening. 
It was reasoned that increased steric hindrance for the ortho-methyl and mesityl Hantzsch esters 
155 and 148 formed a more stable, persistent radical which precluded deleterious side-reactions 
such as homocoupling of the resultant benzyl radical. It may be the case that the steric hindrance 
of the mesityl Hantzsch ester was too large, slightly inhibiting the desired radical-radical 
coupling, providing an optimal result for the slightly less hindered ortho-methyl Hantzsch ester. 
  
Development of selective methionine bioconjugation  
 82 
Table 6 Optimisation of photochemical alkylation of sulfonium diazo conjugate through systematic variance of the 
substituents on the benzyl transferring group. Reactions carried out by Dr M. T. Taylor are denoted in the table. 
 
 
With optimised conditions for the benzylation of the diazosulfonium species in hand, it was 
proposed that a derivative of the C4-substituted Hantzsch ester could be synthesised bearing a 
functional payload. If successfully implemented in the photoredox benzylation reaction, the 
transfer of a biologically relevant functional group would be achieved, using the 
diazosulfonium species as a platform for bioorthogonal functionalisation. The small-molecule 
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binding to the proteins avidin and streptavidin.252 As a result, the introduction of biotin probes 
to biomolecules, using bioorthogonal or bioconjugation techniques, is relatively routine.4 It was 
proposed that the introduction of biotin using this photoredox benzylation would provide a 
useful proof-of-principle result for the transfer of biologically relevant functionality. 
A C4-substituted Hantzsch ester was designed bearing a biotin probe (157, Figure 14). Key 
structural features from the benzyl Hantzsch ester optimisation were incorporated in the hope 
of maintaining the desired reactivity, namely, the glycol ester groups for improved aqueous 
solubility and the ortho-methyl group on the benzyl substituent. As it had been established that 
methyl substituents on the benzyl ring were tolerated, an alkyl linker to the payload was also 
designed. A retrosynthetic analysis of 157 was proposed, incorporating the biotin payload as 
the final step of the synthesis from key intermediate 158 using activated ester 159. 158 could 
be synthesised in the same manner as the benzyl C4-substituted Hantzsch esters, from the 
corresponding aldehyde, 160, 2-methoxyethyl acetoacetate and ammonium acetate. 
 
Figure 14 Design of Hanztsch ester bearing functional payload (biotin) and retrosynthetic analysis 
The synthesis of Hantzsch ester 157 bearing biotin as a functional payload was synthesised in 
collaboration with Dr C. He from commercially available 5-bromo-2-iodotoluene 161 (Scheme 
68). Alcohol 162 was synthesised in 22% yield over 5 steps. 162 could then be oxidised to the 
corresponding aldehyde 163 using Dess-Martin periodinane, yielding the key aldehyde 
intermediate. Aldehyde 163 was subjected to the standard conditions used previously for the 
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protecting group, affording 158. Final incorporation of the biotin payload was achieved through 
reaction with activated ester 159 to deliver the final compound, 157, in 20% yield over 4 steps. 
 
Scheme 68 Synthesis of biotin Hantzsch ester 157. *Carried out by Dr C. He.  
The Hantzsch ester bearing the biotin functional handle 157 was subsequently screened in the 
benzylation reaction with exenatide sulfonium conjugate 86. In all cases, the reaction profile 
was complex, preventing quantitative determination of resulting products. Therefore, a 
qualitative determination of the reaction outcome was recorded by LCMS, determining the 
major and minor products observed. Unfortunately, transfer of the benzyl radical with appended 
biotin payload could not be observed. The predominant product observed under all conditions 
screened was the reduced species 110 (Entries 1-3, Table 7). Interestingly, under the standard 
conditions screened in the reaction, the bibenzyl species 165 was observed in all cases. This 
observation indicates the likely formation of the benzyl radical and suggests that radical 
formation was not the limiting factor in the formation of alkylation product 166. Control 
reactions (Entries 4-6, Table 7) showed that in the absence of the oxidant the bibenzyl species 
could be observed, but only on increasing the reaction time to 20 minutes. Interestingly, the 
bibenzyl species could also be observed in the absence of the photocatalyst. As the Hantzsch 
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hydrogen atom transfer is much more facile compared to transfer of the larger, biotin-derived 
benzyl radical, causing the reduction product to form preferentially.  
Table 7 Attempted alkylation of diazosulfonium conjugate 86 using Hanztsch ester 157. Predominant product formed was 
reduction product 110. Due to messy reaction profile, outcomes of reactions were determined in a qualitative manner. 
 
 
It was hoped that by carrying out additional control reactions on the simple benzylation 
reaction, it would be possible to gain some insight into the role of each reagent. It was found 
that in the absence of the persulfate oxidant, the conversion was dramatically reduced, with 
44% of starting diazo conjugate remaining after the reaction and only 4% of benzylation product 
167 observed (Entry 2, Table 8). The exclusion of the photocatalyst, Ru(bpy)3Cl2, impeded the 
reaction further, with only 25% conversion of starting material and only trace levels of 
benzylation product observed (Entry 3). Finally, carrying out the reaction in the absence of 
visible light resulted in exclusive decomposition of the polypeptide (Entry 4). These relevant 
control reactions indicated the necessity of each component for benzylation. Taken together, 
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a)Light placed at 5 cm distance from reaction vessel. b)Reaction outcome determined by TIC.
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Table 8 Control experiments run to investigate the role of each reagent. Reactions carried out by Dr M. T. Taylor are denoted 
 
 
Additional control reactions were carried out by Dr M. T. Taylor, attempting to observe the 
formation of bibenzyl species 168 (Table 9). It was proposed that the formation of this bibenzyl 
species may be indicative of the formation of radical species 169 or 170, which may give insight 
into the mechanism of the benzylation reaction. Interestingly, 168 was only observed in the 
presence of both the photocatalyst and oxidant, eluding to the importance of both of these 
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Table 9 Control reactions to assist in the identification of the role of each reagent. Conditions which formed bibenzyl 168 
would suggest the formation of either of two radical species 169 or 170. Reactions carried out by Dr M. T. Taylor. 
 
One of the earliest reported photoredox-catalysed transformations of organic molecules was 
reported by Kellogg in 1978 for the reduction of phenacyl sulfonium salts by 1,4-
dihydropyridines 102 (Scheme 69).246,253 In the presence of visible light, the reduction of 
sulfonium salts 171 was observed to be dramatically accelerated in the presence of various 
photosensitisers, with Ru(bpy)3Cl2 providing the greatest rate enhancement. Considering these 
early examples of sulfonium reduction, it is remarkable that no reduction of the sulfonium 
species generated in the methionine bioconjugation was observed on subjecting these species 
to similar photoredox conditions. 
 
Scheme 69 Early photoredox-catalysed transformation reported by Kellogg for the reduction of phenacyl sulfonium salts 
Using the information gained from the control reactions, a mechanism could be suggested for 
the formation of alkylation product 167 (Scheme 70). Upon visible light irradiation, excitation 
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reducing and may donate an electron to diazosulfonium species 116, forming the putative 
radical 118 through loss of N2 and protonation.237,238 The strongly oxidising persulfate species 
may facilitate the generation of the radical cation of the Hanztsch ester 120, through single 
electron oxidation of the Hanztsch ester 119, generating a sulfate anion and a sulfate radical 
anion 172.244 This is supported by the observation of dibenzyl formation in the absence of the 
photocatalyst, suggesting it is the oxidant and not the photocatalyst responsible for the oxidation 
of the Hantzsch ester. The benzyl radical 121 could be generated from the aromatisation of the 
radical cation 120, forming Hantzsch pyridine 122.248 Subsequent radical-radical coupling of 
benzyl radical 121 and putative radical 118 could form the C-benzylation product 123. Benzyl 
Hantzsch ester 119, which is present in excess, may be responsible for the turnover of the 
photocatalyst, reducing Ru(bpy)33+ back to Ru(bpy)32+. Further mechanistic investigation is 
required to validate the proposed mechanism. 
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2.4.7 Summary 
This chapter has described the optimisation, development and characterisation of a novel, 
biocompatible, alkylative bioconjugation strategy targeting the amino acid methionine.254 
Initial work by Dr M. G. Suero and Dr M. T. Taylor identified this interesting reactivity, 
wherein hypervalent iodonium salts bearing a diazo ester moiety could selectively react at the 
sulfide side chain of methionine within small peptide substrates. Subsequent optimisation was 
carried out and identified a number of larger polypeptide and protein substrates, bearing 
multiple nucleophilic amino acid residues, which could be functionalised with exquisite 
selectivity, forming b-sulfonium a-diazo ester conjugates. The stability of the resulting 
functionalised species was investigated, with the half-life proving to be within the range of 30-
96 hours, similar to that of established protein conjugates.230,231 Mass spectral characteristics 
were examined in order to identify the nature of an observed fragmentation pattern, as well as 
extensive characterisation of sulfonium products through MS/MS and CD analysis. A 
Staudinger-inspired phosphine-mediated cleavage of the sulfonium label was developed, 
enabling the triggered regeneration of free methionine-containing polypeptides and proteins. A 
photochemical reduction, initially discovered by Dr M. T. Taylor, reduced the b-sulfonium a-
diazo ester conjugates to form trialkylsulfonium species in quantitative conversion. On 
investigation of the half-life of the resulting reduced species, the trialkylsulfonium conjugates 
exhibited significantly improved stability in relation to the diazo analogue. Finally, an 
alkylative functionalisation was developed, using photoredox catalysis, targeting the diazo 
moiety formed through the initial bioconjugation reaction. Using C4-substituted Hantzsch 
esters, a ruthenium photocatalyst and an oxidant, functionalised benzyl groups could be 
transferred to the a-position of the sulfonium conjugate, providing a method for bioorthogonal 
functionalisation of the non-native diazo group.  
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3 Synthesis of multi-functionalised polypeptides and proteins 
3.1 Introduction 
In recent years, the field of protein modification has advanced beyond mono-functionalisation, 
with increasing interest in the development of dual modification strategies for increasing the 
exogenous functionality of peptides and proteins.255 Interest in the area of the dual-
functionalisation of proteins has grown, as the introduction of at least two functional groups is 
valuable for many applications; namely, targeted biotherapeutics,256–258 Forster Resonance 
Energy Transfer (FRET) for monitoring of protein dynamics259 and also protein folding 
studies.260 Chemical methods for the site-selective dual-modification of proteins remain a 
challenge.255 Therefore, development of operationally simple, versatile methods for the 
introduction of two or more modalities to a protein is fundamental to the advancement of many 
biologically relevant applications.  
A common approach for dual-functionalisation has involved the sequential application of two 
established methods for protein modification, to form multi-functional scaffolds.261 This 
approach generally exploits two different natural or unnatural amino acid residues (Figure 15a). 
A second, distinct approach involves the conjugation of a bifunctional species to a protein, 
bearing two orthogonally reactive functional handles. This bifunctional handle may be reacted 
sequentially to form dual-functionalised scaffolds262 (Figure 15b). The latter approach has had 
limited success due to the complex synthetic challenge presented by the branched structures 
bearing orthogonal handles.255 Additionally, this approach has rarely been exemplified on 
protein scaffolds. Instead, small molecules or simple peptides are more commonly exploited.255 
As a result, this chapter will focus on the synthesis of dual-functionalised proteins via the 
labelling of two different amino acid residues. For a more in-depth account of dual 
functionalisation using multifunctional scaffolds the reader is directed to a recent review.255 
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Figure 15 Two different strategies for dual functionalisation of proteins; a) Through introduction of a single multifunctional 
scaffold bearing two reactive handles b) Exploiting two different amino acids (natural or non-natural)255 
 
3.1.1 Double labelling using identical amino acids with different reactivity 
Site-selective single-functionalisation of proteins can be achieved through exploitation of 
differences in reactivity or accessibility of two identical amino acids.255 It has been 
demonstrated that, in the case of lysine, the pKa of the amine side chain can vary by up to 5 
units depending on the polarity of its microenvironment, its solvent accessibility, protein 
folding and the nature of the surrounding residues (Section 1.2.3).131 Selective reaction of 
‘hyper-reactive’ lysine residues, exploiting differences in reactivity, allows preferential single-
labelling with specifically designed reagents under pH control. This concept can be applied to 
the dual-labelling of proteins, exploiting the differences in reactivity of other residues, including 
cysteine.  
Haas and co-workers engineered a mutant form of Escherichia coli adenylate kinase, in which 
two cysteine residues were carefully positioned so as to induce distinct reactivity.263 By 
exploiting the nucleophilicity difference between two free thiol motifs, initial reaction with 
iodoacetamide 171 occurred selectively at the more reactive site. Subsequently, using unfolding 
conditions to access the less reactive cysteine residue, a second fluorescent probe 172 could be 
attached selectively, forming a dually-functionalised protein scaffold which could be used in 
FRET measurements (Scheme 71). However, the requirement for partial denaturation of the 
protein by unfolding could potentially impair the protein function. 
a) b)
Dual functionalisation via two 
amino acids (natural or non-
natural)
Dual functionalisation via a 
multifunctional scaffold bearing 
two reactive handles
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Scheme 71 Technique for the dual labelling of Escherichia coli mutant containing two distinct cysteine residues 
Brunsveld et al. described a cysteine dual labelling strategy via a temporary protection approach 
(Scheme 72).264 Initial protection of both the N-terminus and the N-terminal cysteine side chain 
as a thioazolidine ring was followed by selective labelling of the C-terminal cysteine residue 
using a maleimide reagent. Subsequent N-terminal cysteine deprotection facilitated a second 
selective labelling using a different maleimide reagent. The temporary protection strategy was 
reported to be effective with a wide range of other site-specific ligation techniques such as 
native chemical ligation or disulfide exchange. However, this temporary protection and 
deprotection approach requires several steps to achieve high selectivity. 
 
Scheme 72 Site-selective dual labelling with maleimide reagents through temporary protection of an N-terminal cysteine 
residue 
In a similar strategy, detailed in Section 1.2.2, Pentelute and co-workers reported the 
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perfluoroarylation of single cysteine residues within proteins.93 The unique microenvironment 
of the clamp’s cysteine residue was exploited in order to selectively form dually functionalised 
proteins. First, nucleophilic aromatic substitution was employed selectively at the p-clamp 
recognition unit, followed by Michael addition of an N-terminal cysteine residue to a 
fluorescein-derived maleimide reagent 173 (Scheme 73). Selective dual labelling in this case 
could be carried out in a one-pot procedure but required pre-installation of the p-clamp 
sequence at the C-terminus of the desired protein. 
 
Scheme 73 Dual labelling of proteins using a pre-installed “p-clamp” recognition motif and subsequent maleimide 
functionalisation 
These strategies, which target two cysteine residues, rely on the differing nucleophilicity of the 
thiol side chains and require careful incorporation of the cysteine residues at specific sites 
within the protein sequence. Rigorous control of the conditions, reagents and reactions times 
must be adhered to in order to maintain high selectivity. A distinct approach employs substrate 
control to achieve selective dual labelling using a single reagent, inducing differing reactivity 
in two cysteine residues.  
Caddick and co-workers were able to exploit the natural microenvironment of Green 
Fluorescent Protein (GFP). They showed that a reaction between two cysteine residues and 2,5-
dibromohexanediamide 174 could result in a dual modified protein (Scheme 74).265 Initial 
reaction of a double cysteine mutant of GFP with 174 formed a bis-sulfonium species. The 
system was engineered so that one cysteine residue had an accessible a-proton, and therefore 
readily eliminated a neutral sulfide species to form dehydroalanine (Dha). The a-proton of the 
second cysteine residue was sufficiently shielded, and it therefore persisted as a stable 
sulfonium moiety. Chemoselective ring opening of the sulfonium motif with sodium azide 
furnished 175, bearing two orthogonal reactive handles. Sequential strain-promoted azide 
alkyne cycloaddition with dibenzylcyclooctyne reagent 176, incorporating a fluorescent dye, 
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was followed by Michael addition of 2-mercaptoethanol to Dha, yielding dual labelled GFP, 
177. 
 
Scheme 74 Exploitation of the microenvironment of Green Fluorescent Protein for distinct reactivity with reagent 174 to 
introduce two different orthogonal handles 
 
3.1.2 Double labelling using two different amino acids 
Rather than exploiting two of the same amino acid residues that exhibit different reactivity, 
different amino acid residues with orthogonal reactivity may be targeted. Puthenveetil et al. 
used this approach to generate dual labelled antibody conjugates by exploiting two different 
native sites on an Immunoglobulin G1 (IgG1) antibody (Scheme 75).266 Deglycosylation, the 
removal of oligosaccharide chains which are covalently attached to amino acid side chains, was 
followed by enzymatic conjugation to allow the selective introduction of the first reactive, 
orthogonal handle (Steps 1 & 2). A reduction and reoxidation sequence reduced the engineered 
cysteine residues on the exterior of the antibody, while retaining the interchain disulfide bonds 
(Step 3). Michael addition to the free thiol residue with maleimide reagents, to introduce the 
first fluorescent probe, was followed by strain-promoted azide-alkyne cycloaddition to 
introduce the second probe molecule (Step 4i & ii). This strategy was reported to be virtually 
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be facile and all IgGs share the same glycosylation site, to which oligosaccharide chains are 
attached post-translationally.255 However, the method required several steps, making dual 
labelling laborious. 
 
Scheme 75 Formation of dual functionalised antibody conjugates targeting native amino acid residues 
Paavola et al. described the combination of traditional cysteine-maleimide chemistry with a 
transamination reaction at the N-terminus (Scheme 76).267 Methodology developed by Francis 
and co-workers was used to install a uniquely reactive ketone or aldehyde at the N-terminus of 
the protein with pyridoxal-5’-phosphate 178.148 Subsequent oxime formation was carried out 
with alkoxyamine reagents bearing a donor fluorescent payload 179. Maleimide chemistry 
could then be employed to incorporate an acceptor fluorophore at a free cysteine residue, 
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Scheme 76 Dual functionalisation of proteins targeting the N-terminus and a cysteine residue for the introduction of two 
complementary fluorophores 
Another potential strategy for dual functionalisation of biomolecules is to target two non-native 
functional groups in a bioorthogonal fashion. However, synthetic genetic code expansion for 
the incorporation of non-natural amino acids is generally limited to the incorporation of a single 
type of non-natural amino acid.268 Methods for the incorporation of multiple non-natural 
residues have been developed independently by Chin268 and Liu.269 However, this dual 
incorporation approach has often been associated with low protein yields.270,271 As a result, 
bioorthogonal strategies for dual labelling generally involve the targeting of one non-native and 
one native amino acid residue. 
An example of this approach was reported by Davis et al. (Scheme 77).272 Incorporation of the 
non-natural amino acid azidohomoalanine (Aha) facilitated the use of the copper-catalysed 
azide-alkyne cycloaddition (CuAAC) which could be carried out with a tri- or tetrasaccharide 
derived alkyne reagent 181. Disulfide ligation could be used to introduce a modification at a 
free cysteine residue using sulfotyrosine mimic 180. The mutual compatibility of the two 
modification reactions was demonstrated by the ability to reverse the order of the sequential 
functionalisations. Additionally, it was shown that different chemical tags could be utilised, 
such as homopropargylglyine amino acid (Hpg), which underwent subsequent reaction with 
azide reagents. The authors demonstrated the applicability of this technique towards the 
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Scheme 77 Schematic depiction of the exploitation of non-natural amino acid azidohomoalanine (Aha) and cysteine in the 
synthesis of dual functionalised protein scaffolds 
A combination of native and non-native amino acid functionalisation was also employed by 
Schultz and Deniz to study the structure and folding of T4 lysozyme. The non-native residue p-
acetylphenylalanine was incorporated and functionalised with a fluorescent probe (Alexa488 
dye, 182), using a selective oxime ligation (Scheme 78).273 Subsequent Michael addition at the 
free cysteine residue with a maleimide reagent 183 selectively introduced a second fluorescent 
tag (Alexa594). The resulting dual-labelled species could be used in FRET analysis. 
 
Scheme 78 Dual labelling of T4 lysozyme with two different fluorescent tags through the use of non-native amino acid p-
acetylphenylalanine and native amino acid cysteine. 
In a similar strategy to that of Davis et al. (Scheme 77), Pluckthun and co-workers developed 
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native amino acid cysteine to form dually functionalised antibody mimetic species known as 
Designed Ankyrin Repeat Proteins (DARPins) (Scheme 79).274 DARPins are a leading 
alternative to antibody proteins for selective binding to molecular targets. In contrast to the 
work described by Davis, Pluckthun opted for selective strain-promoted azide-alkyne 
cycloaddition with dibenzylcyclooctyne reagent 184 and maleimide modification of a single 
cysteine residue. The resulting functionalised DARPins could be used to measure association 
and dissociation kinetics on tumour cells to observe the dynamic blocking effect of the PEG 
chains on DARPin binding. 
 
Scheme 79 Dual functionalisation of DARPins exploiting the non-native amino acid azidohomoalanine (Aha) and native 
amino acids cysteine 
Many methods for the selective, multi-functionalisation of proteins have been developed in 
recent years. However, lengthy syntheses are often required in order to obtain the modified 
scaffolds, and cross reactivity can cause problems with selectivity.255 As a result, the 
development of additional, tailored strategies for the formation of dual-functionalised proteins 
are required to overcome limitations with existing technologies. Alternative methods for the 
facile synthesis of multi-functionalised protein conjugates would provide access to species 
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3.2 Project aims 
Currently, there are no methods which employ methionine functionalisation as a strategy for 
the synthesis of multi-functionalised protein scaffolds. The use of methionine as an orthogonal 
handle, alongside other amino acids, in the dual functionalisation of proteins may address some 
limitations of current strategies, such as lengthy synthesis and variable product stability. 
The aim of this project was to investigate the orthogonality of the methionine-selective 
bioconjugation reaction, developed in Chapter 2, with other protein functionalisation methods 
(Scheme 80). It was envisaged that two bioconjugation techniques could be used in 
combination, enabling the dual-functionalisation of native polypeptides and proteins without 
the need for prior incorporation of non-native groups. 
 
Scheme 80 Schematic representation of proposed synthesis of dual functionalised protein constructs exploiting methionine-
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3.3 Results and discussion 
3.3.1 Dual-labelling of methionine and tryptophan residues 
In 2016, Kanai and co-workers reported a transition metal-free tryptophan-selective 
bioconjugation.139 Using a bicyclic organoradical species, ketoABNO 185, and an oxidant, 
sodium nitrite, site-selective functionalisation of tryptophan residues within peptides and 
proteins could be achieved in up to 95% conversion (Scheme 81). Formation of a C–O bond at 
the 3-position of the indole moiety afforded product 186, and additional products were formed 
through dehydration of 186 across the indole C–N bond, forming dehydrated 187, or 
dehydration of the polypeptide backbone, forming cyclised 187’. The authors reported the 
conversion to product as the total of the three functionalised species; 186, 187 and 187’, 
although no ratio between products was reported. 
 
Scheme 81 Transtition metal-free tryptophan-selective bioconjugation of polypeptides and proteins. Dehydration of product 
186 can occur either across the C–N bond of the indole moiety or across the protein backbone 
It was reported that the reactive species in the bioconjugation reaction was nitroxide 189. 189 
was thought to be formed via acid-promoted disproportionation of 185 and oxidation of 
resultant hydroxylamine 188 by NOx, generated from NaNO2 and acetic acid (Scheme 82). The 
authors proposed that subsequent bioconjugation proceeds via nucleophilic attack of the indole 
ring of a Trp residue towards the reactive nitroxide species 189, followed by attack of water at 
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Scheme 82 Proposed mode of reactivity of ketoABNO reagent with tryptophan residues 
It was proposed that this tryptophan-selective bioconjugation strategy could be used in 
combination with methionine-selective bioconjugation for the synthesis of multi-functionalised 
protein scaffolds. An important additive for the methionine labelling procedure is TEMPO 190, 
used as a scavenger of ROS to protect proteins against oxidative degradation during the 
reaction. It was noted that the organoradical 190, and the tryptophan-selective organoradical 
185, were structurally similar (Scheme 83a). However, although structurally similar, Kanai had 
shown that TEMPO was unreactive in the Trp-labelling strategy. It was hypothesised that the 
additive 190, used in the methionine strategy, could be replaced with the tryptophan-selective 
reagent 185. Oxidation to the reactive nitroxide species 189 may occur in situ due to the fact 
that the reaction proceeds under oxidising conditions, with highly oxidising iodonium salt 54 
present in a large excess. Subsequently, nucleophilic attack of the indole ring of a Trp residue 
to 189 could facilitate selective labelling of Trp, meanwhile iodonium salt 54 may selectively 
label Met using the established strategy.  
If successful, this would provide a strategy for the simultaneous labelling of two different native 
amino acid residues, with two different functional groups, streamlining the synthesis of multi-
functionalised protein scaffolds. Additionally, tryptophan and methionine are the two native 
amino acids with the lowest natural abundance in vertebrates (~1.3% and ~1.8% respectively).23 









+ e—  + H+ - e—
185188 189













Synthesis of multi-functionalised polypeptides and proteins  
 102 
 
Scheme 83 a) Evident structural similarity between TEMPO and ketoABNO. b) Proposed simultaneous dual labelling of 
polypeptides and proteins using methionine labelling strategy, with substitution of TEMPO for Trp-selective reagent 
ketoABNO. 
To initiate the development of the simultaneous dual labelling of methionine and tryptophan, a 
tripeptide model system was designed and synthesised using solid phase peptide synthesis so 
that the reaction could be studied on a small molecule system (Scheme 84). Sequential 
deprotection and amide coupling steps were carried out using Rink amide resin to facilitate the 
synthesis of tripeptide 191. Final cleavage of the peptide from the resin afforded peptide 191 in 
an overall yield of 52% over 8 steps. 
 
Scheme 84 Solid phase peptide synthesis of tripeptide 191. a) 20% piperidine in DMF, rt, 15 mins. b) HCTU (1.5 eq.) 
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Tripeptide was subjected to modified conditions for methionine bioconjugation, developed in 
Section 2.4, with the replacement of the additive TEMPO with ketoABNO, 185, and a reaction 
time of 15 minutes (Scheme 85). Pleasingly, the dehydration product 192 (or other regioisomer 
192’) was observed in >95% conversion by LCMS analysis. This exciting result indicated that 
the dual labelling could be achieved in a single step from a native peptide, allowing the rapid 
formation of structurally complex peptidic scaffolds. 
 
Scheme 85 Initial conditions for simultaneous dual functionalisation of Met and Trp on a model tripeptide substrate 
Following this promising initial result, isolation of the mixture of dual labelled products was 
carried out in order to obtain MS/MS analysis. MS/MS analysis of the products of the reaction 
was required to confirm the two sites of modification in the tripeptide and ensure the selectivity 
of both reagents being used in tandem. As a number of labile bonds were present in the 
tripeptide product (e.g. N–O bond of ketoABNO motif), MS experiments were carried out at a 
low voltage of 10 V in the hope of observing fragment ions corresponding to the intact labelled 
amino acid residues. As discussed in Section 2.4.5, upon ionisation, alkylated methionine 
residues can fragment at the Cg-SR2 bond to produce an [M-(SR2-H)+H]+ ion in addition to the 
formation of the parent molecular ion [M]+.188,232,233 This fragmentation was evident in the 
MS/MS spectrum, and provided evidence that the diazoester species had transferred to the 
methionine residue as anticipated. Additional fragment ions corresponding to a number of bond 
cleavages were observed, depicted in Figure 16. Most notable were the y1-(SMeR) and the -Trp 
fragments, corresponding to the loss of the modified Trp residue and modified Trp side chain 
respectively (Figure 16). This provided evidence that the ketoABNO reagent had reacted 
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Figure 16 MSMS analysis of tripeptide 192 with diagnostic bond fragmentation denoted and colour coded 
Subsequent efforts focused on the application of this novel strategy to larger polypeptide 
architectures. The polypeptide exenatide, of molecular weight 4186.6 Da, contains one 
methionine and one tryptophan residue and hence provided a suitable model polypeptide 
substrate for dual-labelling. Exenatide was subjected to the conditions used on the tripeptide 
system, using iodonium salt 54 (50 mM), ketoABNO 185 (10 mM) and thiourea (20 mM) at 








































Synthesis of multi-functionalised polypeptides and proteins  
 105 
The desired doubly-labelled products 193, 194 and 194’ were observed in a combined 
conversion of 78%, as determined by LCMS total ion count. 4% of undesired product 195 was 
also observed, in which only the methionine residue had been labelled. Additionally, 18% of 
an oxidation side-product was observed, resulting from the dual-labelling and further oxidation 
of the peptide at an undetermined position. Nevertheless, high overall conversion to desired 
products was observed in 78% conversion on a complex scaffold. This preliminary result was 
encouraging and provided an excellent proof-of-concept for the use of this simultaneous 
labelling procedure on a polypeptide system. 
Table 10 Initial attempt for the simultaneous dual labelling of Met and Trp residues in model polypeptide exenatide 
 
 
Unexpectedly, on repeating the dual labelling of exenatide, under identical reaction conditions, 
varied results were obtained, with a combined conversion to desired products 193, 194 and 194’ 
ranging from 16-55% (Entries 2-7, Table 11). Multiple attempts were made at reproducing the 
initial result of 78% conversion (Entry 1) without success. It seemed that irreproducibility was 
a problem with this dual functionalisation technique, with varied levels of oxidative degradation 






























































1a 78>95 18 4 0
a)Reaction outcome determined by TIC. *Dual labelled product+[O]
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incomplete tryptophan functionalisation also appeared problematic, with methionine labelled 
product 195 observed in dramatically different quantities (4-79%, Entries 1-7). 
Table 11 Identical repeat reactions for the simultaneous dual labelling of Met and Trp residues in exenatide 
 
 
Efforts to address the issue of unpredictable oxidative side-product formation began with 
carrying out the reaction under an inert atmosphere and using solvents degassed with N2 (Table 
12). As a large proportion of the oxidation observed was of the desired doubly-labelled species, 
it was envisaged that, under N2, it may be possible to reduce oxidative degradation of dual-
































































1a 78>95 18 4 0
>952a
6a >95
55 4 41 0
>95 48 2 49 0
51 4 44 0
53 14 32 0
>95 45 4 50 05a
7a >95 16 5 79 0
a)Reaction outcome determined by TIC. *Dual labelled product+[O]
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atmosphere and N2-degassed solvents provided no advantageous effect on conversion to 
products, with identical reaction conditions still resulting in inconsistent levels of oxidation (12-
29%, Entries 1 & 2). On shortening the reaction time to 20 minutes, methionine-labelled 
product 195 was observed in only 25% conversion (Entry 3). Unexpectedly, increasing the 
reaction time to 60 minutes under a N2 atmosphere led to reduced dual-labelling, with singly-
labelled product 195 observed in 77% (Entry 4). Given that these attempts under a N2 
atmosphere had little positive effect on oxidation, for operational simplicity subsequent 
screening was carried out under air. 
Table 12 Efforts to reduce oxidative side-products through N2 atmosphere and N2-degassed solvents at various reaction times 
 
 
Efforts to improve the efficiency of the Trp labelling began by varying the amount of the Trp-




































































66 29 5 0
>95 65 10 25 0
15 0 77 0
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the reaction, from 10 mM to 40 mM, caused a decrease in conversion to desired dual-labelled 
products (Entries 1-3, Table 13). The decrease in yield corresponded to an increase in observed 
levels of undesired oxidation, with 42% conversion to oxidative side-products observed at a 
ketoABNO concentration of 40 mM (Entry 3). Decreasing the concentration of ketoABNO 
incrementally from 5 mM to 1 mM also had a detrimental effect on conversion to desired 
products 193, 194 and 194’ (Entries 4-6). At a lower concentration of the Trp-selective reagent 
185, the labelling of Trp was poor, with <17% conversion to dual labelled products observed 
at concentrations <10 mM).  
In the knowledge that TEMPO is unreactive towards tryptophan but can act as a scavenger of 
ROS, the amount of ketoABNO was reduced to 1 equivalent (with respect to the polypeptide) 
and TEMPO introduced as an additive (10 mM). Unfortunately, this achieved almost 
quantitative conversion to the methionine-labelled product 195.  
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Table 13 Effect of varying the amount of ketoABNO used in dual functionalisation of Met and Trp on exenatide 
 
 
Kanai and co-workers reported that the ‘reactive species’ in the tryptophan-selective 
bioconjugation reaction was the oxidised nitroxide species formed from the organoradical 185. 
Therefore, it was proposed that pre-stirring of the ketoABNO organoradical with the oxidising 
iodonium salt species 54 may facilitate the formation of the reactive nitroxide species, prior to 
exposure to the polypeptide. Therefore, pre-stirring of 185 and 54 was carried out, under N2, 
before the subsequent addition of this pre-stirred solution to the reaction mixture (Table 14). 
This pre-stirring technique gave inconsistent and irreproducible results and did not seem to 
correlate with improved conversion to products. For example, pre-stirring 185 and 54 for 10 
minutes, under identical conditions, gave dramatically different results ranging from 0-88% 



























































2a >9530 mM 30 47 24 0 -
>95 52 12 36 0 -20 mM1a
3a >9540 mM 32 42 27 0 -
a)Reaction outcome determined by TIC. *Dual labelled product+[O]
5a >952 mM 4 0 96 0 -
>95 0 2 98 0 -1 mM6a
4a >955 mM 17 2 82 0 -
7a >950.2 mM 0 0 >95 0 10 mM TEMPO additive
%conversion 
of exenatide
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Pre-stirring in the same manner was conducted under air and obtained similarly inconsistent 
results (Table 15). Varying levels of conversion to desired products was observed, with no 
apparent correlation between pre-stirring reagents and improvement of the dual-labelling or 






































































5 min 43 0 52 0
>95 88 0 12 0
32 68 0 0
0 0 >95 0
>95 31 69 0 05 min4a,b,c
a)Reaction outcome determined by TIC. b)Reaction time 30 minutes. c)Reaction conducted under 
N2, using N2 degassed solvents *Dual labelled product+[O]
%conversion 
of exenatide
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In order to observe the formation of products over the course of the reaction, a larger scale 
reaction was carried out, under air, in which aliquots were acquired and analysed periodically 
(Figure 17). The rate of dual-labelled product formation was rapid, with quantitative conversion 
of starting material observed after only 1 minute, forming ~80% of desired dual-labelled 
products 193, 194 and 194’ and ~20% oxidation. At this point it was clear that the reaction was 
complete, with product ratios remaining constant for the duration of the analysis. No singly-
labelled product was observed, indicating that the tryptophan labelling could also occur at a 




















































1a,b >951 min 64 36 0 0
a)Reaction outcome determined by TIC. b)Reaction time 30 minutes. *Dual labelled product+[O]
3a,b 8310 min 41 8 42 0
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Figure 17 Monitoring of the conversion to products for the dual labelling of exenatide. % conversion determined of aliquots 
acquired at time points throughout the reaction using LCMS TIC. 
It had previously been observed that oxidation had occurred over reaction times greater than 1 
minute, the time in which product formation had been observed. Therefore, it was proposed that 
rapid formation of the desired products could be impeded by the subsequent oxidative 
degradation of products occurring in the highly oxidising environment of the reaction over time. 
As a result, the reaction time was shortened and analysed after 1 minute (Table 16). Under 
identical conditions the reaction remained capricious, providing variable conversions to the 
desired products from 50-81% (Entries 1-4). Undesirable oxidation of the dual-labelled product 





















Analysis of dual labelling of exenatide at various time points
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Table 16 Screening of dual labelling of Met and Trp on exenatide with a shortened reaction time 
 
 
It was hypothesised that quenching the reaction with an antioxidant may reduce the amount of 
oxidation side-product formed. In light of the rapid formation of the dual labelled products, it 
was proposed that a short reaction time followed by a reductive quench may circumvent the 
oxidative degradation and afford high conversion to the desired products. The dual-labelling 
procedure was conducted and the reaction was quenched using ascorbic acid, a common 
antioxidant which is known to interact directly with oxidising radical species164 (Table 17). 
Interestingly, the use of ascorbic acid completely halted the formation of oxidation side-
products (Entries 1-4). Depending on the reaction time prior to quenching, the desired dual 
labelled products 193, 194 and 194’ were formed in a combined conversion of 43-81%, with 
the undesired singly-labelled product observed in 8-45% conversion. These promising results 





































































68 32 0 0
>95 50 50 0 0
75 25 0 0
a) Reaction outcome determined by TIC. *Dual labelled product+[O]
%conversion 
of exenatide
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considering the tryptophan labelling was not reaching completion, the conversion to dual 
labelled products now required improvement. 
Table 17 Investigation into the effect of quenching the dual labelling reaction with an antioxidant/basic conditions 
 
 
Having circumvented the problematic oxidation which was occurring during longer reaction 
times, it was proposed that improved conversion could be achieved by lengthening the reaction 
time, potentially allowing full labelling of the tryptophan residue. Reactions were screened with 
durations ranging from 30 seconds to 30 minutes before quenching with ascorbic acid (60 mM) 
(Table 18). Pleasingly, no undesired oxidation side-products were observed and increasing the 
reaction time improved the conversion to dual labelled products slightly, affording the desired 
dual-labelled products in 79% conversion over 10 minutes (Entry 5). Further increase of the 
reaction time provided negligible improvement and after 30 minutes products resulting from 





























































1a 4388 0 45 0
>952a 75 0 18 0
>95 81 0 14 0
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reaction time of 10 minutes provided optimal conversion to dual-labelled products. Singly-
labelled side-product 196 was also observed at 7-9% conversion under these reaction 
conditions, in which the methionine labelling had not gone to completion.  




The purity and origin of the ketoABNO reagent was also found to be important for the 
reproducibility of the dual labelling. Commercial sources possessed variable purity and 





























































1a,b 71>95 0 12 8
>952a,b 74 0 11 7
>95 72 0 11 8










>955a,b 79 0 5 7
>95 79 0 8 7
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Using freshly recrystallised material improved the reproducibility of results for the dual 
labelling. This pure material was used in the remainder of the optimisation. 
 
Scheme 86 Synthesis of ketoABNO 185 
Different concentrations of ascorbic acid were also screened to observe the effect on conversion 
to dual-labelled products (Table 19). It was found that on decreasing the amount of ascorbic 
acid used to quench the reaction, the conversion to dual labelled products 193, 194 and 194’ 
improved, reaching 90% at a concentration of 1 mM ascorbic acid (Entry 6). In this case, no 
singly-labelled products were observed, with the labelling of both the methionine and the 
tryptophan residue having reached completion. Notably, at the lowest concentration of ascorbic 
acid screened, some non-specific labelling of the polypeptide by iodonium salt 54 was 
observed, with the incorporation of two equivalents of the diazoester motif to exenatide. The 
conditions yielding the highest conversion (Entry 6) were repeated and gave consistent 
conversions to desired products of 83-92% (n = 5), providing a reproducible strategy for dual 
functionalisation. 
In the initial tryptophan labelling, reported by Kanai, tryptophan labelling was achieved in the 
range of 15-64% conversion for polypeptide and protein systems with greater than 4 amino 
acids. Using optimal conditions developed herein, the labelling of two different amino acids 
could be achieved on a 39 amino acid polypeptide system in 90% conversion. This demonstrates 
a vast improvement on the reported tryptophan labelling reaction, in addition to conducting the 
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Table 19 Screening of concentration of ascorbic acid used for quenching of the dual labelling reaction 
 
 
With optimised conditions in hand, attention turned to investigating the scope of polypeptide 
or protein substrates which could be efficiently labelled using this simultaneous 
functionalisation technique (Scheme 87). Glucagon is a 29 amino acid, helical polypeptide of 
molecular weight 3482.8 Da which contains one methionine and one tryptophan residue. It was 
found that this substrate could be labelled at both Met and Trp simultaneously, in 77% 
conversion to products 202.  
Teriparatide is the 34-amino acid, bioactive, N-terminal domain of parathyroid hormone and is 
used in the treatment of some forms of osteoporosis.226 The sequence contains two methionine 





























































1a,b,c 72>95 0 11 9
>952a,b,c 74 0 12 8
>95 78 0 11 6
a) Reaction outcome determined by TIC. b)Reaction time = 10 mins. c)Small amount of oxidised 










>955a,b,c 80 0 9 3
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Pleasingly, simultaneous Met and Trp labelling of teriparatide occurred in quantitative 
conversion to triply-labelled products 203. Tetracosactide, a 24-amino acid synthetic peptide 
approved for medical use,225 was also tolerated in the reaction. However, this substrate provided 
lower conversion to desired products 204, with the reaction profile proving more complex. 
 
Scheme 87 Substrate scope for the multi-functionalisation of Met and Trp residues in polypeptides. Products are depicted as 
dehydration products but conversions include formation of hydration product + two dehydration products. aConversion 
determined using LCMS TIC. bFormic acid (0.1 M) used in the reaction. 
Isolation and further characterisation of these multi-functionalised polypeptide scaffolds was 
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reactions (dual labelling product + two dehydration products), isolation proved difficult. As a 
result, MS/MS and CD analysis could not be carried out. However, MS/MS had been performed 
on a smaller peptidic system, confirming the selectivity of the dual labelling.  
It had been established that reduction of the diazo moiety in the b-sulfonium a-diazoester 
improved the stability of the resulting sulfonium conjugates (Section 2.4.6.2). Kanai and co-
workers reported that, on a small molecule system, the tryptophan modification was indefinitely 
stable under a variety of conditions and at various pH levels.139 Therefore, it was proposed that 
subjecting the multi-functionalised polypeptide species to the photoreduction conditions may 
provide a facile strategy for improving conjugate stability. 
Exposing the triply-labelled teriparatide conjugate 203 to the photoreduction conditions, using 
Ir(ppy)3 and Hantzsch ester, gave a promising preliminary result with the conjugate 205 
observed as the major product, with both diazo motifs reduced (Scheme 88). This result, 
indicating that 203 is amenable to photoredox-mediated reduction of the diazo moiety, suggests 
that the stability of these highly modified scaffolds could be improved in an analogous fashion 
to the species singly-labelled at methionine (Section 2.4.6.2). Detailed stability studies on 
multi-functionalised polypeptide scaffolds are currently underway. 
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3.4 Future work 
Moving forward with the simultaneous multi-functionalisation would require investigation into 
the stability of the b-sulfonium a-diazoester dual labelled conjugates to ensure a synthetically 
useful half-life which would enable their use in biologically relevant applications. The visible 
light-mediated reduction of these multi-functionalised scaffolds presented a promising 
preliminary result which may enable the stability of the b-sulfonium a-diazoester conjugates 
to be improved. Since the development of the initial visible light-mediated reduction, it has 
been discovered that the reaction can be conducted in the absence of the photocatalyst when 
using a more powerful, 40 W blue LED Kessil lamp (Scheme 89). Therefore, it would be 
interesting to explore these photocatalyst-free conditions on the multi-functionalised scaffolds 
as a means of improving their half-life. 
 
Scheme 89 Photocatalyst-free, visible light-mediated reduction of exenatide b-sulfonium a-diazoester conjugate 
Kanai and co-workers detailed various functional payloads which could be transferred to 
polypeptide and protein systems using their tryptophan-selective bioconjugation approach, 
including fluorescein, biotin and an anticancer drug molecule (Scheme 90).139 It has also been 
established that various functional handles and payloads can be transferred to polypeptides and 
proteins using the methionine bioconjugation strategy, with functionalised iodonium salt 
reagents (Section 2.4.3). An important future development of the simultaneous multi-
functionalisation would be investigation into the compatibility of these functionalised reagents 
with the dual-labelling strategy, exploring the different biologically relevant payloads which 
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Scheme 90 Scope of functional payloads which could be transferred using the tryptophan-selective bioconjugation procedure 
developed by Kanai et al.139 
Finally, it would be desirable to demonstrate the simultaneous multi-functionalisation on a 
larger protein system. Following identification of a suitable protein substrate in which, ideally, 
a single surface exposed methionine and tryptophan residue are present, it would be useful to 
demonstrate that the labelling is applicable to more complex protein scaffolds, bearing 







































fluorescein methyl ester biotin
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3.5 Summary 
This chapter has described the application of the methionine bioconjugation strategy, developed 
in Section 2, to the synthesis of multi-functionalised polypeptide scaffolds. A reported 
tryptophan-selective bioconjugation technique was identified, which employed an 
organoradical species, ketoABNO, for indole functionalisation. This technique was utilised for 
the development of a selective dual-functionalisation strategy in combination with the 
methionine bioconjugation developed in Section 2. Using the optimised methionine labelling 
conditions, organoradical TEMPO was replaced with the structurally similar organoradical 
ketoABNO to create a simultaneous dual-functionalisation strategy. Extensive optimisation 
identified ascorbic acid as a key reagent in the simultaneous dual-labelling, which prevented 
the formation of undesired side-products resulting from oxidation of the polypeptide. Various 
polypeptides were tolerated in the reaction, facilitating the formation of dual- or even triply-
modified polypeptide scaffolds in a single step from native polypeptides. Finally, a promising 
preliminary result identified that the photoredox-mediated reduction of the b-sulfonium a-
diazoester (developed in Section 2.4.6.2) was applicable to multi-functionalised species, 
providing a potential strategy for improving the stability of resulting conjugates. 
 
 
Conclusions and Outlook 
 123 
4 Conclusions and Outlook 
Bioconjugation, the selective functionalisation of native chemical functionality within 
biomolecules, has emerged as an effective platform for the introduction of exogenous functional 
groups into polypeptides and proteins. The resulting functionalised scaffolds are exploited for 
myriad biological applications, including targeted drug delivery and cellular imaging. Many 
bioconjugation techniques have exploited the reactivity of the amino acids cysteine and lysine, 
whose nucleophilic side chains are susceptible to nucleophilic attack.2 In contrast, strategies 
targeting the amino acid methionine for selective bioconjugation have remained underexplored. 
To address this, a general strategy for methionine bioconjugation has been developed. Through 
the use of hypervalent iodine reagents, alkylation at the thioether side chain of methionine could 
be achieved selectively in under 5 minutes, forming a b-sulfonium a-diazoester moiety. The 
reaction was found to have exceptional functional group tolerance, although free cysteine 
residues were concomitantly oxidised to the corresponding disulfide.  
While incompatibility with free cysteine residues is known for other oxidative functionalisation 
strategies,192 it is acknowledged that overcoming this limitation would represent an important 
advance for methionine bioconjugation. Future work will involve the development of a more 
general platform for methionine functionalisation which can tolerate free cysteine residues. It 
has been established that through prior reaction of a free cysteine with N-methylmaleimide 206, 
a methionine residue in a 16 amino acid synthetic peptide can be selectively functionalised 
using iodonium salt 54 without cysteine oxidation (Scheme 91). Interestingly, iodonium salt 54 
displayed selectivity for methionine over the thioether present at the functionalised cysteine 
residue of 207. This not only allows the selective formation of a desirable dual-labelled scaffold 
(see Section 3), it presents a strategy for circumventing the incompatibility of the methionine 
bioconjugation with free cysteine residues. It would be desirable to find a more general solution 
to this problem and efforts to this end may involve exploring, for example, a milder hypervalent 
iodine reagent which could result in less deleterious oxidation. 
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Scheme 91 Sequential dual labelling of GTP binding protein fragment Ga exploiting cysteine-maleimide chemistry and 
methionine bioconjugation. Conversions determined by LCMS TIC. Starting material was acquired in ~75% purity, therefore 
conversions were determined excluding the residual impurity carried through the synthesis. 
Various functional groups and biologically relevant payloads were shown to be transferred 
effectively to the biomolecule of interest using this bioconjugation method, through the 
synthesis and exploitation of functionalised hypervalent iodine reagents. It was observed that 
alteration of the ester group of the iodonium salt reagent had an effect on the stability of the 
sulfonium products, modulating the rate of ester hydrolysis. Future endeavours aiming to 
exploit ester hydrolysis under stability control may be advantageous as a controlled drug 
delivery mechanism, with a pharmaceutical agent appended to the ester payload. 
The selective methionine labelling could be applied to numerous polypeptide and protein 
substrates, however was attempted only on commercially available proteins bearing a surface 
exposed methionine residue. It would be desirable to demonstrate that larger protein scaffolds 
were tolerated in the reaction, incorporating more complex tertiary or even quaternary structural 
elements. Additionally, it would be interesting to determine the compatibility of this 
bioconjugation technique for the labelling of a monoclonal antibody, engineered to display 
surface exposed methionine residues, for the synthesis of antibody-drug conjugates. 
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The mechanism for the functionalisation of methionine using hypervalent iodine reagents is 
currently not well understood. It has been observed that thiourea plays a key role in the 
functionalisation, with a rate enhancement effect enabling labelling of methionine residues in 
<5 minutes. Speculative proposals for the role of thiourea include its role in the formation of a 
reactive intermediate species 209, which could potentially be displaced by methionine followed 
by reductive ligand coupling (pathway A, Scheme 92), or direct nucleophilic attack of 
methionine at the diazo carbon of intermediate 210 (pathway B, Scheme 92). Investigations to 
elucidate the mechanism of the reaction will form an important part of ongoing research. It is 
envisaged that experimental and computational studies will assist in the mechanistic 
investigation and may give an insight into likely intermediates involved in the reaction. 
 
Scheme 92 Potential mechanistic pathways for the functionalisation of methionine using hypervalent iodine reagent 54 and 
thiourea.  
Using phosphine reagents, a Staudinger-inspired cleavage of the methionine modification was 
developed, exhibiting the stimuli-responsive reversibility of the labelling strategy. A visible 
light-mediated reduction of the diazo moiety was also developed, which generated 
trialkylsulfonium products using photoredox catalysis. Stability studies were carried out on the 
b-sulfonium a-diazoester and reduced trialkylsulfonium conjugates, with the trialkylsulfonium 
products displaying significantly improved stability. The b-sulfonium a-diazoester products 
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which confirmed both the site of modification at methionine and the retention of secondary 
structural features following modification. 
While stability studies of reduced trialkylsulfonium conjugates indicated longer half-lives 
compared to the b-sulfonium a-diazoester analogues, future improvements to stability would 
be desirable to facilitate in vivo application of this bioconjugation technique. It has been shown 
by Deming et al. that demethylation of alkylated methionine derivatives could be achieved to 
form alkylated homocysteine analogues using ammonium pyrrolidinedithiocarbamate, APDC 
(see Section 1.3).188 Investigation into the demethylation of trialkylsulfonium products, formed 
in the two-step methionine bioconjugation and visible light-mediated reduction sequence, could 
provide further stability improvements for resulting conjugates (Scheme 93). Additionally, the 
incipient species would be neutral rather than cationic and would likely possess distinct physical 
properties in comparison to the sulfonium analogues, potentially rendering purification and 
handling more facile. 
 
Scheme 93 Proposed demethylation of trialkylsulfonim conjugates to form neutral methionine analogues, based upon 
previous work by Deming.188  
Building on the success of the visible light-mediated reduction of the diazo motif in b-sulfonium 
a-diazoester conjugates, a visible light-mediated benzylation was developed using C4-
substituted Hantzsch ester reagents. A benzyl radical, generated from the Hantzsch ester 
reagent, could be formally transferred to the a-position of the b-sulfonium a-diazoester, with 
extrusion of dinitrogen, yielding a C-benzylation product. This functionalisation of the non-
native diazo moiety provided a platform for subsequent bioorthogonal transformations of 
biomolecules, following methionine bioconjugation. Ongoing work within the group involves 
the exploration of alternative radical sources which may facilitate the transfer of more varied 
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It has been established that the selenium analogue of methionine, selenomethionine 211, can 
react with iodonium salt 54 in quantitative conversion to form cationic selenium species 212 
(Scheme 94a). A competition experiment found that selenomethionine 211 can react with 
iodonium salt 54 in preference to methionine 213 in the ratio of 1:0.28 (alongside formation of 
selenoxide 214, Scheme 94b). Selenomethionine was able to react with 54 approximately 3.5 
times faster than methionine due to its increased nucleophilicity. This superior reactivity of 
selenomethionine could facilitate the development of an analogous functionalisation reaction, 
in which this naturally occurring amino acid could be incorporated in place of a methionine 
residue.275 Selectivity for selenomethionine over methionine using this method may find useful 
application in the profiling of complex proteomes.132  
 
Scheme 94 a) Reaction of selenomethionine with iodonium salt 54. b) Competition experiment between methionine and 
selenomethionine with iodonium salt 54 
Considering the emergence of interest in the development of dual modification strategies for 
peptides and proteins, the methionine bioconjugation developed herein was applied to the 
synthesis of multi-functionalised polypeptides via combination with a tryptophan-selective 
bioconjugation technique. Through merging a tryptophan-selective organoradical reagent with 
the optimised methionine labelling conditions, a simultaneous dual-functionalisation was 
developed. The dual-labelling strategy was shown to be compatible with various polypeptide 
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native biomolecules. It is hoped that the simultaneous dual-labelling will find valuable 
application in FRET imaging for biochemical use.276 
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5 Experimental  
5.1 General Information 
Proton nuclear magnetic resonance (1H NMR) spectra were recorded at ambient temperature 
on a Bruker AM 400 (400 MHz) or an Avance 500 (500 MHz) spectrometer. Chemical shifts 
(δ) are reported in ppm and quoted to the nearest 0.01 ppm relative to the residual protons in 
chloroform-d (7.26 ppm) or acetonitrile-d3 (1.94 ppm) and coupling constants (J) are quoted in 
Hertz (Hz). Data are reported as follows: Chemical shift (multiplicity, coupling constants, 
number of protons, assignment). Multiplicity is reported according to the following convention: 
s = singlet, d = doublet, t = triplet, q = quartet, qn = quintet, sext = sextet, sp = septet, m = 
multiplet, br = broad. Where coincident coupling constants have been observed, the apparent 
(app) multiplicity of the proton resonance has been reported. Carbon nuclear magnetic 
resonance (13C NMR) spectra were recorded at ambient temperature on a Bruker AM 400 (100 
MHz) or an Avance 500 (125 MHz) spectrometer. 19F NMR spectra were recorded at 376 MHz 
on a Bruker AVIII spectrometer. Chemical shift (δ) was measured in ppm and quoted to the 
nearest 0.1 ppm relative to the residual solvent peaks in chloroform-d (77.16 ppm) or 
acetonitrile-d3 (1.32 ppm). Infrared (IR) spectra were recorded on a Perkin Elmer 1FT-IR 
Spectrometer fitted with an ATR sampling accessory as either solids or neat films, either 
through direct application or deposited in chloroform, with absorptions reported in 
wavenumbers (cm-1) Analytical thin layer chromatography (TLC) was performed using pre-
coated Merck glass backed silica gel plates (Silicagel 60 F254). Flash column chromatography 
was performed using Material Harvest silica gel (230–400 mesh) under a positive pressure of 
compressed air unless otherwise stated. Visualization was achieved using ultraviolet light (254 
nm) or with basic potassium permanganate solutions as appropriate. Tetrahydrofuran, toluene, 
hexane, diethyl ether and dichloromethane were dried and distilled using standard methods.  
For reactions requiring degassed solvents, the solvents were degassed with a positive pressure 
of nitrogen for a minimum of one hour before use. High-resolution mass spectrometry was 
performed by the University of Cambridge, Department of Chemistry Mass Spectrometry 
Service.  MS/MS spectra were obtained by the Oncology iMED Biotech unit, AstraZeneca, 
Cambridge and Analytical Sciences, MedImmune, Cambridge, UK.  Circular Dichroism 
experiments were performed on an Applied Photophysics Chirascan Circular Dichroism 
Spectrophotometer.   
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Reactions that did not involve protein modification were carried out using glassware that was 
dried under vacuum using a heat gun and run under an atmosphere of nitrogen unless otherwise 
stated. All reactions were monitored by TLC or LCMS (Shimadzu LCMS 2020; solvents: A: 
0.05% Formic acid in H2O B: 0.05% formic acid in 95:5 CH3CN:H2O; method: 5-95%B over 
3.5 min, then hold 0.5 min, then 95-5% B over 0.5 min, hold 0.5 min, 0.7 mL/min) as 
appropriate. Exenatide•OAc, teriparatide•OAc, and aviptadil•OAc were purchased from 
Selleckchem; tetracosactide•OAc was purchased from Alpha-Diagnostics. Met-Gly, Aprotinin 
(from bovine lung, 3–7 TIU/mg, received containing carrying amounts of methionine 
sulfoxide), Ubiquitin (from bovine erythrocytes, BioUltra grade) and a-Lactalbumin (type III, 
>85%) were purchased from Sigma-Aldrich. All peptides and proteins were used without any 
additional purification. All other reagents were acquired from commercial sources and used as 
received. Protein modification reactions were monitored and outcomes assessed using either a 
Shimadzu LCMS-2020 (solvents: A: 0.05% Formic acid in H2O B: 0.05% formic acid in 95:5 
CH3CN:H2O) equipped with an APCI probe, or a Waters XEVO GII-S Q-TOF equipped with 
an ESI probe (solvent system:  A: 0.1% formic acid in H2O, B: 0.1% formic acid in 95:5 
CH3CN:H2O).  Conversions and product ratios were estimated either using total ion count (TIC, 
Shimadzu LCMS-2020), or MaxEnt software7 (Waters XEVO).  Note:  Due to the formation of 
cationic sulfur, the MaxEnt software underestimates the mass of the parent protein+label peak 
by 1 hydrogen.  
For MS/MS analysis, frozen peptide stocks were thawed on ice followed by gentle vortexing. 
Each peptide was diluted to a final concentration of 1 µM in 50% v/v acetonitrile, 0.1% v/v 
acetic acid for mass spectrometry analysis. Peptide ions were generated by electrospray 
ionisation (ESI) using a TriVersa NanoMate (Advion BioSciences, Inc., Ithaca, NY) from a 10 
µL injection with an applied spray voltage of 1.55 kV and a gas pressure of 0.7 psi. Ions 
generated by ESI were introduced directly into an Orbitrap Fusion tribrid mass spectrometer 
(Thermo Fisher Scientific, San Jose, CA). An accurate mass full scan from 100-2000 m/z was 
performed at a resolution of 120,000 (full width at half-maximum, FWHM) with data 
acquisition for 1 minute using the mass spectrometer instrument control software, Orbitrap 
Tune Application 2.0.  Peptide species charge states in the collected raw spectra were 
determined by manual interpretation using the theoretical monoisotopic mass. The most intense 
observed charge state for each peptide was selected for higher energy collisional dissociation 
(HCD) and electron transfer dissociation (ETD) fragmentation. 
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Precursor ion isolation was performed in the mass selecting quadrupole with an isolation 
window of 2 m/z. The precursor automatic gain control (AGC) target value was 1.5x105 with a 
maximum injection time of 200 msec. The normalised collision energy (NCE) for HCD 
fragmentation was optimised to 30%. ETD ion reaction time was set to 100 msec with an anion 
AGC of 2.5e5 and a maximum injection time of 200 msec. Supplemental collisional activation 
(SA) in EThcD was optimised to 25%. Spectra for both fragmentation methods were acquired 
over a mass range of 100-4000 m/z. Each accurate mass full scan and subsequent MS2 
fragmentation strategy was analysed in duplicate.  
Peptide MS2 spectra from HCD and ETD fragmentation approaches were loaded into mMass 
5.5 (http://www.mmass.org) for processing and deconvolution.277 Observed peptide fragments 
were matched to theoretical fragment predictions for each peptide allowing a maximum charge 
state of 5 and a match tolerance of 20 ppm. The Lorikeet spectrum viewer 
(http://code.google.com/p/lorikeet/) was used to view combined ETD and HCD MS2 spectra 
annotated with y, b, c and z fragment ions. Fragmentation data were further validated by manual 
inspection of the spectra. 
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5.2 Experimental procedures for the synthesis of hypervalent iodine reagents 
General Procedure A:  Synthesis of substituted α-bromo esters 
 
The synthesis of substituted α-bromoesters was achieved by adapting the procedure of 
Fukuyama.278 To a stirring solution of sodium bicarbonate (5.0 eq.) in CH3CN (0.15 M in 
alcohol), under N2, was added the desired alcohol (1.0 eq.), and the resulting mixture cooled to 
0 °C. Bromoacetyl bromide (1.5 eq.) was added, and the resulting mixture stirred for 1 - 1.5 
hours at room temperature. The reaction mixture was quenched with NaHCO3 (sat. aq.) and 
diluted with CH2Cl2. The organic layer was washed with NaHCO3 (sat. aq.) and brine, dried 
over MgSO4, filtered and evaporated to yield the desired α-bromoester. 
 
General Procedure B:  Synthesis of substituted α-diazo esters from α-bromoesters 
 
The synthesis of substituted α-diazoesters was achieved by adapting the procedure of 
Fukuyama.278 To a stirring solution of N,N’-ditosylhydrazine (1.5 eq.) in tetrahydrofuran (0.2 
M in α-bromoester) under N2, was added the desired α-bromoester (1.0 eq.) and the resulting 
solution cooled to 0 °C. 1,8-diaza-[4.4.0]-bicyclo-undec-7-ene (3.0 eq.) was added dropwise 
and the resulting mixture stirred for 1 hour at 0 °C. The reaction was quenched with NaHCO3 
(sat. aq.) and diluted with specified solvent. The aqueous layer was extracted with specified 
solvent and the combined organic layers washed with brine, dried over MgSO4, filtered and 
evaporated to yield the crude product. Purification by silica gel column chromatography 






























General Procedure C:  Synthesis of iodonium salts from α-diazoesters 
 
A vigorously stirring solution of freshly recrystallized (2,4-difluorophenyl)-λ3-iodanediyl 
diacetate (1.0 eq.) in CH2Cl2 (0.15 M in diacetate) under N2, was cooled to 0 °C. To the stirring 
solution was added BF3.OEt2 (1.1 - 1.3 eq.) and the resulting solution stirred for 5 minutes. The 
desired α-diazocarbonyl (1.1 - 1.3 eq.) was added rapid dropwise and the resulting solution 
stirred for 30 minutes at 0 °C. The solvent was evaporated, and the resulting orange/red residue 
was triturated using a sonicator with specified solvent to yield the desired iodonium salt. 
 
(2,4-Difluorophenyl)-λ3-iodanediyl diacetate 76 
 
Sodium perborate tetrahydrate (19.3 g, 125 mmol) was added portion-wise over 20 minutes to 
a stirring solution of 2,4-difluoroiodobenzene (1.5 mL, 12.5 mmol) in acetic acid (110 mL) at 
45 °C. Trifluoromethanesulfonic acid (6.7 mL, 75.2 mmol) was added and the resulting 
suspension stirred overnight at 45 °C. The solvent was removed in vacuo and the resulting 
slurry diluted with H2O (50 mL). The aqueous layer was extracted with CH2Cl2 (3 × 60 mL), 
dried over MgSO4, filtered and evaporated. The crude solid was recrystalised from CH2Cl2 and 
petroleum ether to yield 76 (1.99 g, 45%) as a white solid. 1H-NMR (400 MHz, CDCl3) δ: 8.16 
– 8.08 (m, 1H, H2), 7.10 (app. td, J = 8.4, 2.6 Hz, 1H, H5), 7.05 – 6.95 (m, 1H, H3), 1.98 (s, 6H, 
H8); 13C-NMR (100 MHz, CDCl3) δ: 177.1 (C7), 165.97 (dd, J = 257, 11 Hz, C4 or C6), 160.8 
(dd, J = 255, 13 Hz, C4 or C6), 138.5 (dd, J = 10, 3 Hz, C2), 114.3 (dd, J = 22, 3 Hz, C3), 105.4 
(app. t, J = 26 Hz, C5), 104.4 (dd, J = 24, 4 Hz, C1), 20.3 (C8); 19F{1H}-NMR (376 MHz, 
CD3CN) δ: -91.4 (d, J = 12 Hz), -100.7 (d, J = 12 Hz) 
































p-Toluenesulfonyl chloride (8.3 g, 43.5 mmol) was added to a solution of p-toluenesulfonyl 
hydrazide (6.2 g, 33.5 mmol) in CH2Cl2 (34 mL), under N2, and the resulting solution cooled 
to 0 °C. Pyridine (3.5 mL, 43.5 mmol) was added dropwise over 5 minutes and the reaction 
mixture turned yellow and became homogeneous. The reaction mixture was stirred at 0 °C for 
30 minutes, then n-hexane (50 mL) and H2O (75 mL) were added and the mixture stirred for a 
further 15 minutes at 0 °C. The resultant suspension was filtered and the crude solid 
recrystalised from acetone (80 mL) and H2O (38 mL). The precipitates were collected by 
filtration, washed with ice-cooled Et2O (25 mL) and dried in vacuo to yield 70 (9.8 g, 86%) as 
a white solid. 1H-NMR (400 MHz, (CD3)2SO) δ: 9.58 (br. s, 2H, H6), 7.64 (d, J = 8.3 Hz, 4H, 
H4), 7.38 (d, J = 8.3 Hz, 4H, H3), 2.39 (s, 6H, H1); 13C-NMR (100 MHz, (CD3)2SO) δ: 143.5 
(C2), 135.6 (C5), 129.5 (C3), 127.8 (C4), 21.1 (C1) 
*Data in accordance with literature278  
 
(1-Diazo-2-ethoxy-2-oxoethyl)(2,4-difluorophenyl)iodonium tetrafluoroborate 54 
 
54 was prepared according to General Procedure C using (2,4-difluorophenyl)-λ3-iodanediyl 
diacetate (1.0 g, 2.8 mmol), boron trifluoride diethyl etherate (0.45 mL, 3.6 mmol), and ethyl 
diazoacetate (0.46 mL (15% wt. CH2Cl2), 3.6 mmol), with a reaction time of 30 minutes.  
Sequential trituration using a sonicator (1:9 CH2Cl2:diethyl ether (5 × 20 mL), 40-60 petroleum 
(5 × 10 mL), diethyl ether (3 × 10 mL)) afforded 54 (1.0 g, 81%) as a yellow, free-flowing 
powder. 54 shows good stability (>3 months) when stored in a –20 °C freezer. 54 displays the 






































NMR (400 MHz, CD3CN) δ: 8.26 – 8.18 (m, 1H, H6), 7.36 (app. td, J = 8.8, 2.7 Hz, 1H, H3), 
7.25 – 7.19 (m, 1H, H5), 4.28 (q, J = 7.1 Hz, 2H, H9), 1.26 (t, J = 7.2 Hz, 3H, H10); 13C-NMR 
(125 MHz, CD3CN) δ: 168.0 (dd, J = 257, 12 Hz, C2 or C4), 162.5 (dd, J = 257, 12 Hz, C2 or 
C4), 161.5 (C8), 140.1 (dd, J = 12, 2 Hz, C6), 116.4 (dd, J = 23, 3 Hz, C5), 107.5 – 106.9 (m, 
C3), 97.6 (dd, J = 24, 4 Hz, C1), 65.4 (C9), 42.4 (br. s, C7), 14.5 (C10); 19F{1H}-NMR (376 MHz, 
CD3CN) δ: -90.8 (d, J = 12 Hz), -96.8 (d, J = 12 Hz), -144.1 (s), -144.2 (m); 1H{19F}-NMR 
(400 MHz, CD3CN) δ: 8.20 (d, J = 9.0 Hz, 1H, H6), 7.37 (d, J = 2.8 Hz, 1H, H3), 7.22 (dd, J = 
9.0, 2.8 Hz, 1H, H5), 4.28 (q, J = 7.1 Hz, 2H, H9), 1.26 (t, J = 7.1 Hz, 3H, H10); IR nmax/cm-1 
(film): 2989, 2117, 1682; HRMS: (ESI)+ (m/z) [M – BF4]+: Found 352.9590, Calc. 
C10H8F2IN2O2+ requires 352.9593; m.p.: 64-66 °C 
 
Cyclohexyl 2-bromoacetate 65 
 
65 was prepared according to General Procedure A using cyclohexanol (0.21 mL, 2.0 mmol), 
NaHCO3 (0.50 g, 6.0 mmol) and bromoacetyl bromide (0.25 mL, 2.8 mmol) in CH3CN (10 
mL), with a reaction time of 2 hours. The reaction mixture was diluted with CH2Cl2 (20 mL) 
and NaHCO3 (sat. aq.) (10 mL). The organic layer was washed with NaHCO3 (sat. aq.) (2 × 10 
mL) and brine (10 mL), dried over MgSO4, filtered and evaporated to yield 65 (0.43 g, 98%) 
which was used directly without further purification. 1H-NMR (400 MHz, CDCl3) δ: 4.80 (app. 
sp, J = 3.9 Hz, 1H), 3.79 (s, 2H), 1.89 – 1.80 (m, 2H), 1.77 – 1.67 (m, 2H), 1.57 – 1.23 (m, 6H) 
 
Cyclohexyl 2-diazoacetate 71 
 
71 was prepared according to General Procedure B using 65 (0.22 g, 1.0 mmol), N,N’- 
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3.0 mmol), with a reaction time of 1 hour. Column chromatography (10% diethyl ether/40-60 
petroleum ether) afforded 71 (0.12 g, 72%) as a yellow oil. 1H-NMR (500 MHz, CDCl3) δ: 
4.81 (app. sp, J = 4.0 Hz, 1H, H3), 4.69 (br. s, 1H, H1), 1.90 – 1.78 (m, 2H, H4’ and H8’), 1.76 
– 1.63 (m, 2H, H5’ and H7’), 1.56 – 1.46 (m, 1H, H6’), 1.45 – 1.29 (m, 4H, H4’’, H5’’, H7’’, 
H8’’), 1.28 – 1.16 (m, 1H, H6’’); 13C-NMR (125 MHz, CDCl3) δ: 166.4 (C2), 73.3 (C3), 46.3 
(C1), 31.9 (C4 and C8), 25.4 (C6), 23.7 (C5 and C7); IR nmax/cm-1 (film): 2935, 2860, 2102, 1677, 
1181; HRMS: (ESI)+ (m/z) [M+H]+: Found 169.0971, Calc. C10H8F2IN2O2+ requires 169.0972 
 
(2-(Cyclohexyloxy)-1-diazo-2-oxoethyl)(2,4-difluorophenyl)iodonium tetrafluoroborate 77 
 
77 was prepared according to General Procedure C using (2,4-difluorophenyl)-λ3-iodanediyl 
diacetate 76 (0.36 g, 1.0 mmol), boron trifluoride diethyl etherate (0.18 mL, 1.3 mmol), and 
cyclohexyl diazoacetate 71 (0.16 g, 1.3 mmol), with a reaction time of 30 minutes.  Trituration 
using a sonicator (9:1 diethyl ether:40-60 petroleum ether, 20 mL, followed by 1:1 diethyl 
ether:40-60 petroleum ether, 20 mL) afforded 77 (0.27 g, 66%) as a yellow, free-flowing, 
powder. 1H-NMR (500 MHz, CD3CN) δ: 8.22 – 8.15 (m, 1H, H6), 7.37 (app. td, J = 8.6, 2.6 
Hz, 1H, H3), 7.26 – 7.19 (m, 1H, H5), 4.86 (app. sp, J = 3.9 Hz, 1H, H9), 1.87 – 1.78 (m, 2H, 
H10’), 1.75 – 1.65 (m, 2H, H11’), 1.55 – 1.26 (m, 6H, H10’’, H11’’, H12); 13C-NMR (125 MHz, 
CD3CN) δ: 167.9 (dd, J = 257, 11 Hz, C2 or C4), 162.5 (dd, J = 256, 13 Hz, C2 or C4), 160.7 
(C8), 139.9 (dd, J = 11, 2 Hz, C6), 116.4 (dd, J = 23, 3 Hz, C5), 107.4 – 106.9 (m, C3), 97.6 (dd, 
J = 23, 4 Hz, C1), 78.3 (C9), 31.9 (C10’), 25.7 (C12), 23.9 (C11’)*; 19F{1H}-NMR (376 MHz, 
CD3CN) δ: -90.7 (d, J = 12 Hz), -96.9 (d, J = 12 Hz), -144.1 (s), -144.2 (s); IR nmax/cm-1 (film): 
2951, 2114, 1698, 1034; HRMS: (ESI)+ (m/z) [M – BF4]+: Found 407.0068, Calc. 
C14H14F2IN2O2+ requires 407.0063; m.p.: 78-80 °C (decomp.) 





















Notes: additional precipitate can be collected. While the carbon possessing the diazo moiety 
was not observable by 13C-NMR, the IR stretch8 at 2114 cm-1 as well as the correct mass being 
observed confirms the presence of the diazo group. 
 
Allyl 2-bromoacetate 66 
 
66 was prepared according to General Procedure A using allyl alcohol (0.55 mL, 8.0 mmol), 
NaHCO3 (2.02 g, 24.0 mmol) and bromoacetyl bromide (0.98 mL, 11.2 mmol) in CH3CN (40 
mL), with a reaction time of 2 hours. The reaction mixture was diluted with CH2Cl2 (20 mL) 
and washed with NaHCO3 (sat. aq.) (3 × 10 mL) and brine (10 mL), dried over MgSO4, filtered 
and evaporated to yield the 66 (1.17 g, 82%) which was used directly without further 
purification. 1H-NMR (400 MHz, CDCl3) δ: 5.97 – 5.86 (m, 1H), 5.40 – 5.24 (m, 2H), 4.68 – 
4.63 (m, 2H), 3.86 (br. s, 2H) 
 
Allyl 2-diazoacetate 72 
 
72 was prepared according to General Procedure B using 66 (1.2 g, 6.5 mmol), N,N’- 
ditosylhydrazine (3.3 g, 9.8 mmol), and 1,8-diazo-bicyclo-[5.4.0]-undec-7-ene (3.6 mL, 26.0 
mmol), with a reaction time of 1 hour. Diethyl ether (3 × 50 mL) was used in the workup. 
Column chromatography (10-30% diethyl ether/40-60 petroleum ether) afforded 72 (0.5 g, 
61%) as a volatile yellow oil which was used directly. 1H-NMR (500 MHz, CDCl3) δ: 6.00 – 
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Allyl 2-diazo-2-((2,4-difluorophenyl)(tetrafluoro-λ5-boraneyl)-λ3-iodaneyl)acetate 78 
 
78 was prepared according to General Procedure C using (2,4-difluorophenyl)-λ3-iodanediyl 
diacetate 76 (1.1 g, 3.1 mmol), boron trifluoride diethyl etherate (0.5 mL, 4.0 mmol), and allyl 
diazoacetate 72 (0.50 g, 4.0 mmol), with a reaction time of 30 minutes.  Trituration using a 
sonicator (9:1 diethyl ether:40-60 petroleum ether, 20 mL, followed by 3:1 diethyl ether:40-60 
petroleum ether, 20 mL) afforded 78 (0.68 g, 60%) as a yellow oil. 1H-NMR (500 MHz, 
CD3CN) δ: 8.25 – 8.18 (m, 1H, H6), 7.35 (app. td, J = 8.7, 2.6 Hz, H3), 7.26 – 7.18 (m, 2H, H5), 
5.98 – 5.87 (m, 1H, H10), 5.39 – 5.25 (m, 2H, H11), 4.73 (app. d, J = 5.7 Hz, 2H, H9); 13C-NMR 
(125 MHz, CD3CN) δ: 168.0 (dd, J = 257, 12 Hz, C2 or C4), 162.5 (dd, J = 254, 13 Hz, C2 or 
C4), 161.3 (C8), 140.1 (dd, J = 11, 1 Hz, C6), 132.3 (C10), 119.8 (C11), 116.5 (dd, J = 24, 3 Hz, 
C5), 107.6 – 106.9 (m, C3), 97.7 (dd, J = 24, 4 Hz, C1), 69.2 (C9)*; 19F{1H}-NMR (376 MHz, 
CD3CN) δ: -92.4 (d, J = 12 Hz), -99.7 (d, J = 12 Hz), -148.8 (s), -150.5 (s); IR nmax/cm-1 (film): 
2988, 2118, 1701, 1036; HRMS: (ESI)+ (m/z) [M – BF4]+: Found 364.9591, Calc. 
C11H8F2IN2O2+ requires 364.9593 
* C7 not observed 
Notes: While the carbon possessing the diazo moiety was not observable by 13C-NMR, the IR 
stretch8 at 2118 cm-1 as well as the correct mass being observed confirms the presence of the 
diazo group. 
 
Hex-5-en-1-yl 2-bromoacetate 67 
 
67 was prepared according to General Procedure A using 5-hexen-1-ol (0.24 mL, 2.0 mmol), 
NaHCO3 (0.50 g, 6.0 mmol) and bromoacetyl bromide (0.25 mL, 2.8 mmol) in CH3CN (10 































and washed with NaHCO3 (sat. aq.) (3 × 10 mL) and brine (10 mL), dried over MgSO4, filtered 
and evaporated to yield the 67 (0.24 g, 56%) which was used directly without further 
purification. 1H-NMR (400 MHz, CDCl3) δ: 5.81 – 5.70 (m, 1H), 5.02 – 4.91 (m, 2H), 4.15 (t, 
J = 6.2 Hz, 2H), 3.80 (s, 2H), 2.11 – 2.01 (m, 2H), 1.71 – 1.61 (m, 2H), 1.50 – 1.39 (m, 2H) 
 
Hex-5-en-1-yl 2-diazoacetate 73 
 
73 was prepared according to General Procedure B using 76 (0.25 g, 1.1 mmol), N,N’- 
ditosylhydrazine 70 (0.57 g, 1.7 mmol), and 1,8-diazo-bicyclo-[5.4.0]-undec-7-ene (0.46 mL, 
3.3 mmol), with a reaction time of 1 hour. Column chromatography (10% diethyl ether/40-60 
petroleum ether) afforded 73 (0.09 g, 48%) as a yellow oil. 1H-NMR (400 MHz, CDCl3) δ: 
5.83 – 5.71 (m, 1H, H7), 5.03 – 4.91 (m, 2H, H8), 4.72 (br. s, 1H, H1), 4.14 (t, J = 6.8 Hz, 2H, 
H3), 2.10 – 2.02 (m, 2H, H6), 1.68 – 1.59 (m, 2H, H4), 1.48 – 1.38 (m, 2H, H5); 13C-NMR (125 
MHz, CDCl3) δ: 166.9 (C2), 138.4 (C7), 115.0 (C8), 64.8 (C3), 46.2 (C1), 33.4 (C6), 28.3 (C4), 
25.2 (C5); IR nmax/cm-1 (film): 2935, 2105, 1685, 1179; HRMS: (ESI)+ (m/z) [M+H]+: Found 
169.0971, Calc. C8H13O2N2+ requires 169.0972 
 
Hex-5-en-1-yl 2-diazo-2-((2,4-difluorophenyl)(tetrafluoro-λ5-boraneyl)-λ3-iodaneyl)acetate 79 
 
79 was prepared according to General Procedure C using (2,4-difluorophenyl)-λ3-iodanediyl 
diacetate 76 (1.15 g, 3.2 mmol), boron trifluoride diethyl etherate (0.51 mL, 4.2 mmol), and 
hexenyl diazoacetate 73 (0.70 g, 4.1 mmol), with a reaction time of 30 minutes.  Trituration 
using a sonicator (9:1 diethyl ether:40-60 petroleum ether, 40 mL, followed by 3:1 diethyl 
ether:40-60 petroleum ether, 20 mL) afforded 79 (1.14 g, 88%) as a yellow oil. 1H-NMR (500 
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(m, 1H, H5), 5.87 – 5.74 (m, 1H, H13), 5.09 – 4.90 (m, 2H, H14), 4.24 (t, J = 6.5 Hz, 2H, H9), 
2.10 – 2.02 (m, 2H, H12), 1.68 – 1.62 (m, 2H, H10), 1.44 – 1.37 (m, 2H, H11); 13C-NMR (125 
MHz, CDCl3) δ: 168.1 (dd, J = 257, 12 Hz, C2 or C4), 162.6 (dd, J = 254, 12 Hz, C2 or C4), 161.5 
(C8), 140.0 (app. d, J = 11 Hz, C6), 139.5 (C13), 116.5 (dd, J = 23, 3 Hz, C5), 115.3 (C14), 107.6 
– 106.9 (m, C3), 97.7 (dd, J = 24, 4 Hz, C1), 69.1 (C9), 33.8 (C12), 28.7 (C10), 25.6 (C11)*; 
19F{1H}-NMR (376 MHz, CD3CN) δ: -92.6 (d, J = 12 Hz), -99.7 (d, J = 12 Hz), -150.7 (s), -
150.8 (s); IR nmax/cm-1 (film): 2952, 2117, 1702, 1031; HRMS: (ESI)+ (m/z) [M – BF4]+: Found 
407.0067, Calc. C11H8F2IN2O2+ requires 407.0063 
* C7 not observed 
Notes: While the carbon possessing the diazo moiety was not observable by 13C-NMR, the IR 
stretch8 at 2117 cm-1 as well as the correct mass being observed confirms the presence of the 
diazo group. 
 
Hex-5-yn-1-yl 2-bromoacetate 68 
 
68 was prepared according to General Procedure A using 5-hexyn-1-ol (0.22 mL, 2.0 mmol), 
NaHCO3 (0.50 g, 6.0 mmol) and bromoacetyl bromide (0.25 mL, 2.8 mmol) in CH3CN (10 
mL), with a reaction time of 2 hours. The reaction mixture was diluted with CH2Cl2 (20 mL) 
and washed with NaHCO3 (sat. aq.) (3 × 10 mL) and brine (10 mL), dried over MgSO4, filtered 
and evaporated to yield 68 (0.39 g, 89%) which was used directly without further purification. 
1H-NMR (400 MHz, CDCl3) δ: 4.18 (t, J = 6.6 Hz, 2H), 3.81 (s, 2H), 2.22 (td, J = 7.0, 2.7 Hz, 















Hex-5-yn-1-yl 2-diazoacetate 74 
 
74 was prepared according to General Procedure B using 68 (0.23 g, 1.0 mmol), N,N’- 
ditosylhydrazine 70 (0.53 g, 1.5 mmol), and 1,8-diazo-bicyclo-[5.4.0]-undec-7-ene (0.41 mL, 
3.0 mmol), with a reaction time of 1 hour. Column chromatography (10% diethyl ether/40-60 
petroleum ether) afforded 74 (0.12 g, 69%) as a yellow oil. 1H-NMR (400 MHz, CDCl3) δ: 
4.71 (br. s, 1H, H1), 4.12 (t, J = 7.2 Hz, 2H, H3), 2.17 (td, J = 7.2, 2.7 Hz, 2H, H6), 1.92 (t, J = 
2.7 Hz, 1H, H8), 1.76 – 1.67 (m, 2H, H4), 1.58 – 1.49 (m, 2H, H5); 13C-NMR (125 MHz, CDCl3) 
δ: 167.1 (C2), 83.7 (C7), 68.8 (C8), 64.3 (C3), 46.1 (br. s, C1), 27.8 (C4), 24.8 (C5), 18.0 (C6); IR 
nmax/cm-1 (film): 2953, 2105, 1682, 1179; HRMS: (ESI)+ (m/z) [M+H]+: Found 167.0817, Calc. 
C8H11N2O2+ requires 167.0815 
 
Hex-5-yn-1-yl 2-diazo-2-((2,4-difluorophenyl)(tetrafluoro-λ5-boraneyl)-λ3-iodaneyl)acetate 80 
 
80 was prepared according to General Procedure C using (2,4-difluorophenyl)-λ3-iodanediyl 
diacetate 76 (1.0 g, 2.8 mmol), boron trifluoride diethyl etherate (0.45 mL, 3.7 mmol), and 
hexynyl diazoacetate 74 (0.61 g, 3.7 mmol), with a reaction time of 30 minutes.  Trituration 
using a sonicator (9:1 diethyl ether:40-60 petroleum ether, 40 mL, followed by 3:1 diethyl 
ether:40-60 petroleum ether, 20 mL) afforded 80 (1.3 g, 87%) as a yellow oil. 1H-NMR (500 
MHz, CD3CN) δ: 8.25 – 8.18 (m, 1H, H6), 7.36 (app. td, J = 8.7, 2.7 Hz, H3), 7.25 – 7.19 (m, 
1H, H5), 4.25 (t, J = 6.3 Hz, 2H, H9), 2.23 – 2.17 (m, 3H, H12 and H14), 1.79 – 1.69 (m, 2H, 
H10), 1.57 – 1.48 (m, 2H, H11); 13C-NMR (125 MHz, CDCl3) δ: 168.0 (dd, J = 256, 11 Hz, C2 
or C4), 162.5 (dd, J = 256, 13 Hz, C2 or C4), 161.5 (C8), 140.0 (dd, J = 11, 2 Hz, C6), 116.5 (dd, 
J = 23, 3 Hz, C5), 107.5 – 106.9 (m, C3), 97.7 (dd, J = 23, 4 Hz, C1), 84.9 (C13), 70.2 (C14), 68.7 
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Hz), -99.7 (d, J = 12 Hz), -150.5 (s), -150.6 (s); IR nmax/cm-1 (film): 3282, 2118, 1702, 1029; 
HRMS: (ESI)+ (m/z) [M – BF4]+: Found 404.9906, Calc. C14H12F2IN2O2+ requires 404.9906 
* C7 not observed 
Notes: While the carbon possessing the diazo moiety was not observable by 13C-NMR, the IR 
stretch8 at 2118 cm-1 as well as the correct mass being observed confirms the presence of the 
diazo group. 
 
Tetradecyl 2-bromoacetate 69 
 
69 was prepared according to General Procedure A using 1-tetradecanol (0.43 mL, 2.0 mmol), 
NaHCO3 (0.50 g, 6.0 mmol) and bromoacetyl bromide (0.25 mL, 2.8 mmol) in CH2Cl2 (10 
mL), with a reaction time of 2 hours. The reaction mixture was diluted with CH2Cl2 (20 mL) 
and washed with NaHCO3 (sat. aq.) (3 × 10 mL) and brine (10 mL), dried over MgSO4, filtered 
and evaporated to yield the 69 (0.61 g, 91%) which was used directly without further 
purification. 1H-NMR (400 MHz, CDCl3) δ: 4.16 (t, J = 6.7 Hz, 2H), 3.82 (s, 2H), 1.69 – 1.61 
(m, 2H), 1.35 – 1.21 (m, 22H), 0.90 – 0.85 (m, 3H). 
 
Tetradecyl 2-diazoacetate 75 
 
75 was prepared according to General Procedure B using 69 (0.30 g, 0.9 mmol), N,N’- 
ditosylhydrazine (0.46 g, 1.4 mmol), and 1,8-diazo-bicyclo-[5.4.0]-undec-7-ene (0.37 mL, 2.7 
mmol), with a reaction time of 1 hour, affording 75 (0.19 g, 74%) as a yellow oil which was 
used without further purification. 1H-NMR (500 MHz, CD3CN) δ: 4.72 (br. s, 1H, H1), 4.14 (t, 
J = 6.7 Hz, 2H, H3), 1.68 – 1.58 (m, 2H, H4), 1.38 – 1.22 (m, 22H, H5-H15), 0.90 – 0.84 (m, 3H, 









































(CH2), 29.78 (CH2), 29.77 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 28.9 (C4), 
25.9 (CH2), 22.8 (CH2), 14.2 (C16)*; IR nmax/cm-1 (film): 2922, 2853, 2107, 1694, 1181; 
HRMS: (ESI)+ (m/z) [M+H]+: Found 283.2375, Calc. C16H31N2O2+ requires 283.2386 
* C2 not observed 
Notes: While the carbon possessing the diazo moiety was not observable by 13C-NMR, the IR 
stretch8 at 2107 cm-1 as well as the correct mass being observed confirms the presence of the 
diazo group. 
 
Tetradecyl 2-diazo-2-((2,4-difluorophenyl)(tetrafluoro-λ5-boraneyl)-λ3-iodaneyl)acetate 81 
 
81 was prepared according to General Procedure C using (2,4-difluorophenyl)-λ3-iodanediyl 
diacetate 76 (0.50 g, 1.4 mmol), boron trifluoride diethyl etherate (0.22 mL, 1.8 mmol), and 75 
(0.51 g, 1.8 mmol), with a reaction time of 30 minutes.  The reaction mixture was diluted with 
water (5 mL) and extracted with CH2Cl2 (4 × 5 mL). The combined organic extracts were 
filtered through cotton and concentrated in vacuo. The resultant orange oil was dissolved in 40-
60 petroleum (15 mL) and cooled to between -30 oC and -40 oC, resulting in the formation of a 
yellow oil. The solvent was decanted and the resulting oil dried under vacuum to afford 81 (0.52 
g, 70%) as a yellow oil. 1H-NMR (500 MHz, CD3CN) δ: 8.24 – 8.18 (m, 1H, H6), 7.37 (app. 
td, J = 8.8, 2.8 Hz, 1H, H3), 7.25 – 7.20 (m, 1H, H5), 4.23 (t, J = 6.6 Hz, 2H, H9), 1.67 – 1.60 
(m, 2H, H10), 1.33 – 1.24 (m, 22H, H11, H12, H13, H14, H15, H16, H17, H18, H19, H20, H21), 0.88 
(app. t, J = 6.6 Hz, 3H, H22); 13C-NMR (125 MHz, CDCl3) δ: 168.0 (dd, J = 257, 12 Hz, C2 or 
C4), 162.4 (dd, J = 255, 13 Hz, C2 or C4), 161.4 (br. s, C8), 140.0 (dd, J = 11, 2 Hz, C6), 116.5 
(dd, J = 23, 3 Hz, C5), 107.5 – 107.0 (m, C3), 97.7 (dd, J = 24, 4 Hz, C1), 69.3 (C9), 32.7 (CH2), 
30.4 (CH2), 30.38 (CH2), 30.36 (CH2), 30.35 (CH2), 30.27 (CH2), 30.21 (CH2), 30.1 (CH2), 29.8 
(CH2), 29.2 (C10), 26.3 (CH2), 23.4 (CH2), 14.5 (C22)*; 19F{1H}-NMR (376 MHz, CD3CN) δ: 
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2117, 1706, 1051; HRMS: (ESI)+ (m/z) [M – BF4]+: Found 521.1475, Calc. C22H32F2IN2O2+ 
requires 521.1471 
* C7 not observed 
Notes: While the carbon possessing the diazo moiety was not observable by 13C-NMR, the IR 





5.3 Experimental procedures for polypeptide and protein functionalisation 
General Procedure D:  Polypeptide and Protein Functionalization 
A 2 mL vial equipped with a magnetic stirrer was charged with a solution containing the desired 
protein (2 mM in 0.1 M thiourea (aq.), 20 µL). To the vial was added thiourea (100 mM in H2O, 
20 µL) and H2O (10 µL). To the solution was added TEMPO (40 mM in H2O, 50 µL) and the 
vial was stirred vigorously. To the stirring solution was added the iodonium salt (100 mM in 
CH3CN or H2O, 100 µL) and the resulting solution stirred for 5 minutes at room temperature. 
The resulting mixture was then washed with diethyl ether or ethyl acetate, the organic layer was 
decanted and discarded while the remaining organic volatiles were then removed from the 
aqueous layer in vacuo. The resulting solution was analyzed directly via LC/MS. 
 
General Procedure E:  Polypeptide and Protein Functionalization 
A 2 mL vial equipped with a magnetic stirrer was charged with a solution containing the desired 
protein (2 mM in 0.1 M thiourea (aq.), 20 µL). To the vial was added thiourea (100 mM in H2O, 
20 µL) and formic acid (100 mM in H2O, 10 µL). To the solution was added TEMPO (40 mM 
in H2O, 50 µL) and the vial was stirred vigorously. To the stirring solution was added the 
iodonium salt (100 mM in CH3CN or H2O, 100 µL) and the resulting solution stirred for 5 
minutes at room temperature. The resulting mixture was then washed with diethyl ether or ethyl 
acetate, the organic layer was decanted and discarded while the remaining organic volatiles 
were then removed from the aqueous layer in vacuo. The resulting solution was analyzed 
directly via LC/MS. 
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((S)-3-amino-4-((carboxymethyl)amino)-4-oxobutyl)(1-diazo-2-ethoxy-2-oxoethyl) 
(methyl)sulfonium tetrafluoroborate 52 
 
A round-bottomed flask equipped with a magnetic stir-bar was charged with methionine-
glycine 51 (52 mg, 0.25 mmol) and H2O (0.5 mL) then evacuated/backfilled with N2 (3 cycles). 
To the flask was added a freshly degassed solution of 54 (164 mg in H2O (1.0 mL)), and the 
resulting solution stirred for 1 hour at room temperature. The resulting suspension was then 
diluted with water and ethyl acetate the organic layer decanted. The aqueous layer was washed 
twice more with ethyl acetate, then evaporated to dryness in vacuo. The resulting yellow residue 
was then redissolved in a minimal amount of acetonitrile and precipitated with ether at 4 °C. 
The supernatant was decanted, and the residue was dried in vacuo to yield 52 as a faint yellow 
residue (62 mg, 78%, 1:1 mixture of diastereomers). 52 was considerably hygroscopic and was 
stored at –20 °C. 1H-NMR (500 MHz, CD3CN) δ: 4.42 (q, J = 7.2 Hz, 2H, H8), 4.31 – 4.20 (m, 
1H, H2), 4.07 – 3.90 (m, 3H, H4  and H12), 3.85 – 3.67 (m, 1H, H4’), 3.33 (app. d, J = 3.2 Hz, 
3H, H5, H5’), 2.60 – 2.40 (m, 2H, H3 and H3’), 1.34 (t, J = 7.2 Hz, 3H, H9); 13C-NMR (125 
MHz, CDCl3) δ: 174.3 (C13, C13’), 167.9 (C10), 167.8 (C10’), 161.3 (C7), 161.2 (C7’), 64.7 (C8), 
53.8 (2C6), 51.4 (C2), 51.3 (C2’), 42.4 (2C12), 39.5 (C4), 39.4 (C4’), 26.5 (C5, C5’), 25.6 (C3), 
25.5 (C3’), 13.3 (C9); IR nmax/cm-1 (film): 2988, 2150, 1684, 1005; HRMS: (ESI)+ (m/z) [M]+: 























5.3.1 Substrate scope for polypeptide and protein functionalisation 
Exenatide acetate functionalization with 54 in aqueous conditions forming 56 
 
The labelling of exenatide was performed at room temperature using General Procedure D 
using 54 (100 mM in H2O) and 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL) for the extraction.  
The resulting solution was then analysed directly via LC/MS C18 column (50 × 2.1 mm, 
2.6µm), Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 ml/min) and was observed 
to have proceeded in >95% conversion. 
 
Figure 18 Mass trace of crude reaction mixture of exenatide with 54, with mass chromatogram overlayed. ’ denotes 
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Large Scale Synthesis of 56 
A 2 mL vial equipped with a magnetic stirrer was charged with Exenatide•OAc (~1.8 mg, ~0.6 
µmol). To the vial was added thiourea (100 mM in H2O, 160 µL), H2O (120 µL) and TEMPO 
(67 mM in H2O, 120 µL) and the vial was stirred vigorously before 54 (100 mM in H2O, 400 
µL) was added and the resulting solution stirred for 5 minutes at room temperature. The reaction 
mixture was then extracted with 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL). The remaining 
organic volatiles were then removed in vacuo.  Purification via reverse-phase HPLC* (C18 
column (150 × 10 mm, 10 µm), Gradient: 5-55% B over 9 min then 55-95% B over 1 min, hold 
for 1.5 min, then 95-5%B over 0.5 min, hold for 3 min, 5 ml/min), followed by lyophilization 
yielded 56 as a sticky, off-white solid that was immediately redissolved in H2O (500 µL) and 
stored at –20 °C. Concentration analysis by A280 indicated a 1.4 mg/mL solution ~79% isolated 
yield).  
*Note:  Purification of 56 should be carried out expediently as prolonged purification times can 
lead to low levels of peptide backbone hydrolysis.  
 
 







Figure 20 Mass trace of purified exenatide conjugate 56, with mass chromatogram shown as an insert. Diagnostic 
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Tetracosactide functionalization with 54 in aqueous conditions to form 57 
 
The labelling of tetracosactide was performed at room temperature using General Procedure D 
using 54 (100 mM in H2O) and 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL) for the extraction. 
The resulting solution was then analysed directly via LC/MS (C18 column, 50 × 2.1 mm, 2.6 
µm, Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 ml/min) and was observed to have 
proceeded in >95% conversion.  
 
Figure 21 Mass trace of tetracosactide conjugate 57, with mass chromatogram shown as an insert. Diagnostic fragmentation 
of C–S bond (indicated with ‘) giving: M+label-(label+SMe) = M+113-160. 
  





















Large Scale Synthesis of 57 
A 2 mL vial equipped with a magnetic stirrer was charged with Tetracosactide•OAc (~1.8 mg, 
~0.6 µmol). Thiourea (100 mM in H2O, 160 µL), H2O (120 µL) and TEMPO (67 mM in H2O, 
120 µL) were added and the vial stirred vigorously before 54 (100 mM in H2O, 400 µL) was 
added and the resulting solution stirred for 5 minutes at room temperature. The reaction mixture 
was extracted with 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL) and the remaining organic 
volatiles were then removed from the aqueous layer in vacuo.  Purification via reverse-phase 
HPLC* (C18 column, 150 × 10 mm, 10µm, Gradient: 5-55% B over 9 min then 55-95% B over 
1 min, hold for 1.5 min, then 95-5%B over 0.5 min, hold for 3 min, 5 ml/min), followed by 
lyophilization yielded 57 as a sticky, off-white solid that was immediately redissolved in H2O 
(500 µL) and stored at –20 °C.  Concentration analysis by A280 indicated a 1.0 mg/mL solution 
~56% isolated yield).  
*Note:  Purification of 57 should be carried out expediently as prolonged purification times can 
lead to low levels of peptide backbone hydrolysis.  
 
Figure 22 HPLC trace of the crude reaction mixture of tetracosactide•OAc and 54 
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Figure 23 Mass trace of purified tetracosactide conjugate 57, with mass chromatogram shown as an insert. Diagnostic 
fragmentation of C–S bond (indicated with ‘) giving: M+label-(label+SMe) = M+113-160. 
 
 











Peptide4 #91 RT: 0.62 AV: 1 NL: 3.47E6
T: FTMS + p NSI Full ms [100.0000-2000.0000]





















































Figure 25 MS/MS spectra of tetracosactide conjugate 57 with the difference between c32+ and c42+ ions of 245.13 Da 
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Aviptadil functionalization with 54 in aqueous conditions to form 58 
 
The labelling of aviptadil was performed according to General Procedure D using 54 (100 mM 
in H2O) and 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL) for the extraction.  The resulting 
solution was then analysed directly via LC/MS (pentafluorophenyl column, 50 × 2.1 mm, 
2.6µm, Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 ml/min), and was observed to 
have proceeded in >95% conversion. 
 
Figure 27 Mass trace of crude reaction mixture of aviptadil with 54, with mass chromatogram shown as an insert. Diagnostic 
fragmentation of C–S bond (indicated with ‘) giving: M+label-(label+SMe) = M+113-160. 
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Large Scale Synthesis of 58 
A 2 mL vial equipped with a magnetic stir bar was charged with Aviptadil•OAc (~1.4 mg, ~0.4 
µmol). Thiourea (100 mM in H2O, 160 µL), H2O (120 µL) and TEMPO (67 mM in H2O, 120 
µL) were added and the vial was stirred vigorously before 54 (100 mM in H2O 400 µL) was 
added. The reaction mixture was stirred for 5 minutes at room temperature before being 
extracted with 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL).  The remaining organic volatiles 
were then removed in vacuo.  Purification via reverse-phase HPLC* (C18 column,150 × 10 
mm, 10µm, Gradient: 5-55% B over 9 min then 55-95% B over 1 min, hold for 1.5 min, then 
95-5%B over 0.5 min, hold for 3 min, 5 ml/min), followed by lyophilization yielded 58 as a 
sticky, off-white solid that was immediately redissolved in H2O (500 µL) and stored at –20 °C.  
Concentration analysis by A280 indicated a 1.3 mg/mL solution (>90% isolated yield).  
*Note:  Purification of 58 should be carried out expediently as prolonged purification times can 
lead to low levels of peptide backbone hydrolysis. 
 






Figure 29 Mass trace of purified aviptadil conjugate 58, with mass chromatogram shown as an insert. Diagnostic 
fragmentation of C–S bond (indicated with ‘) giving: M+label-(label+SMe) = M+113-160. 
 
Figure 30 MS  of aviptadil conjugate 58 
Peptide2_1µM #388 RT: 2.35 AV: 1 NL: 1.55E6
T: FTMS + p NSI Full ms [100.0000-2000.0000]





































































Figure 31 MS/MS spectra of aviptadil conjugate 58 with the difference between c163+ and c173+ ions of 245.1 Da confirming 
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Aviptadil conjugate 58 CD spectrum
Unmodified Modified
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Teriparatide functionalization with 54 in aqueous conditions to form 59 
 
The labelling of teriparatide was performed at room temperature using General Procedure E 
using 54 (100 mM in H2O) and 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL) for the extraction.  
The resulting solution was then analysed directly via LC/MS (C18 column 50 × 2.1 mm, 2.6 
µm, Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 ml/min) and was observed to have 
proceeded in >95% conversion. 
 
Figure 33 Mass trace of crude reaction mixture of teriparatide with 54, mass chromatogram shown as an insert. Diagnostic 
fragmentation of C–S bond (indicated with ‘) giving: M+2(label)-(label+SMe) = M+2(113)-160.  The M+2(label)-




























Large Scale Synthesis of 59 
A 2 mL vial equipped with a magnetic stirrer was charged with teriparatide•OAc (~1.2 mg, 
~0.3 µmol). Thiourea (100 mM in H2O, 160 µL), formic acid (0.1 M in H2O, 40 µL), H2O (80 
µL) and TEMPO (67 mM in H2O, 120 µL) were added and the vial was stirred vigorously 
before 54 (100 mM in H2O, 400 µL) was added.  The reaction mixture was stirred for 5 minutes 
at room temperature, then extracted with 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL).  The 
remaining organic volatiles were then removed in vacuo. Purification via reverse-phase HPLC* 
(C18 column, 150 × 10 mm, 10 µm, Gradient: 5-55% B over 9 min then 55-95% B over 1 min, 
hold for 1.5 min, then 95-5% B over 0.5 min, hold for 3 min, 5 mL/min), followed by 
lyophilization yielded 59 as a sticky, off-white solid that was immediately redissolved in H2O 
(500 µL) and stored at –20 °C.  Concentration analysis by A280 indicated a 1.0 mg/mL solution 
~92% isolated yield).  
*Note: Purification of 59 should be carried out expediently as prolonged purification times can 
lead to low levels of peptide backbone hydrolysis.  
 
Figure 34 HPLC trace of the crude reaction mixture of teriparatide•OAc and 54 
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Figure 35 Mass trace of purified teriparatide conjugate 59, mass chromatogram shown as an insert. Diagnostic fragmentation 
of C–S bond (indicated with ‘) giving: M+2(label)-(label+SMe) = M+2(113)-160. The M+2(label)-2(label+SMe) = 
M+2(113)-2(160) is indicated by ’’. 
  






Peptide6 #69-101 RT: 0.48-0.69 AV: 33 NL: 9.72E5
T: FTMS + p NSI Full ms [100.0000-2000.0000]































































Figure 37 MS/MS spectra of teriparatide conjugate 59 with the difference between b7+ and c8+ ions of 261.2 Da and 
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CD Spectrum of teriparatide conjugate 59 
 











































































Large Scale Synthesis of Ubiquitin conjugate 63 
A 2 mL vial equipped with a magnetic stirrer was charged with Ubiquitin (~1.5 mg, ~0.2 µmol). 
To the vial was added thiourea (100 mM in H2O, 100 µL), formic acid (0.1M in H2O, 25 µL) 
and H2O (125 µL) and the vial stirred vigorously before 54 (100 mM in H2O, 250 µL) was 
added. The reaction mixture was stirred for 5 minutes at room temperature, then extracted twice 
with 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL).  The remaining organic volatiles were then 
removed from the aqueous layer using a rotary evaporator.  63 was purified by ion exchange 
chromatography (MonoS 4.6/100 PE column, GE Healthcare) using a NaCl gradient (0-1 M) 
in 50 mM ammonium acetate pH 4.5 on an ÄKTAexplorer (Pharmacia Biotech), and fractions 
directly analysed my MS. 
 
 
Figure 39 FPLC trace of Ubiquitin conjugate 63, purified using MonoS 4.6/100 PE column, GE Healthcare. Clear separation 
of unmodified Ubiquitin and modified conjugate 63 was achieved due to the differing elution times of the charged species 63 








Figure 40 Gel of purified Ubiquitin fractions from FPLC purification run with Bolt 4-12% Bis-Tris gels (Thermo Scientific), 
run for 30 min at 165V (constant) using MES buffer (Thermo Scientific). The ladder on the gel is ProSieve QuadColor 
protein marker (4.6 kDa – 300 kDa;  Lonza) and the gel was stained using InstantBlue (Generon). Run with the assistance of 
Dr N. Hugenin. 
 
 
Figure 41 Protein LCMS and deconvoluted MS of purified ubiquitin conjugate 63 after FPLC purification. Deconvoluted 










5.3.2 Substrate scope of hypervalent iodine reagents for polypeptide functionalisation 
Exenatide acetate functionalization with 77 to form 86 
 
The labelling of exenatide was performed at room temperature using General Procedure D using 
77 (100 mM in H2O) and 1:1 diethyl ether:ethyl acetate ( 2 × 0.5 mL) for the extraction.  The 
resulting solution was then analysed directly via LC/MS (C18 column, 50 × 2.1 mm, 2.6 µm, 
Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 mL/min) and was observed to have 
proceeded in >95% conversion.  
 
Figure 42 Mass trace of crude reaction mixture of exenatide with 77, mass chromatogram shown as an insert. Diagnostic 
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Large Scale Synthesis of 86 
A 2 mL vial equipped with a magnetic stirrer was charged with Exenatide•OAc (~1.2 mg, ~0.3 
µmol). Thiourea (100 mM in H2O, 160 µL), formic acid (0.1 M in H2O, 40 µL), H2O (80 µL) 
and TEMPO (67 mM in H2O, 120 µL) were added and the vial was stirred vigorously before 
the addition of 77 (100 mM in H2O, 400 µL). The reaction mixture was stirred for 5 minutes at 
room temperature before being extracted with 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL). The 
remaining organic volatiles were then removed in vacuo. Purification via reverse-phase HPLC* 
(C18 column 150 × 10 mm, 10µm, Gradient: 5-55% B over 9 min then 55-95% B over 1 min, 
hold for 1.5 min, then 95-5% B over 0.5 min, hold for 3 min, 5 mL/min), followed by 
lyophilization yielded 86 as a sticky, off-white solid that was immediately redissolved in H2O 
(500 µL) and stored at –20 °C.  Concentration analysis by A280 indicated a 1.5 mg/mL solution 
~63% isolated yield).  
*Note:  Purification of 86 should be carried out expediently as prolonged purification times can 
lead to low levels of peptide backbone hydrolysis. 
  
 






Figure 44 Mass trace of purified exenatide conjugate 86, with mass chromatogram shown as an insert. Diagnostic 
fragmentation of C–S bond (indicated with ‘) giving: M+label-(label+SMe) = M+167-214. 
 
Exenatide acetate functionalization with 78 to form 87  
 
The labelling of exenatide was performed at room temperature using General Procedure D using 
78 (100 mM in CD3CN) and 1:1 diethyl ether:ethyl acetate for the extraction.  The resulting 
solution was then analysed directly via LC/MS (C18 column (50 × 2.1 mm, 2.6 µm), Gradient: 
5-95% B over 5 min then hold for 0.5 min, 0.7 mL/min) and was observed to have proceeded 
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Figure 45 Mass trace of crude reaction mixture of exenatide with 78, mass chromatogram shown as an insert. Diagnostic 
fragmentation of C–S bond (indicated with ‘) giving: M+label-(label+SMe) = M+125-172. 
 
Exenatide acetate functionalization with 79 to form 88 
 
The labelling of exenatide was performed at room temperature using General Procedure D using 
79 (100 mM in CH3CN) and 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL) for the extraction.  The 
resulting solution was then analysed directly via LC/MS (C18 column (50 × 2.1 mm, 2.6 µm), 
Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 mL/min) and was observed to have 
























Figure 46 Mass trace of crude reaction mixture of exenatide with 79, with mass chromatogram shown as an insert. 
Diagnostic fragmentation of C–S bond (indicated with ‘) giving: M+label-(label+SMe) = M+(167)-214. 
 
Exenatide acetate functionalization with 80 to form 89  
 
The labelling of exenatide was performed at room temperature using General Procedure D using 
80 (100 mM in CH3CN) and 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL) for the extraction.  The 
resulting solution was then analysed directly via LC/MS (C18 column (50 × 2.1 mm, 2.6 µm), 
Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 mL/min) and was observed to have 
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Figure 47 Mass trace of crude reaction mixture of exenatide with 80, mass chromatogram shown as an insert. Diagnostic 
fragmentation of C–S bond (indicated with ‘) giving: M+label-(label+SMe) = M+(165)-212. 
 
Glucagon functionalization with 80  
 
The labelling of glucagon was performed at room temperature using General Procedure D using 
80 (100 mM in CH3CN) and 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL) for the extraction.  The 
resulting solution was then analysed directly via LC/MS (C18 column (50 × 2.1 mm, 2.6 µm), 
Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 mL/min) and was observed to have 























Figure 48 Mass trace of crude reaction mixture of glucagon with 80, mass chromatogram shown as an insert. Diagnostic 
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Exenatide acetate functionalization with 81 to form 90  
 
The labelling of exenatide was performed at room temperature using General Procedure D using 
81 (100 mM in CH3CN) and 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL) for the extraction.  The 
resulting solution was then analysed directly via LC/MS (C18 column (50 × 2.1 mm, 2.6 µm), 
Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 mL/min) and was observed to have 
proceeded in ~90% conversion. 
 
Figure 49 Mass trace of crude reaction mixture of exenatide with 81, mass chromatogram shown as an insert. Diagnostic 
























5.4 Cyanogen bromide mediated backbone cleavage of Aviptadil 
Aviptadil (1.1 mg, 0.33 µmol) was added to a 2 mL vial equipped with a magnetic stirrer. To 
the vial was added a solution of cyanogen bromide (8.5 mg, 83 µmol) in formic acid (200 µL). 
The resulting solution was stirred at room temperature for 2 hours. The solution was diluted 
with water then analysed directly via LC/MS (C18 column (50 ´ 2.1 mm, 2.6µm), Gradient: 5-
95% B over 5 min then hold for 0.5 min, 0.7 ml/min), and was observed to have proceeded in 




Figure 50 Crude LCMS trace for reaction of aviptadil with CNBr in formic acid. Left; crude mass trace of reaction, right; 
mass spectra of both peaks corresponding to cleaved polypeptide fragments 96 and 97. 
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5.5 Experimental procedures for exploitation of diazo motif in b-sulfonium a-diazoester 
conjugates 
5.5.1 Experimental procedures for phosphine promoted cleavage of methionine label 
Phosphine promoted “deligation” of 58 
 
A vial was charged with a solution of sulfonium conjugate 58 (750 µM, 25 µL).  To the vial 
was added tris-(2-carboxyethyl) phosphine (1.7 mM in pH 8 phosphate buffer, 50 µL) and H2O 
(25 µL). The vial was stirred vigorously for 30 minutes.  The resulting solution was then 
analysed directly via LC/MS (C18 column (50 × 2.1 mm, 2.6 µm), Gradient: 5-95% B over 5 
min then hold for 0.5 min, 0.7 mL/min). The deligation was observed to have proceeded in 
>95% conversion.  
 


























Phosphine promoted “deligation” of 57 
 
A vial was charged with a solution of sulfonium conjugate 57 (650 µM, 15 µL).  To this was 
added tris-(2-carboxyethyl) phosphine (1.7 mM in pH 8 phosphate buffer, 50 µL) and H2O (35 
µL). The vial was stirred vigorously for 30 minutes.  The resulting solution was then analysed 
directly via LC/MS (C18 column (50 × 2.1 mm, 2.6 µm), Gradient: 5-95% B over 5 min then 
hold for 0.5 min, 0.7 mL/min), and the ligation reversal was observed to have proceeded in 
>95% conversion.  
 
Figure 52 Mass trace of crude reaction mixture of tetracosactide conjugate 57 with TCEP at pH 8, mass chromatogram 
























Experimental    
 178 
Phosphine promoted “deligation” of 59 
 
A vial was charged with a solution of sulfonium conjugate 59 (500 µM, 20 µL).  To this was 
added a solution of tris-(2-carboxyethyl) phosphine (1.7 mM in pH 8 phosphate buffer, 50 µL) 
and H2O (30 µL). The vial was stirred vigorously for 30 minutes.  The resulting solution was 
then analysed directly via LC/MS (C18 column (50 × 2.1 mm, 2.6 µm), Gradient: 5-95% B 
over 5 min then hold for 0.5 min, 0.7 mL/min), and the ligation reversal was observed to have 
proceeded in >95% conversion.  
 




























5.5.2 Experimental procedures for photochemical reduction of a-sulfonium diazoesters 
Two-step sequential Methionine-Labelling/photochemical Reduction of Exenatide  
 
A 5 mL microwave tube equipped with a magnetic stirrer was charged with a solution of 
exenatide•OAc (3.7 mM in 0.1 M thiourea (aq), 70 µL, 1 mg).  To the vial was added formic 
acid (100 mM in H2O, 20 µL), and the resulting solution chilled in an ice bath before TEMPO 
(33 mM in H2O, 50 µL), H2O (30 µL) and 77 (100 mM in CH3CN, 170 µL) were added. The 
reaction mixture was stirred for 5 minutes then extracted with 1:1 ethyl acetate:diethyl ether (3 
´ 0.5 mL), and the excess volatiles were removed in vacuo. To the resulting solution was added 
a magnetic stirrer and the Hantzsch ester 102 (1.8 mg, 1.0 ´ 10-5 mmol).  The tube was then 
capped with a septum and subsequently evacuated/backfilled with N2 (´ 5).  To the tube was 
added added fac-Ir(ppy)3 (560 µM in freshly degassed CH3CN, 180 µL) and freshly degassed 
H2O (180 µL). The mixture was irradiated with a Prolite 30 W fluorescent light bulb that was 
placed at a 5 cm distance from the microwave tube for 45 minutes.  A constant temperature was 
maintained by placing the microwave tube under a stream of air over the course of the 
irradiation.  The reaction mixture was then extracted with 1:1 ethyl acetate:diethyl ether (3 ´ 
0.5 mL) and the excess volatiles were removed in vacuo. The resulting solution was then 
analysed directly via LC/MS (C18 column (50 ´ 2.1 mm, 2.6 µm), Gradient: 5-95% B over 5 
min then hold for 0.5 min, 0.7 ml/min), and the ligation was observed to have proceeded in 
>95% conversion.  Purification via reverse-phase HPLC (C18 column (150 ´ 10 mm, 10µm), 
Gradient: 5-55% B over 9 min then 55-95%B over 1 min, hold for 1.5 min, then 95-5%B over 
0.5 min, hold for 3 min, 5 ml/min), followed by lyophilisation yielded 110 as a free-flowing, 
white solid that was immediately re-dissolved in H2O (0.5 mL) and stored at –20°C.  






























Figure 54 a) Mass spectrum of the crude reaction mixture of the labeling/photoreduction of exenatide with 77 to form 110 b) 


















Two-step sequential Methionine-Labelling/photochemical Reduction of Ubiquitin 
 
A 2 mL vial equipped with a magnetic stirrer was charged with Ubiquitin (~1.0 mg, ~0.12 
µmol) and evacuated/backfilled with N2 (´ 5).  To the vial was added formic acid (100 mM in 
H2O, 25 µL) and thiourea (0.1 M in H2O, 100 µL) and H2O (125 µL) and the solution stirred 
vigorously before 54 (100 mM in CH3CN, 250 µL) was added. The reaction mixture was stirred 
for 5 minutes then extracted with 1:1 ethyl acetate: diethyl ether (3 ´ 0.5 mL), and the excess 
volatiles were removed in vacuo. To the resulting solution was added a magnetic stirrer and the 
Hantzsch ester (2.0 mg, 1.0 ´ 10-5 mmol).  The tube was then capped with a septum and 
subsequently evacuated/backfilled with N2 (´ 5). To the tube was added fac-Ir(ppy)3 (560 µM 
in freshly degassed CH3CN, 200 µL). The mixture was irradiated with a Prolite 30 W 
fluorescent light bulb that was placed at a 5 cm distance from the microwave tube for 30 
minutes.  A constant temperature was maintained by placing the microwave tube under a stream 
of air over the course of the irradiation.  The reaction mixture was then extracted with 1:1 ethyl 
acetate:diethyl ether (3 × 0.5 mL) and the excess volatiles were removed in vacuo. The resulting 
solution was then purified directly using MonoS 4.6/100 PE column (GE Healthcare) using a 















20 mM Thiourea, MeCN:H2O
rt, 5 min
Ir(ppy)3, visible light, Hantzsch ester 102









Figure 55 FPLC trace of Ubiquitin conjugate 215, purified using MonoS 4.6/100 PE column (GE Healthcare) using a NaCl 
gradient (0-1 M) in 50 mM ammonium acetate pH 4.5. Clear separation of unmodified Ubiquitin and modified conjugates 63 
and 215 was achieved due to the differing elution times of the charged species and uncharged species, unmodified ubiquitin 
using an ion exchange column. 
 
 
Figure 56 Gel of purified Ubiquitin fractions from FPLC purification run with Bolt 4-12% Bis-Tris gels (Thermo Scientific) 
and were run for 30 min at 165V (constant) using MES buffer (Thermo Scientific). The ladder on the gel is ProSieve 








Figure 57 Protein LCMS trace and deconvolution of purified 215 showing only two species present, the total ion of product 
215 (8651 Da) and the fragment ion for 215-134 (8517 Da). 
 
 
Figure 58 Protein LCMS trace of mixed fraction of 215 and 63 showing the total ion of product 215 (8651 Da) and the total 
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5.5.3 Experimental procedures for a photoredox-mediated bioorthogonal transformation at 
b-sulfonium a-diazoesters 
5.5.3.1 Experimental procedures for the synthesis of Hantzsch ester reagents 
General Procedure F: Synthesis of aldehyde from alcohol 
 
A solution of alcohol (1.0 eq.) in CH2Cl2 (0.1 M) was added to a stirring solution of Dess-
Martin Periodinane (1.1 eq.) in CH2Cl2 (0.1 M) and the resulting solution stirred under air for 
3 hours at room temperature. The reaction was quenched with Na2S2O3 (sat. aq.) and the organic 
layer washed with NaHCO3 (sat. aq.), Na2S2O3 (sat. aq.) (x 2) and H2O. The crude solid was 
flushed through a plug of silica (50% EtOAc/petroleum ether) and used directly. 
 
General Procedure G: Synthesis of aldehyde from carboxylic acid 
 
Step 1: A solution of carboxylic acid (1.0 eq.) in Et2O (0.15 M) was added dropwise to a stirring 
solution of LiAlH4 (1.5 eq.) in Et2O (0.15 M) at 0 °C, under N2. The resulting suspension was 
allowed to warm to room temperature and stirred for 4 hours. The reaction was quenched with 
Na2SO4•10H2O and stirred for a further 10 minutes. The residue was filtered, and the filtrate 
evaporated and used directly without further purification. 
Step 2: A solution of alcohol from step 1 (1.0 eq.) in CH2Cl2 (0.1 M) was added to a stirring 
solution of Dess-Martin Periodinane (1.1 eq.) in CH2Cl2 (0.1 M) and the resulting solution 
stirred under air for 3 hours at room temperature. The reaction was quenched with Na2S2O3 (sat. 
aq.) and the organic layer washed with NaHCO3 (sat. aq.), Na2S2O3 (sat. aq.) (´ 2) and H2O. 
The crude solid was flushed through a plug of silica (50% EtOAc/petroleum ether) and used 


















General Procedure H: Synthesis of Hantzsch ester from aldehyde 
 
A solution of aldehyde (1 eq.), 2-methoxyethylacetoacetate (4 eq.) and ammonium acetate (2 
eq.) in water (0.5 M in aldehyde) was stirred at reflux under air for 4 hours then allowed to cool 
to room temperature. The reaction mixture was diluted with EtOAc and the aqueous layer 
extracted with EtOAc (´ 3). The combined organic layers were washed with brine, dried over 
MgSO4, filtered and evaporated to yield the crude product. The crude product was purified by 





















Experimental    
 186 
Dimethyl 4-benzhydryl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 128 
 
Diphenyl acetaldehyde (0.89 mL, 5.0 mmol) and methyl-3-aminocrotonate (1.15 g, 10.0 mmol) 
in AcOH (5 mL) were added to a microwave tube and sealed. The solution was degassed with 
N2 for 15 minutes then stirred at 110 °C for 5 hours before allowing the solution to cool to room 
temperature. The reaction mixture was extracted with EtOAc (3 ´ 5 mL) and the combined 
organic layers carefully quenched with NaHCO3 (sat. aq.) (15 mL), washed with brine (25 mL), 
dried over MgSO4, filtered and evaporated to afford the crude product. Purification via flash 
column chromatography on silica gel (50% EtOAc/petroleum ether) and recrystallization from 
EtOAc/petroleum ether yielded 128 (0.72 g, 37%) as a pale yellow solid. 1H-NMR (400 MHz, 
CDCl3) d: 7.31 (d, J = 7.5 Hz, 4H, H10), 7.21 (t, J = 7.7 Hz, 4H, H11), 7.13 (t, J = 7.3 Hz, 2H, 
H12), 5.78 (s, 1H, H3), 4.86 (d, J = 8.9 Hz, 1H, H7), 3.66 (d, J = 8.9 Hz, 1H, H8), 3.41 (s, 6H, 
H6), 2.23 (s, 6H, H1); 13C-NMR (100 MHz, CDCl3) d: 168.3 (C5), 144.6 (C2), 141.5 (C9), 129.7 
(C10), 127.6 (C11), 126.3 (C12), 102.3 (C4), 58.0 (C8), 50.7 (C6), 39.5 (C7), 19.3 (C1); HRMS: 
(ESI)+ (m/z) Found (M+H): 392.1859, Calc’d C24H26O4N requires 392.1856; IR nmax/cm-1 
(film): 3341, 3081, 3023, 3000, 2948, 2888, 1702, 1661, 1623, 1487, 1429, 1213, 1118, 1110, 




2-mesitylacetaldehyde 142 was synthesised according to General Procedure G, using 2-
mesitylacetic acid (0.71 g, 4.0 mmol), LiAlH4 (0.23 g, 6.0 mmol) and Et2O (13 mL) in Step 1. 
Dess-Martin periodinane (1.86 g, 4.4 mmol) and CH2Cl2 (40 mL) were used in Step 2. 142 was 



































1H, H1), 6.92 (s, 2H, H5), 3.73 (d, J = 2.1 Hz, 2H, H2), 2.29 (s, 3H, H8), 2.26 (s, 6H, H7); 13C-
NMR (100 MHz, CDCl3) d: 199.2 (C1), 137.3 (C4), 137.1 (C6), 129.3 (C5), 126.4 (C3), 44.9 
(C2), 21.0 (C8), 20.5 (C7); HRMS: (ESI)+
 (m/z) Found (M+H): 163.1121, Calc’d C11H15O+ 





148 was synthesised according to General Procedure H, using 142 (0.32 g, 2 mmol), 2-
methoxyethyl acetoacetate (1.17 g, 8.0 mmol) and ammonium acetate (0.31 g, 4.0 mmol) in 
water (4 mL). Purification by flash column chromatography on silica gel (10-50% EtOAc/40-
60 petroleum ether) followed by recrystallization from diethyl ether/EtOAc/hexane afforded 
148 (0.16 g, 18%) as an off-white solid. 1H-NMR (400 MHz, CDCl3) d: 6.75 (s, 2H, H14), 5.71 
(br. s, 1H, H3), 4.34 (t, J = 7.9 Hz, 1H, H9), 4.06 (dt, J = 4.8, 12.0 Hz, 2H, H6), 3.82 (dt, J = 4.8, 
12.0 Hz, 2H, H6), 3.48 (t, J = 4.8 Hz, 4H, H7), 3.36 (s, 6H, H8), 2.66 (d, J = 7.9 Hz, 2H, H10), 
2.31 – 2.28 (m, 12H, H1 and H13), 2.19 (s, 3H, H16); 13C-NMR (100 MHz, CDCl3) d: 167.8 
(C5), 145.3 (C2), 137.8 (C11), 135.0 (C15), 132.2 (C12), 128.7 (C14), 103.4 (C4), 70.6 (C7), 62.7 
(C6), 59.0 (C8), 35.2 (C10), 32.7 (C9), 20.9 (C16), 20.1 (C13), 19.6 (C1); HRMS: (ESI)+ (m/z) 
Found (M+H): 446.2515, Calc’d C25H36O6N requires 446.2537; IR nmax/cm-1 (film): 3303, 
2912 (br), 2806, 1701, 1690, 1619, 1491, 1305, 1266, 1198, 1084, 1058, 1017, 847, 773, 766, 






























2-(4-methoxyphenyl)acetaldehyde 139 was synthesised according to General Prodedure F, 
using 2-(4-methoxyphenyl)ethan-1-ol (2.28 g, 15.0 mmol), Dess-Martin periodinane (7.00 g, 
16.5 mmol) and CH2Cl2 (150 mL). 139 was isolated as a colourless oil (0.98 g, 43%). 1H-NMR 
(400 MHz, CDCl3) d: 9.71 (t, J = 2.5 Hz, 1H, H1), 7.15 – 7.11 (m, 2H, H4), 6.93 – 6.88 (m, 2H, 
H5), 3.80 (s, 3H, H7), 3.62 (d, J = 2.5 Hz, 2H, H2); 13C-NMR (100 MHz, CDCl3) d: 199.8 (C1), 
159.0 (C6), 130.8 (C4), 123.8 (C3), 114.6 (C5), 55.4 (C7), 49.8 (C2); HRMS: (ESI)+
 (m/z) Found 






145 was prepared according to General Procedure H using 139 (0.98 g, 6.5 mmol), 2-
methoxyethyl acetoacetate (3.8 g, 26.0 mmol) and ammonium acetate (1.0 g, 13.0 mmol) in 
water (13 mL). Purification by flash column chromatography on silca gel (20-50% EtOAc/40-
60 petroleum ether) followed by recrystallization from diethyl ether/hexane afforded 145 (0.97 
g, 34%) as an off-white solid. 1H-NMR (400 MHz, CDCl3) d: 6.94 (d, J = 8.3 Hz, 2H, H12), 
6.72 (d, J = 8.3 Hz, 2H, H13), 5.18 (br. s, 1H, H3), 4.23 – 4.12 (m, 5H, H9 and H6), 3.76 (s, 3H, 
H15), 3.61 – 3.54 (m, 4H, H7), 3.40 (s, 6H, H8), 2.55 (d, J = 5.4 Hz, 2H, H10), 2.16 (s, 6H, H1); 
13C-NMR (100 MHz, CDCl3) d: 167.8 (C5), 158.0 (C14), 145.8 (C2), 131.56 (C11), 131.2 (C12), 
112.9 (C13), 101.8 (C4), 70.8 (C7), 62.8 (C6), 59.1 (C8), 55.4 (C15), 41.4 (C10), 35.7 (C9), 19.4 


































nmax/cm-1 (film): 3337, 2985, 2941, 2862, 2885, 2838, 1684, 1653, 1625, 1609, 1497, 1470, 




2-(4-(trifluoromethyl)phenyl)acetaldehyde 140 was synthesised according to General 
Procedure G, using 2-(4-(trifluoromethyl)phenyl)acetic acid (3.06 g, 15.0 mmol), LiAlH4 (0.85 
g, 22.5 mmol) and Et2O (50 mL) in Step 1 and Dess-Martin periodinane (7.00 g, 16.5 mmol) 
and CH2Cl2 (150 mL) in Step 2. 140 was isolated as a colourless oil (2.03 g) which was used 





146 was prepared according to General Procedure H using crude aldehyde 140 (0.75 g, 4.0 
mmol), 2-methoxyethyl acetoacetate (2.34 g, 16.0 mmol) and ammonium acetate (0.62 g, 8.0 
mmol) in water (13 mL). Purification by flash column chromatography on silca gel (10-50% 
EtOAc/40-60 petroleum ether) followed by recrystallization from diethyl ether/hexane afforded 
146 (0.60 g, 32%) as an off-white solid. 1H-NMR (400 MHz, CDCl3) d: 7.43 (d, J = 7.9 Hz, 
2H, H13), 7.16 (d, J = 7.9 Hz, 2H, H12), 5.33 (br. s, 1H, H3), 4.25 (t, J = 5.6 Hz, 1H, H9), 4.21 – 
4.07 (m, 4H, H6), 3.60 – 3.50 (m, 4H, H7), 3.39 (s, 6H, H8), 2.67 (d, J = 5.6 Hz, 2H, H10), 2.18 
(s, 6H, H1); 13C-NMR (100 MHz, CDCl3) d: 167.5 (C5), 146.0 (C2), 143.9 (C11), 130.5 (C12), 
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(C7), 62.9 (C6), 59.1 (C8), 42.4 (C10), 35.7 (C9), 19.4 (C1); 19F{H}-NMR (376 MHz, CDCl3) δ: 
-64.3; HRMS: (ESI)+ (m/z) Found (M+H): 472.1949, Calc’d C23H29F3O6N requires 472.1941; 
IR nmax/cm-1 (film): 3339, 2934 (br), 2885 (br), 1673, 1652, 1615, 1477, 1323, 1224, 1165, 




2-(4-bromophenyl)acetaldehyde 141 was synthesised according to General Procedure G, using 
2-(4-bromophenyl)acetic acid (3.23 g, 15.0 mmol), LiAlH4 (0.85 g, 22.5 mmol) and Et2O (50 
mL) in Step 1 and Dess-Martin periodinane (7.00 g, 16.5 mmol) and CH2Cl2 (150 mL) in Step 
2. 141 was isolated as a colourless oil (1.91 g, 64%). 1H-NMR (400 MHz, CDCl3) d: 9.74 (t, J 
= 2.1 Hz, 1H, H1), 7.51 – 7.47 (m, 2H, H5), 7.11 – 7.07 (m, 2H, H4), 3.66 (d, J = 2.1 Hz, 2H, 
H2); 13C-NMR (100 MHz, CDCl3) d: 198.7 (C1), 132.2 (C4), 131.4 (C5), 130.9 (C3), 121.7 (C6), 
50.0 (C2); HRMS: (ESI)+ (m/z) Found (M+H): 198.9758, Calc’d C8H879BrO+ requires 





147 was prepared according to General Procedure H using 141 (0.80 g, 4.0 mmol), 2-
methoxyethyl acetoacetate (2.3 g, 16.0 mmol) and ammonium acetate (0.62 g, 8.0 mmol) in 
water (8 mL). Purification by flash column chromatography on silica gel (10-50% EtOAc/40-
































g, 24%) as an off-white solid. 1H-NMR (400 MHz, CDCl3) d: 7.29 (d, J = 8.1 Hz, 2H, H13), 
6.91 (d, J = 8.1 Hz, 2H, H12), 5.23 (br. s, 1H, H3), 4.23 – 4.15 (m, 5H, H6 and H9), 3.62 – 3.51 
(m, 4H, H7), 3.40 (s, 6H, H8), 2.57 (d, J = 5.4 Hz, 2H, H10), 2.17 (s, 6H, H1); 13C-NMR (100 
MHz, CDCl3) d: 167.6 (C5), 146.0 (C2), 138.6 (C11), 132.0 (C12), 130.4 (C13), 119.8 (C14), 101.6 
(C4), 70.8 (C7), 62.8 (C6), 59.1 (C8), 41.7 (C10), 35.6 (C9), 19.5 (C1); HRMS: (ESI)+ (m/z) Found 
(M+H): 484.1162, Calc’d C22H2981BrO6N requires 484.1152; IR nmax/cm-1 (film): 3338, 3043, 





2-(2-bromophenyl)acetaldehyde 143 was synthesised according to General Prodedure F, using 
2-(2-bromophenyl)ethan-1-ol (1.36 mL, 10.0 mmol), Dess-Martin periodinane (4.67 g, 11.0 
mmol) and CH2Cl2 (100 mL). 143 was isolated as a colourless oil (1.21 g, 61%). 1H-NMR (400 
MHz, CDCl3) d: 9.77 – 9.75 (m, 1H, H1), 7.65 – 7.60 (m, 1H, H7), 7.35 – 7.29 (m, 1H, H5), 
7.27 – 7.22 (m, 1H, H4), 7.22 – 7.16 (m, 1H, H6), 3.88 – 3.86 (m, 2H, H2); 13C-NMR (100 
MHz, CDCl3) d: 198.4 (C1), 133.2 (C7), 132.8 (C3), 131.9 (C4), 129.4 (C6), 128.0 (C5), 125.1 
(C8), 50.6 (C2); HRMS: (ESI)+
 (m/z) Found (M+H): 198.9754, Calc’d C8H879BrO+ requires 
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149 was prepared according to General Procedure H using 143 (0.40 g, 2.0 mmol), 2-
methoxyethyl acetoacetate (1.17 g, 8.0 mmol) and ammonium acetate (0.31 g, 4.0 mmol) in 
water (4 mL). Purification by flash column chromatography on silica gel (20-50% EtOAc/40-
60 petroleum ether) followed by recrystallization from diethyl ether/hexane afforded 149 (0.36 
g, 38%) as an off-white solid. 1H-NMR (400 MHz, CDCl3) d: 7.45 (m, 1H, H15), 7.12 (m, 1H, 
H13), 7.04 (dd, J = 1.6, 7.7 Hz, 1H, H12), 6.99 (td, J = 1.6, 7.7 Hz, 1H, H14), 5.56 (br. s, 1H, H3), 
4.38 (t, J = 6.1 Hz, 1H, H9), 4.20 – 4.13 (m, 2H, H6), 4.05 – 3.99 (m, 2H, H6), 3.57 (t, J = 5.0 
Hz, 4H, H7), 3.39 (s, 6H, H8), 2.80 (d, J = 6.1 Hz, 2H, H10), 2.24 (s, 6H, H1); 13C-NMR (100 
MHz, CDCl3) d: 167.6 (C5), 146.2 (C2), 138.8 (C11), 132.7 (C12), 132.3 (C15), 127.5 (C14), 126.4 
(C13), 125.8 (C16), 101.8 (C4), 70.8 (C7), 62.9 (C6), 59.1 (C8), 41.2 (C10), 34.3 (C9), 19.6 (C1); 
HRMS: (ESI)+ (m/z) Found (M+H): 484.1140, Calc’d C22H2981BrO6N requires 484.1152; IR 
nmax/cm-1 (film): 3337, 2923 (br), 2890, 2812, 1687, 1635, 1616, 1486, 1471, 1263, 1200, 1089, 




2-(2-(trifluoromethyl)phenyl)acetaldehyde 144 was synthesised according to General 
Procedure F, using 2-(2-(trifluoromethyl)phenyl)ethan-1-ol (1.59 mL, 10.0 mmol), Dess-
Martin periodinane (4.67 g, 11.0 mmol) and CH2Cl2 (100 mL). 144 was isolated as a colourless 








































150 was prepared according to General Procedure H using 144 (0.38 g, 2.0 mmol), 2-
methoxyethyl acetoacetate (1.17 g, 8.0 mmol) and ammonium acetate (0.31 g, 4.0 mmol) in 
water (4 mL). Purification by flash column chromatography on silica gel (10-50% EtOAc/40-
60 petroleum ether) followed by recrystallization from diethyl ether/hexane afforded 150 (0.35 
g, 37%) as an off-white solid. 1H-NMR (400 MHz, CDCl3) d: 7.56 (d, J = 7.6 Hz, 1H, H15), 
7.38 (t, J = 7.6 Hz, 1H, H13), 7.23 (m, 2H, H12 and H14), 5.85 (br. s, 1H, H3), 4.36 (t, J = 7.3 Hz, 
1H, H9), 4.13 – 4.06 (m, 2H, H6), 3.91 – 3.84 (m, 2H, H6), 3.53 – 3.44 (m, 4H, H7), 3.36 (s, 6H, 
H8), 2.76 (d, J = 7.3 Hz, 2H, H10), 2.32 (s, 6H, H1); 13C-NMR (100 MHz, CDCl3) d: 167.5 (C5), 
146.1 (C2), 137.9 (C11), 133.5 (C12 or C14), 130.8 (C13), 129.14 (q, 2JC–F = 30.0 Hz, C16), 125.9 
(C12 or C14), 125.6 (q, 3JC–F  = 5.7 Hz, C15), 124.8 (q, 1JC–F = 275.1 Hz, C17), 102.5 (C4), 70.5 
(C7), 62.7 (C6), 59.0 (C8), 38.4 (C10), 34.9 (C9), 19.6 (C1); 19F{H}-NMR (376 MHz, CDCl3) δ: 
-60.9; HRMS: (ESI)+ (m/z) Found (M+H): 472.1925, Calc’d C23H29F3O6N requires 472.1941; 
IR nmax/cm-1 (film): 3327, 2928 (br), 2821, 1691, 1639, 1617, 1489, 1310, 1265, 1206, 1206, 




n-Butyl lithium (4.2 mL, 10.5 mmol, 2.5M in hexanes) was added dropwise to a solution of 5-
bromo-2-iodotoluene (1.5 mL, 10.5 mmol) in diethyl ether (65 mL) at -78 °C. The resulting 
mixture was stirred at -78 °C for 10 minutes then ethylene oxide (6.3 mL, 15.8 mmol, 2.5M in 
THF) was added dropwise. The solution was warmed to room temperature and stirred for a 
further 2 hours. The reaction was quenched with NH4Cl (aq.) (30 mL) and extracted with EtOAc 
(3 ´ 50 mL). The combined organic layers were washed with water (35 mL) and brine (35 mL), 
dried over MgSO4, filtered and evaporated to yield the crude product. Purification by flash 
column chromatography on silica gel (10-30% diethyl ether/40-60 petroleum ether) yielded the 
title compound (1.43 g, 63%) as a colourless oil. 1H-NMR (400 MHz, CDCl3) d: 7.33 – 7.29 
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Hz, 2H), 2.30 (s, 3H), 1.80 (t, J = 5.6 Hz, 1H); 13C-NMR (100 MHz, CDCl3) d: 138.8, 135.7, 
133.1, 131.2, 129.0, 120.2, 62.5, 35.8, 19.3.* 




Synthesised by Dr C. He. 
 
Benzyl (3-(4-(2-(benzyloxy)ethyl)-3-methylphenyl)prop-2-yn-1-yl)carbamate 161c 
 



















Benzyl (3-(4-(2-hydroxyethyl)-3-methylphenyl)propyl)carbamate 161e 
 






Step 1: A solution of 162 (2.38 g, 7.3 mmol) in CH2Cl2 (25 mL) was added dropwise to a 
solution of Dess-Martin Periodinane (3.39 g, 8.0 mmol) in CH2Cl2 (50 mL) and the resulting 
solution stirred for 4 hours at room temperature. The reaction was quenched with Na2S2O3 (sat. 
aq.) (50 mL) and the organic layer washed with NaHCO3 (sat. aq.) (50 mL), Na2S2O3 (sat. aq.) 
(2 ́  50 mL) and H2O (50 mL). The organic layer was dried over MgSO4, filtered and evaporated 
to yield the title compound as a crude oil (1.78 g, 76%) which was used directly without further 
purification. 
Step 2: According to General Procedure H, the crude aldehyde 163 (1.71 g, 5.3 mmol), 2-
methoxyethyl acetoacetate (3.07 g, 21.0 mmol) and ammonium acetate (0.81 g, 11 mmol) in 
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on silica gel (10-50% EtOAc/40-60 petroleum ether) afforded 164 as an impure orange gum 
which was used directly without further purification. 
Step 3: Palladium on carbon (0.36 g, 3.4 mmol, 10 mol% Pd) was added to a solution of 164 
(1.86 g, 3.0 mmol) in MeOH (30 mL) under N2. The flask was evacuated and refilled with a 
balloon of H2 gas (´ 3). The resulting reaction mixture was stirred for 3 hours at room 
temperature then filtered through a plug of celite® to afford a crude, pale yellow gum which 
was used without further purification.  
Step 4: 158 (1.26 g, 2.7 mmol) was dissolved in DMF (27 mL) and 159 (2.22 g, 5.4 mmol) was 
added and the reaction was stirred at room temperature for 2 hours. A further portion of 159 
(0.55 g, 1.4 mmol) was added and the reaction stirred for a further 1 hour then the solvent 
removed. Purification via flash column chromatography on silica gel (0-5% MeOH:CH2Cl2) 
yielded 157 (1.04 g, 1.5 mmol, 20% over 4 steps) as a yellow gum. 1H-NMR (400 MHz, CDCl3) 
d: 6.96 (s, 1H), 6.83 (s, 1H), 6.80 – 6.73 (m, 2H), 6.10 – 6.02 (m, 2H), 5.17 (s, 1H), 4.53 – 4.48 
(m, 1H), 4.31 – 4.28 (m, 2H), 4.23 – 4.18 (m, 4H), 3.61 (app. t, J = 5.1 Hz, 4H), 3.40 (s, 6H), 
3.15 – 3.10 (m, 1H), 3.08 – 3.02 (m, 2H), 2.93 – 2.88 (m, 1H), 2.71 (d, J = 12.9 Hz, 1H), 2.65 
(d, J = 4.8 Hz, 2H), 2.56 (t, J = 6.7 Hz, 2H), 2.21 (s, 3H), 2.13 (t, J = 7.4 Hz, 2H), 2.10 (s, 6H), 
1.77 – 1.71 (m, 2H), 1.68 – 1.56 (m, 4H), 1.44 – 1.36 (m, 2H); 13C-NMR (100 MHz, CDCl3) 
d: 172.9, 168.1, 163.7, 147.7, 138.5, 137.3, 135.3, 131.9, 129.7, 124.5, 100.2, 70.9, 62.7, 62.0, 
60.3, 59.1, 55.7, 51.0, 40.7, 38.6, 38.0, 36.2, 34.9, 32.8, 31.5, 28.3, 25.7, 19.6, 18.9 ; HRMS: 
(ESI)+ (m/z) Found (M+H): 701.3577, Calc’d C36H53O8N4S+ requires 701.3579; IR nmax/cm-1 




5.5.3.2 Experimental procedures for photoredox-mediated C-benzylation 
Photochemical benzylation procedure of exenatide conjugate 167 
 
A 5 mL microwave tube was charged with a solution of aqueous, unpurified conjugate 86 (400 
μM, 50 μL). To the resulting solution was added a magnetic stirrer and Hantzsch ester 155 (2.5 
mg, 6.0 ´ 10-3 mmol, final sol’n conc = 30 mM). The tube was then capped with a septum and 
subsequently evacuated and refilled with N2 (´ 5). To the tube was added added [Ru(bpy)3]2+Cl2 
• 6H2O (5 mM in 3:1 CH3CN:H2O, freshly degassed with N2, 40 μL, final conc = 1 mM), freshly 
degassed CH3CN (70 μl), and freshly degassed H2O (20 μL) . To this resulting mixture was 
added K2S2O8 (100 mM in H2O, 20 μL, final conc = 10 mM), and the mixture was immediately 
irradiated with a Kessil 40 W light bulb that was placed at a 5 cm distance from the microwave 
tube for 5 minutes. A constant temperature was maintained by placing the microwave tube 
under a stream of air over the course of the irradiation. The reaction mixture was then extracted 
with 1:1 ethyl acetate:diethyl ether (2 ́  0.5 mL) and the excess volatiles were removed in vacuo. 
The resulting solution was then analysed directly via LC/MS, (C4 column, Gradient: 5-100% 
B over 5.2 min then hold for 1 min, then 100-5%B over 1 min, 0.2 ml/min). The reaction was 
repeated 5 times by two different contributors and was found to have converted to alkylated 
conjugate 167 in an average of 86% (range from 82-90%) over the 5 runs.  










Figure 59 a) Mass chromatogram of the crude reaction of exenatide conjugate 86 in C-benzylation reaction. b) Deconvoluted 


























5.6 Experimental procedures for the multi-functionalisation of polypeptides 
5.6.1 Dual labelling of methionine and cysteine 
 
A 2 mL vial equipped with a magnetic stirrer was charged with a solution of GTP Binding 
Protein Fragment Ga (1 mM in pH 6 buffer, 50 µL). To the vial was added a solution of N-
methyl maleimide (10 mM in MeCN, 50 µL) and the resulting solution stirred vigorously for 
30 minutes at room temperature, then analysed directly via LCMS C18 column ((150 ´ 10 mm, 
10 µm), gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 mL/min), and was observed 
to have proceeded in >90% conversion in relation to starting material (Figure 60b). A 2 mL vial 
equipped with a magnetic stirrer was charged with the crude reaction solution (500 µM in 1:1 
pH6 buffer:MeCN, 100 µL). To the vial was added thiourea (100 mM in H2O, 30 µL) and 
TEMPO (67 mM in H2O, 30 µL), immediately followed by iodonium salt 54 (250 mM in H2O, 
40 µL) and the reaction stirred vigorously for 2 minutes at room temperature. The resulting 
mixture was extracted with ethyl acetate:diethyl ether (1:1) (2 ́  0.5 mL). The remaining organic 
volatiles were removed in vacuo, and the aqueous layer analysed directly via LC/MS C18 
column ((150 ´ 10 mm, 10 µm), gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 
mL/min), and was observed to have proceeded in >90% conversion in relation to starting 
material (Figure 60c).  
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Figure 60 A) GTP BPF Ga starting material (purity ~75%). B) Crude mass spectrum of step I, reaction with maleimide to 































5.6.2 Dual labelling of methionine and tryptophan 
General Procedure I: simultaneous dual-labelling of methionine and tryptophan
A 2 mL vial equipped with a magnetic stirrer was charged with a solution containing the desired 
polypeptide/protein (2 mM in 0.1M thiourea (aq), 20 μL). To the solution was added ketoABNO 
(40 mM in H2O, 50 μL) and H2O (10 µL) and the vial was stirred vigorously before the 
iodonium salt (100 mM in H2O, 100 μL) was added and the resulting solution stirred for 30 
minutes at room temperature. Ascorbic acid was added (5 mM, 50 μL) and the resulting mixture 
was then extracted with diethyl ether:ethyl acetate (1:1). The volatile organics were then 
removed in vacuo. The resulting solution was analysed directly via LC/MS. 
General Procedure J: simultaneous dual-labelling of methionine and tryptophan
A 2 mL vial equipped with a magnetic stirrer was charged with a solution containing the desired 
polypeptide/protein (2 mM in 0.1M thiourea (aq), 20 μL). To the solution was added ketoABNO 
(40 mM in H2O, 50 μL) and formic acid (10 µL) before the iodonium salt (100 mM in H2O, 
100 μL) was added and the resulting solution stirred for 30 minutes at room temperature. 
Ascorbic acid was added (5 mM, 50 μL) and the resulting mixture was then extracted with 
diethyl ether:ethyl acetate (1:1). The volatile organics were then removed in vacuo. The 
resulting solution was analysed directly via LC/MS. 
 
  




A solution of benzylamine hydrochloride (5.65 g, 39.5 mmol) and glutaraldehyde (13.2 mL, 
32.9 mmol, 25% in H2O) in H2O (15 mL) was cooled to 0 °C, under air. Acetone dicarboxylic 
acid (4.80 g, 32.9 mmol) and NaOAc (11.3 mL, 10% aq.) were added and the reaction mixture 
was stirred for 2 hours at room temperature then heated to 50 °C and stirred overnight. CHCl3 
(50 mL) was added and the organic layer extracted. The aqueous layer was extracted with 
further portions of CHCl3 (3 ´ 50 mL). The combined organic layers were washed with brine 
(75 mL), dried over MgSO4, filtered and evaporated to yield the crude product. Purification via 
flash column chromatography on silica gel (30 – 50% EtOAc/40-60 petroleum ether) afforded 
the title compound (2.14 g, 28%) as a white crystalline solid. 1H-NMR (400 MHz, CDCl3) d: 
7.45 – 7.41 (m, 2H), 7.39 – 7.33 (m, 2H), 7.32 – 7.27 (m, 1H), 3.93 (s, 2H), 3.36 – 3.31 (m, 
2H), 2.76 (dd, J = 16.6, 6.7 Hz, 2H), 2.28 (d, J = 16.6 Hz, 2H), 2.04 – 1.91 (m, 2H), 1.65 – 1.52 
(m, 4H); 13C-NMR (100 MHz, CDCl3) d: 211.8, 139.4, 128.5, 128.4, 127.3, 57.2, 53.7, 43.0, 
29.5, 16.8; 




Palladium on carbon (0.43 g, 0.4 mmol, 10 mol% Pd) was added to a solution of 200 (1.84 g, 
8.0 mmol) in MeOH (80 mL) under N2. The flask was evacuated and refilled with a balloon of 
H2 gas (´ 3). The resulting reaction mixture was stirred for 3 hours at 50 °C then cooled to room 
temperature and filtered through a plug of celite® to afford the title compound (1.02 g, 93%) as 
a pale yellow gum which formed a semi-solid on standing. 1H-NMR (400 MHz, CDCl3) d: 3.63 
– 3.57 (m, 2H), 2.61 (dd, J = 16.5, 6.8 Hz, 2H), 2.41 (d, J = 16.5 Hz, 2H), 1.83 – 1.74 (m, 3H), 







d: 211.1, 49.3, 47.5, 32.0, 16.7; HRMS: (ESI)+ (m/z) [M+2H]+: Found 140.1078, Calc. 
C8H14NO+ requires 140.1075; 
*Data in accordance with literature281  
 
9-Azabicyclo[3.3.1]nonan-3-one N-oxyl (keto-ABNO) 185 
 
To a solution of 201 (0.70 g, 5.0 mmol) in acetonitrile (17 mL), Na2WO4·2H2O (0.17 g, 0.5 
mmol) and urea hydrogen peroxide (3.68 g, 39.0 mmol) were added and the reaction mixture 
was stirred at room temperature for 6 hours. H2O was added to the reaction mixture and the 
aqueous solution was extracted with CHCl3 (3 ´ 25 mL). The organic layer was dried over 
K2CO3 and concentrated. The residue was purified by flash column chromatography on silica 
gel (50% EtOAc/46-60 petroleum ether) followed by recrystallisation from EtOAc/40-60 
petroleum ether to afford the title compound (0.52 g, 68%) as a yellow solid. HRMS: (ESI)+ 
(m/z) [M+2H]+: Found 154.0866, Calc. C8H12NO2+ requires 154.0868; IR: 2964, 1704, 1353, 
1192; 
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Tripeptide 191  
 
Peptide synthesis was carried out according to literature procedures,282 using Rink amide 
MBHA resin (0.40 – 0.80 mmol g-1) for Fmoc-based solid-phase synthesis with 20% 
piperidine/DMF deprotection and HCTU/DIPEA activation. The resulting resin-bound peptide 
was cleaved and side-chains deprotected using a solution of TFA, triisopropylsilane, CH2Cl2, 
H2O (92.5:2.5:2.5:2.5) for 2 hours. The resin was filtered from the cleaved peptide and the 
filtrate concentrated by bubbling N2 gas through the solution. The crude peptide was 
precipitated with diethyl ether, centrifuged, dried in vacuo and purified using reverse phase 
semi-preparative HPLC (C18 column (150 ´ 10 mm, 10µm), Gradient: 5-10% B over 9 min 
then 10-95% B over 2 min, hold for 1 min, then 95-5% B over 2 min, hold for 1 min, 5 ml/min), 
followed by lyophilisation to yield the title compound as a white solid (0.12 g, 52%). 1H-NMR 
(500 MHz, CD3CN) δ: 9.43 (br. s, 1H), 7.88 (d, J = 7.1 Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H), 7.43 
– 7.40 (m, 1H), 7.35 – 7.30 (m, 1H), 7.23 (d, J = 2.4 Hz, 1H), 7.17 – 7.12 (m, 1H), 7.09 – 7.05 
(m, 1H), 6.56 (br. s, 1H), 5.94 (br. s, 1H), 4.38 – 4.31 (m, 1H), 4.27 (t, J = 7.1 Hz, 1H), 3.77 
(dd, J = 16.9, 6.1 Hz, 1H), 3.66 (dd, J = 16.9, 5.7 Hz, 1H), 3.39 (dd, J = 14.8, 6.3 Hz, 1H), 32.6 
(dd, J = 14.8, 7.6 Hz, 1H), 2.51 – 2.33 (m, 4H), 2.02 (s, 3H); 13C-NMR (125 MHz, CDCl3) δ: 
172.8, 172.2, 162.8, 137.7, 128.3, 125.7, 122.9, 120.2, 119.5, 112.5, 109.5, 55.6, 54.0, 43.2, 
31.9, 30.6, 29.4, 15.3; HRMS: (ESI)+ (m/z) [M+H]+: Found 392.1745, Calc. C18H26N5O3S+ 
















Dual labelled tripeptide 192/192’ 
 
A 2 mL vial equipped with a magnetic stirrer was charged with a solution containing the 
tripeptide (0.2 mM in H2O, 25 μL). To the solution was added ketoABNO (40 mM in H2O, 500 
μL), thiourea (0.1 M in H2O, 400 µL) and H2O (75 µL) and the vial was stirred vigorously, 
before iodonium salt 54 (100 mM in CH3CN, 1.0 mL) was added and the resulting solution 
stirred for 15 minutes at room temperature. The reaction mixture was then extracted with diethyl 
ether:ethyl acetate (1:1) (2 ´ 0.5 mL). The volatile organics were then removed in vacuo. The 
resulting solution was analysed directly via LC/MS C18 column (50 ´ 2.1 mm, 2.6 µm), 
Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 ml/min) and was observed to have 
proceeded in >95% conversion. Purification via reverse-phase HPLC (C18 column (150 ´ 10 
mm, 10µm), Gradient: 5-95% B over 11 min then hold for 0.5 min, then 95-5%B over 0.5 min, 
hold for 3 min, 5 ml/min), followed by lyophilization yielded 192 as an off-white solid that was 
immediately redissolved in H2O (500 µL) and stored at –20°C. *192 was isolated as a mixture 
of 3 products; one hydrated and two dehydrated forms, which made NMR analysis intractable. 


















Experimental    
 206 
 
Figure 61 Mass trace of crude reaction of tripeptide with 54, with mass chromatogram shown as an insert. ’ denotes 












5.6.3 Substrate scope for the multi-functionalisation of polypeptides 
Dual labelling of exenatide to form 193, 194 & 194’ 
 
The dual labelling of exenatide was performed at room temperature using General Procedure I 
using 54 (100 mM in H2O) and 1:1 diethyl ether:ethyl acetate (2 ´ 0.5 mL) in the extraction 
step.  The resulting solution was then analysed directly via LC/MS C18 column (50 ´ 2.1 mm, 
2.6 µm), Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 ml/min) and was observed 




Figure 62 Mass trace of crude reaction of exenatide with 54, with mass chromatogram shown as an insert. ’ denotes 









Met only labelled 
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Dual labelling of glucagon to form 202 
 
The dual labelling of glucagon was performed at room temperature using General Procedure J 
using 54 (100 mM in H2O) and 1:1 diethyl ether:ethyl acetate (2 × 0.5 mL) in the extraction 
step.  The resulting solution was then analysed directly via LC/MS C18 column (50 ´ 2.1 mm, 
2.6 µm), Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 ml/min) and was observed 
to have proceeded in 77% conversion.  
 
Figure 63 Mass trace of crude reaction of glucagon with 54, with mass chromatogram shown as an insert. ’ denotes 




















Dual labelling of teriparatide to form 203 
 
The dual labelling of teriparatide was performed at room temperature using General Procedure 
J using 54 (100 mM in H2O) and 1:1 diethyl ether:ethyl acetate (2 ´ 0.5 mL) in the extraction 
step.  The resulting solution was then analysed directly via LC/MS C18 column (50 ´ 2.1 mm, 
2.6 µm), Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 ml/min) and was observed 
to have proceeded in >95% conversion.  
 
Figure 64 Mass trace of crude reaction of teriparatide with 54, with mass chromatogram shown as an insert. ’ denotes 
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Dual labelling of tetracosactide to form 204 
 
The dual labelling of tetracosactide was performed at room temperature using General 
Procedure I using 54 (100 mM in H2O) and 1:1 diethyl ether:ethyl acetate (2 ´ 0.5 mL) in the 
extraction step.  The resulting solution was then analysed directly via LC/MS C18 column (50 
´ 2.1 mm, 2.6 µm), Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 ml/min) and was 





Figure 65 Mass trace of crude reaction of tetracosactide with 54, with mass chromatograms shown as an insert. P1 = 
tetracosactide +met label+O (14% conversion). P2 = tetracosactide+Met label+Trp label+29 (10% conversion). P3 = desired 
product 204 (tetracosactide+Met label+Trp label) (63% conversion). P4 = tetracosactide+Met label+ 2(Trp label) (12% 
conversion). 




























Preliminary result for photoreduction of multi-functionalised teriparatide conjugate 203 to 
form 205 
 
The dual labelling of teriparatide was performed at room temperature using General Procedure 
J using 54 (100 mM in H2O) and 1:1 diethyl ether:ethyl acetate (2 ´ 0.5 mL) in the extraction 
step. To the resulting solution was added a magnetic stirrer and the Hantzsch ester 102 (1.8 mg, 
1.0 ´ 10-5 mmol). The tube was then capped with a septum and subsequently 
evacuated/backfilled with N2 (´ 5). To the tube was added added fac-Ir(ppy)3 (560 µM in 
freshly degassed CH3CN, 160 µL) and freshly degassed H2O (160 µL).  The resulting 
heterogeneous mixture was then stirred rapidly. The mixture was irradiated with a Prolite 30 W 
fluorescent light bulb that was placed at a 5 cm distance from the microwave tube for 45 
minutes. A constant temperature was maintained by placing the microwave tube under a stream 
of air over the course of the irradiation. The reaction mixture was then extracted with 1:1 ethyl 
acetate:diethyl ether (3 ́  0.5 mL) and the excess volatiles were removed in vacuo. The resulting 
solution was then analysed directly via LC/MS (C18 column (50 ´ 2.1 mm, 2.6µm), Gradient: 
5-95% B over 5 min then hold for 0.5 min, 0.7 ml/min), and the doubly reduced species was 
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Figure 66 Mass trace of crude reaction of teriparatide with 54 followed by photoreduction, with mass chromatogram shown 
as an insert. ’ denotes diagnostic fragmentation of C-S bond giving M+label-(label+SMe) = M+(154+2(113))-160. ’’ denotes 
diagnostic fragment M+(154+2(113))-2(160). 
 
Photoreduction of exenatide conjugate 86 with photocatalyst-free conditions 
 
The labelling of exenatide was performed at room temperature using General Procedure E using 
77 (100 mM in H2O) and 1:1 diethyl ether:ethyl acetate (2 ´ 0.5 mL) in the extraction step. To 
the resulting solution was added a magnetic stirrer and the Hantzsch ester 102 (1.0 mg, 4.0 ´ 
10-6 mmol). The tube was then capped with a septum and subsequently evacuated/backfilled 
with N2 (´ 5). To the tube was added freshly degassed CH3CN (100 µL) and freshly degassed 
H2O (50 µL).  The resulting heterogeneous mixture was then stirred rapidly. The mixture was 
irradiated with a Kessil 40 W light bulb that was placed at a 5 cm distance from the microwave 



















under a stream of air over the course of the irradiation. The reaction mixture was then extracted 
with 1:1 ethyl acetate:diethyl ether (3 ́  0.5 mL) and the excess volatiles were removed in vacuo. 
The resulting solution was then analysed directly via LC/MS (C18 column (50 ´ 2.1 mm, 
2.6µm), Gradient: 5-95% B over 5 min then hold for 0.5 min, 0.7 ml/min), and reaction was 
observed to have proceeded in >95% conversion. 
 



















(1)  McKay, C. S.; Finn, M. G. Chem. Biol. 2014, 21 (9), 1075–1101. 
(2)  Koniev, O.; Wagner, A. Chem. Soc. Rev. 2015, 44 (15), 5495–5551. 
(3)  Stephanopoulos, N.; Francis, M. B. Nat. Chem. Biol. 2011, 7 (12), 876–884. 
(4)  Sletten, E. M.; Bertozzi, C. R. Angew. Chem. Int. Ed. 2009, 48 (38), 6974–6998. 
(5)  Chalker, J. M.; Bernardes, G. J. L.; Lin, Y. A.; Davis, B. G. Chem. Asian J. 2009, 4 (5), 
630–640. 
(6)  Spicer, C. D.; Davis, B. G. Nat. Commun. 2014, 5, 1–14. 
(7)  Carrico, I. S. Chem. Soc. Rev. 2008, 37 (7), 1423–1431. 
(8)  Lang, K.; Chin, J. W. ACS Chem. Biol. 2014, 9 (1), 16–20. 
(9)  Lang, K.; Chin, J. W. Chem. Rev. 2014, 114 (9), 4764–4806. 
(10)  Wang, L.; Schultz, P. G. Angew. Chem. Int. Ed. 2005, 44 (1), 34–66. 
(11)  Chin, J. W. Nature 2017, 550 (7674), 53–60. 
(12)  Lang, K.; Chin, J. W. Chem. Commun. 2010, 46 (10), 1589–1600. 
(13)  Sletten, E. M.; Bertozzi, C. R. Acc. Chem. Res. 2011, 44, 666–676. 
(14)  Li, F.; Mahato, R. I. Mol. Pharm. 2017, 14, 1321–1324. 
(15)  Uttamchandani, M.; Li, J.; Sun, H.; Yao, S. Q. ChemBioChem 2008, 9 (5), 667–675. 
(16)  Speers, A. E.; Cravatt, B. F. ChemBioChem 2004, 5 (1), 41–47. 
(17)  Prescher, J. A.; Dube, D. H.; Bertozzi, C. R. Nature 2004, 430, 873–877. 
(18)  King, M.; Wagner, A. Bioconjugate Chem. 2014, 25, 825–839. 
(19)  Devaraj, N. K. ACS Cent. Sci. 2018, 4, 952–959. 
(20)  Hermanson, G. T. Bioconjugate Techniques, 2nd edition.; Academic Press, 2008. 
(21)  Brotzel, F.; Mayr, H. Org. Biomol. Chem. 2007, 5 (23), 3814–3820. 
(22)  Goddard, D. R.; Michaelis, L. J. Biol. Chem. 1935, 112 (6), 361–371. 
(23)  King, J. L.; Jukes, T. H. Science 1969, 164 (3881), 788–798. 
References  
 215 
(24)  Dan, N.; Setua, S.; Kashyap, V. K.; Khan, S.; Jaggi, M.; Yallapu, M. M.; Chauhan, S. 
C. Pharmaceuticals 2018, 11 (2), 32–54. 
(25)  Góngora-Benítez, M.; Tulla-Puche, J.; Albericio, F. Chem. Rev. 2014, 114 (2), 901–
926. 
(26)  Mamathambika, B. S.; Bardwell, J. C. Annu. Rev. Cell Dev. Bi. 2008, 24 (1), 211–235. 
(27)  Petersen, M. T. N.; Jonson, P. H.; Petersen, S. B. Protein Eng. Des. Sel. 1999, 12 (7), 
535–548. 
(28)  Burns, J. A.; Butler, J. C.; Moran, J.; Whitesides, G. M. J. Org. Chem. 1991, 56 (8), 
2648–2650. 
(29)  Getz, E. B.; Xiao, M.; Chakrabarty, T.; Cooke, R.; Selvin, P. R. Anal. Biochem. 1999, 
273 (1), 73–80. 
(30)  Rosendahl, M. S.; Doherty, D. H.; Smith, D. J.; Carlson, S. J.; Chlipala, E. A.; Cox, G. 
N. Bioconjugate Chem. 2005, 16, 200–207. 
(31)  Glockshuber, R.; Schmidt, T.; Plueckthun, A. Biochemistry 1992, 31 (5), 1270–1279. 
(32)  Friedmann, E.; Marrian, D. H.; Simon-reuss, I. Brit. J. Pharmacol. 1949, 4 (1), 105–
108. 
(33)  Friedmann, E. Biochim. Biophys. Acta 1952, 9, 65–75. 
(34)  Philippe, S.; Christophe, B.; Benoît, F.; Francis, S. Bioconjugate Chem. 2000, 11, 118–
123. 
(35)  Tedaldi, L. M.; Smith, M. E. B.; Nathani, R. I.; Baker, J. R. Chem. Commun. 2009, 43, 
6583–6585. 
(36)  Zhang, Y.; Bhatt, V. S.; Sun, G.; Wang, P. G.; Palmer, A. F. Bioconjugate Chem. 2008, 
19 (11), 2221–2230. 
(37)  Saito, F.; Noda, H.; Bode, J. W. ACS Chem. Biol. 2015, 10, 1026–1033. 
(38)  Alley, S. C.; Okeley, N. M.; Senter, P. D. Curr. Opin. Chem. Biol. 2010, 14 (4), 529–
537. 
(39)  Kim, J.-R.; Yoon, H. W.; Kwon, K.-S.; Lee, S.-R.; Rhee, S. G. Anal. Biochem. 2000, 
283 (2), 214–221. 
(40)  Davis, N. J.; Flitsch, S. L. Tetrahedron Lett. 1991, 32 (46), 6793–6796. 
References   
 216 
(41)  Lindley, H. Nature 1956, 178 (4534), 647–648. 
(42)  Raftery, M. A.; Cole, R. D. J. Biol. Chem. 1966, 241 (15), 3457–3461. 
(43)  Simon, M. D.; Chu, F.; Racki, L. R.; De La Cruz, C. C.; Burlingame, A. L.; Panning, 
B.; Narlikar, G. J.; Shokat, K. M. Cell 2007, 128, 1003–1012. 
(44)  Smith, H. B.; Hartman, F. C. J. Biol. Chem. 1988, 263 (10), 4921–4925. 
(45)  Morpurgo, M.; Veronese, F. M.; Kachensky, D.; Milton Harris, J. M. Bioconjugate 
Chem. 1996, 7 (3), 363–368. 
(46)  Morales-Sanfrutos, J.; Lopez-Jaramillo, F. J.; Hernandez-Mateo, F.; Santoyo-Gonzalez, 
F. J. Org. Chem. 2010, 75 (12), 4039–4047. 
(47)  Ovaa, H.; van Swieten, P. F.; Kessler, B. M.; Leeuwenburgh, M. A.; Fiebiger, E.; van 
den Nieuwendijk, A. M. C. H.; Galardy, P. J.; van der Marel, G. A.; Ploegh, H. L.; 
Overkleeft, H. S. Angew. Chem. Int. Ed. 2003, 42 (31), 3626–3629. 
(48)  Bernardim, B.; Cal, P. M. S. D.; Matos, M. J.; Oliveira, B. L.; Martínez-Sáez, N.; 
Albuquerque, I. S.; Perkins, E.; Corzana, F.; Burtoloso, A. C. B.; Jiménez-Osés, G.; 
Bernardes, G. J. L. Nat. Commun. 2016, 7 (13128), 1–9. 
(49)  Hoyle, C. E.; Bowman, C. N. Angew. Chem. Int. Ed. 2010, 49 (9), 1540–1573. 
(50)  Dondoni, A.; Marra, A. Chem. Soc. Rev. 2012, 41 (2), 573–586. 
(51)  Dondoni, A.; Massi, A.; Nanni, P.; Roda, A. Chem. Eur. J. 2009, 15 (43), 11444–
11449. 
(52)  Stolz, R. M.; Northrop, B. H. J. Org. Chem. 2013, 78 (16), 8105–8116. 
(53)  Massi, A.; Nanni, D. Org. Biomol. Chem. 2012, 10 (19), 3791–3807. 
(54)  Bader, H.; Cross, L. C.; Heilbron, I.; Jones, E. R. H. J. Chem. Soc. 1949, 0 (0), 619–
623. 
(55)  Lo Conte, M.; Pacifico, S.; Chambery, A.; Marra, A.; Dondoni, A. J. Org. Chem. 2010, 
75 (13), 4644–4647. 
(56)  Conte, M. Lo; Staderini, S.; Marra, A.; Sanchez-Navarro, M.; Davis, B. G.; Dondoni, 
A. Chem. Commun. 2011, 47 (39), 11086–11088. 
(57)  Ellman, G. L. Arch. Biochem. Biophys. 1959, 82 (1), 70–77. 
(58)  Fontana, A.; Scoffone, E.; Benassi, C. A. Biochemistry 1968, 7 (3), 980–986. 
References  
 217 
(59)  Davis, B. G.; Maughan, M. A. T.; Green, M. P.; Ullman, A.; Jones, B. Tetrahedron-
Asymmetr 2000, 11, 245–262. 
(60)  Gamblin, D. P.; Garnier, P.; Ward, S. J.; Oldham, N. J.; Fairbanks, A. J.; Davis, B. G. 
Org. Biomol. Chem. 2003, 1 (21), 3642–3644. 
(61)  Pollack, S. J.; Schultz, P. G. J. Am. Chem. Soc. 1989, 111 (5), 1929–1931. 
(62)  Gamblin, D. P.; Garnier, P.; van Kasteren, S.; Oldham, N. J.; Fairbanks, A. J.; Davis, 
B. G. Angew. Chem. Int. Ed. 2004, 43 (7), 828–833. 
(63)  Smith, M. E. B.; Schumacher, F. F.; Ryan, C. P.; Tedaldi, L. M.; Papaioannou, D.; 
Waksman, G.; Caddick, S.; Baker, J. R. J. Am. Chem. Soc. 2010, 132 (6), 1960–1965. 
(64)  Castañeda, L.; Wright, Z. V. F.; Marculescu, C.; Tran, T. M.; Chudasama, V.; Maruani, 
A.; Hull, E. A.; Nunes, J. P. M.; Fitzmaurice, R. J.; Smith, M. E. B.; Jones, L. H.; 
Caddick, S.; Baker, J. R. Tetrahedron Lett. 2013, 54 (27), 3493–3495. 
(65)  Jones, M. W.; Strickland, R. A.; Schumacher, F. F.; Caddick, S.; Baker, J. R.; Gibson, 
M. I.; Haddleton, D. M. J. Am. Chem. Soc. 2012, 134 (3), 1847–1852. 
(66)  Forte, N.; Chudasama, V.; Baker, J. R. Drug Discov. Today Technol. 2018, 30, 11–20. 
(67)  Walsh, S. J.; Omarjee, S.; Galloway, W. R. J. D.; Kwan, T. T.-L.; Sore, H. F.; Parker, 
J. S.; Hyvönen, M.; Carroll, J. S.; Spring, D. R. Chem. Sci. 2019, 10, 694–700. 
(68)  Toda, N.; Asano, S.; Barbas, C. F. Angew. Chem. Int. Ed. 2013, 52 (48), 12592–12596. 
(69)  Lyon, R. P.; Setter, J. R.; Bovee, T. D.; Doronina, S. O.; Hunter, J. H.; Anderson, M. 
E.; Balasubramanian, C. L.; Duniho, S. M.; Leiske, C. I.; Senter, P. D. Nat. Biotechnol. 
2014, 32 (10), 1059–1062. 
(70)  Szijj, P. A.; Bahou, C.; Chudasama, V. Drug Discov. Today Technol. 2018, 30, 27–34. 
(71)  Bernardes, G. J. L.; Chalker, J. M.; Errey, J. C.; Davis, B. G. J. Am. Chem. Soc. 2008, 
130 (15), 5052–5053. 
(72)  Dadová, J.; Galan, S. R.; Davis, B. G. Curr. Opin. Chem. Biol. 2018, 46, 71–81. 
(73)  Strumeyer, D. H.; White, W. N.; Koshland, D. E. P. Natl. A. Sci. USA. 1963, 50 (5), 
931–935. 
(74)  Okeley, N. M.; Zhu, Y.; Van der Donk, W. A. Org. Lett. 2000, 2 (23), 3603–3606. 
(75)  Chalker, J. M.; Gunnoo, S. B.; Boutureira, O.; Gerstberger, S. C.; Fernández-González, 
References   
 218 
M.; Bernardes, G. J. L.; Griffin, L.; Hailu, H.; Schofield, C. J.; Davis, B. G. Chem. Sci. 
2011, 2 (9), 1666–1676. 
(76)  Hashimoto, K.; Sakai, M.; Okuno, T.; Shirahama, H. Chem. Commun. 1996, 0 (10), 
1139–1140. 
(77)  Seebeck, F. P.; Szostak, J. W. J. Am. Chem. Soc. 2006, 128 (22), 7150–7151. 
(78)  Wang, J.; Schiller, S. M.; Schultz, P. G. Angew. Chem. Int. Ed. 2007, 46 (36), 6849–
6851. 
(79)  You, Y. O.; Levengood, M. R.; Ihnken, L. A. F.; Knowlton, A. K.; van der Donk, W. 
A. ACS Chem. Biol. 2009, 4 (5), 379–385. 
(80)  Galonić, D. P.; van der Donk, W. A.; Gin, D. Y. Chem. Eur. J. 2003, 9 (24), 5997–
6006. 
(81)  Tamura, T.; Hamachi, I. J. Am. Chem. Soc. 2019, 141 (7), 2782–2799. 
(82)  Wright, T. H.; Bower, B. J.; Chalker, J. M.; Bernardes, G. J. L.; Wiewiora, R.; Ng, W.-
L.; Raj, R.; Faulkner, S.; Vallée, M. R. J.; Phanumartwiwath, A.; Coleman, O. D.; 
Thézénas, M.-L.; Khan, M.; Galan, S. R. G.; Lercher, L.; Schombs, M. W.; 
Gerstberger, S.; Palm-Espling, M. E.; Baldwin, A. J.; Kessler, B. M.; Claridge, T. D. 
W.; Mohammed, S.; Davis, B. G. Science 2016, 354 (6312), aag1465. 
(83)  Galan, S. R. G.; Wickens, J. R.; Dadova, J.; Ng, W. L.; Zhang, X.; Simion, R. A.; 
Quinlan, R.; Pires, E.; Paton, R. S.; Caddick, S.; Chudasama, V.; Davis, B. G. Nat. 
Chem. Biol. 2018, 14 (10), 955–963. 
(84)  Antos, J. M.; Francis, M. B. Curr. Opin. Chem. Biol. 2006, 10 (3), 253–262. 
(85)  Simmons, R. L.; Yu, R. T.; Myers, A. G. J. Am. Chem. Soc 2011, 133, 15870–15873. 
(86)  Yang, M.; Li, J.; Chen, P. R. Chem. Soc. Rev. 2014, 43 (18), 6511–6526. 
(87)  Cheng, G.; Lim, R. K. V.; Li, N.; Lin, Q. Chem. Commun. 2013, 49 (60), 6809–6811. 
(88)  Vinogradova, E. V.; Zhang, C.; Spokoyny, A. M.; Pentelute, B. L.; Buchwald, S. L. 
Nature 2015, 526, 687–691. 
(89)  Zhao, W.; Lee, H. G.; Buchwald, S. L.; Hooker, J. M. J. Am. Chem. Soc. 2017, 139 
(21), 7152–7155. 




(91)  Rojas, A. J.; Pentelute, B. L.; Buchwald, S. L. Org. Lett. 2017, 19 (16), 4263–4266. 
(92)  Willwacher, J.; Raj, R.; Mohammed, S.; Davis, B. G. J. Am. Chem. Soc. 2016, 138 
(28), 8678–8681. 
(93)  Zhang, C.; Welborn, M.; Zhu, T.; Yang, N. J.; Santos, M. S.; Voorhis, T. Van; 
Pentelute, B. L. Nat. Chem. 2016, 8, 120–128. 
(94)  Dai, P.; Williams, J. K.; Zhang, C.; Welborn, M.; Shepherd, J. J.; Zhu, T.; Voorhis, T. 
V.; Hong, M.; Pentelute, B. L. Sci. Rep. 2017, 7 (7954), 1–9. 
(95)  Evans, E. D.; Pentelute, B. L. ACS Chem. Biol. 2018, 13, 527–532. 
(96)  Zhang, C.; Dai, P.; Vinogradov, A. A.; Gates, Z. P.; Pentelute, B. L. Angew. Chem. Int. 
Ed. 2018, 57 (22), 6459–6463. 
(97)  Bernard-Gauthier, V.; Wängler, C.; Schirrmacher, E.; Kostikov, A.; Jurkschat, K.; 
Wängler, B.; Schirrmacher, R. Biomed Res. Int. 2014, 2014, 1–20. 
(98)  Verhoog, S.; Kee, C. W.; Wang, Y.; Khotavivattana, T.; Wilson, T. C.; Kersemans, V.; 
Smart, S.; Tredwell, M.; Davis, B. G.; Gouverneur, V. J. Am. Chem. Soc. 2018, 140, 
1572–1575. 
(99)  Boutureira, O.; Martínez-Sáez, N.; Brindle, K. M.; Neves, A. A.; Corzana, F.; 
Bernardes, G. J. L. Chem. Eur. J. 2017, 23 (27), 6483–6489. 
(100)  Lee, B.; Sun, S.; Jiménez-Moreno, E.; Neves, A. A.; Bernardes, G. J. L. Bioorg. Med. 
Chem. 2018, 26 (11), 3060–3064. 
(101)  Becker, J. M.; Wilchek, M. BBA-Gen. Subjects 1972, 264 (1), 165–170. 
(102)  Staros, J. V.; Wright, R. W.; Swingle, D. M. Anal. Biochem. 1986, 156 (1), 220–222. 
(103)  Traut, R. R.; Bollen, A.; Sun, T.-T.; Hershey, J. W. B.; Sundberg, J.; Pierce, L. R. 
Biochemistry 1973, 12 (17), 3266–3273. 
(104)  Wofsy, L.; Singer, S. J. Biochemistry 1963, 2 (1), 104–116. 
(105)  Lee, Y. C.; Stowell, C. P.; Krantz, M. J. Biochemistry 1976, 15 (18), 3956–3963. 
(106)  Annunziato, M. E.; Patel, U. S.; Ranade, M.; Palumbo, P. S. Bioconjugate Chem. 1993, 
4 (3), 212–218. 
(107)  Riggs, J. L.; Seiwald, R. J.; Burckhalter, J. H.; Downs, C. M.; Metcalf, T. G. Am. J. 
References   
 220 
Pathol. 1958, 34 (6), 1081–1097. 
(108)  Tuls, J.; Geren, L.; Millett, F. J. Biol. Chem. 1989, 264 (28), 16421–16425. 
(109)  Rosa-Neto, P.; Wängler, B.; Iovkova, L.; Boening, G.; Reader, A.; Jurkschat, K.; 
Schirrmacher, E. ChemBioChem 2009, 10 (8), 1321–1324. 
(110)  Hartley, B. S.; Massey, V. Biochim. Biophys. Acta 1956, 21 (1), 58–70. 
(111)  Lefevre, C.; Kang, H. C.; Haugland, R. P.; Malekzadeh, N.; Arttamangkul, S.; 
Haugland, R. P. Bioconjugate Chem. 1996, 7 (4), 482–489. 
(112)  Evangelista, R. A.; Pollak, A.; Allore, B.; Templeton, E. F.; Morton, R. C.; Diamandis, 
E. P. Clin. Biochem. 1988, 21 (3), 173–178. 
(113)  Herzig, D. J.; Rees, A. W.; Day, R. A. Biopolymers 1964, 2 (4), 349–360. 
(114)  Wurm, F.; Dingels, C.; Frey, H.; Klok, H.-A. Biomacromolecules 2012, 13 (4), 1161–
1171. 
(115)  Wurm, F.; Steinbach, T.; Klok, H.-A. Chem. Commun. 2013, 49 (71), 7815. 
(116)  Gavrilyuk, J. I.; Wuellner, U.; Barbas, C. F. Bioorg. Med. Chem. Lett. 2009, 19 (5), 
1421–1424. 
(117)  Gavrilyuk, J. I.; Wuellner, U.; Salahuddin, S.; Goswami, R. K.; Sinha, S. C.; Barbas, C. 
F. Bioorg. Med. Chem. Lett. 2009, 19 (14), 3716–3720. 
(118)  Nanna, A. R.; Li, X.; Walseng, E.; Pedzisa, L.; Goydel, R. S.; Hymel, D.; Burke, T. R.; 
Roush, W. R.; Rader, C. Nat. Commun. 2017, 8 (1112), 1–9. 
(119)  Imai, K.; Watanabe, Y. Anal. Chim. Acta 1981, 130 (2), 377–383. 
(120)  Sutton, D. A.; Drewes, S. E.; Welz, U. Biochem. J. 1972, 130 (2), 589–595. 
(121)  Ladd, D. L.; Snow, R. A. Anal. Biochem. 1993, 210 (2), 258–261. 
(122)  Marshall, J. J. Trends Biochem. Sci. 1978, 3 (2), 79–83. 
(123)  Bentley, M. D.; Roberts, M. J.; Harris, J. M. J. Pharm. Sci. 1998, 87 (11), 1446–1449. 
(124)  Lee, R. T.; Lee, Y. C. Biochemistry 1980, 19 (1), 156–163. 
(125)  McFarland, J. M.; Francis, M. B. J. Am. Chem. Soc. 2005, 127 (39), 13490–13491. 
(126)  Degruyter, J. N.; Malins, L. R.; Baran, P. S. Biochemistry 2017, 56, 3863–3873. 
(127)  Chaubet, G.; Thoreau, F.; Wagner, A. Drug Discov. Today Technol. 2018, 30, 21–26. 
References  
 221 
(128)  Akkapeddi, P.; Azizi, S.-A.; Freedy, A. M.; Cal, P. M. S. D.; Gois, P. M. P.; Bernardes, 
G. J. L. Chem. Sci. 2016, 7 (5), 2954–2963. 
(129)  Lee, H. G.; Lautrette, G.; Pentelute, B. L.; Buchwald, S. L. Angew. Chem. Int. Ed. 
2017, 56 (12), 3177–3181. 
(130)  Matos, M. J.; Oliveira, B. L.; Martínez-Sáez, N.; Guerreiro, A.; Cal, P. M. S. D.; 
Bertoldo, J.; Maneiro, M.; Perkins, E.; Howard, J.; Deery, M. J.; Chalker, J. M.; 
Corzana, F.; Jiménez-Osés, G.; Bernardes, G. J. L. J. Am. Chem. Soc. 2018, 140 (11), 
4004–4017. 
(131)  Isom, D. G.; Castañeda, C. A.; Cannon, B. R.; García-Moreno, B. P. Natl. A. Sci. USA. 
2011, 108 (13), 5260–5265. 
(132)  Hacker, S. M.; Backus, K. M.; Lazear, M. R.; Forli, S.; Correia, B. E.; Cravatt, B. F. 
Nat. Chem. 2017, 9 (12), 1181–1190. 
(133)  Choi, S.; Connelly, S.; Reixach, N.; Wilson, I. A.; Kelly, J. W. Nat. Chem. Biol. 2010, 
6 (2), 133–139. 
(134)  Asano, S.; Patterson, J. T.; Gaj, T.; Barbas, C. F. Angew. Chem. Int. Ed. 2014, 53 (44), 
11783–11786. 
(135)  Foettinger, A.; Melmer, M.; Leitner, A.; Lindner, W. Bioconjugate Chem. 2007, 18 (5), 
1678–1683. 
(136)  Antos, J. M.; Francis, M. B. J. Am. Chem. Soc. 2004, 126, 10256–10257. 
(137)  Popp, B. V; Ball, Z. T. J. Am. Chem. Soc. 2010, 132 (19), 6660–6662. 
(138)  Schischko, A.; Ren, H.; Kaplaneris, N.; Ackermann, L. Angew. Chem. Int. Ed. 2017, 56 
(6), 1576–1580. 
(139)  Seki, Y.; Ishiyama, T.; Sasaki, D.; Abe, J.; Sohma, Y.; Oisaki, K.; Kanai, M. J. Am. 
Chem. Soc. 2016, 138 (34), 10798–10801. 
(140)  Uchida, K.; Stadtman, E. R. P. Natl. A. Sci. USA. 1992, 89 (10), 4544–4548. 
(141)  Li, X.; Ma, H.; Dong, S.; Duan, X.; Liang, S. Talanta 2004, 62 (2), 367–371. 
(142)  Jia, S.; Chang, C. Bioinspired Thiophosphorodichloridate Reagents for Chemoselective 
Histidine Bioconjugation 
https://chemrxiv.org/articles/Bioinspired_Thiophosphorodichloridate_Reagents_for_C
References   
 222 
hemoselective_Histidine_Bioconjugation/7250201 (accessed Jan 8, 2019). 
(143)  Neel S. Joshi; Leanna R. Whitaker; Francis, M. B. J. Am. Chem. Soc. 2004, 126 (49), 
15942–15943. 
(144)  Ban, H.; Gavrilyuk, J.; Barbas, C. F. J. Am. Chem. Soc. 2010, 132 (5), 1523–1525. 
(145)  Alvarez-Dorta, D.; Thobie-Gautier, C.; Croyal, M.; Bouzelha, M.; Mével, M.; Deniaud, 
D.; Boujtita, M.; Gouin, S. G. J. Am. Chem. Soc. 2018, 140 (49), 17120–17126. 
(146)  Allan, C.; Kosar, M.; Burr, C. V.; Mackay, C. L.; Duncan, R. R.; Hulme, A. N. 
ChemBioChem 2018, 19 (23), 2443–2447. 
(147)  Ohata, J.; Miller, M. K.; Mountain, C. M.; Vohidov, F.; Ball, Z. T. Angew. Chem. Int. 
Ed. 2018, 57 (11), 2827–2830. 
(148)  Gilmore, J. M.; Scheck, R. A.; Esser-Kahn, A. P.; Joshi, N. S.; Francis, M. B. Angew. 
Chem. Int. Ed. 2006, 45 (32), 5307–5311. 
(149)  Scheck, R. A.; Dedeo, M. T.; Iavarone, A. T.; Francis, M. B. J. Am. Chem. Soc. 2008, 
130 (35), 11762–11770. 
(150)  Obermeyer, A. C.; Jarman, J. B.; Francis, M. B. J. Am. Chem. Soc. 2014, 136, 9572–
9579. 
(151)  Chen, D.; Disotuar, M. M.; Xiong, X.; Wang, Y.; Chou, D. H.-C. Chem. Sci. 2017, 8, 
2717–2722. 
(152)  Bloom, S.; Liu, C.; Kölmel, D. K.; Qiao, J. X.; Zhang, Y.; Poss, M. A.; Ewing, W. R.; 
MacMillan, D. W. C. Nat. Chem. 2017, 10 (2), 205–211. 
(153)  Valley, C. C.; Cembran, A.; Perlmutter, J. D.; Lewis, A. K.; Labello, N. P.; Gao, J.; 
Sachs, J. N. J. Biol. Chem. 2012, 287 (42), 34979–34991. 
(154)  Cirino, P. C.; Tang, Y.; Takahashi, K.; Tirrell, D. A.; Arnold, F. H. Biotechnol. Bioeng. 
2003, 83 (6), 729–734. 
(155)  Ferla, M. P.; Patrick, W. M. Microbiology 2014, 160, 1571–1584. 
(156)  Struck, A.-W.; Thompson, M. L.; Wong, L. S.; Micklefield, J. ChemBioChem 2012, 13 
(18), 2642–2655. 
(157)  Kim, G.; Weiss, S. J.; Levine, R. L. BBA-Gen. Subjects 2014, 1840 (2), 901–905. 
(158)  Martínez, Y.; Li, X.; Liu, G.; Bin, P.; Yan, W.; Más, D.; Valdivié, M.; Hu, C.-A. A.; 
References  
 223 
Ren, W.; Yin, Y. Amino Acids 2017, 49, 2091–2098. 
(159)  Fu, X.; Adams, Z.; Liu, R.; Hepowit, N. L.; Wu, Y.; Bowmann, C. F.; Moskovitz, J.; 
Maupin-Furlow, J. A. MBio 2017, 8 (5), e01169-17. 
(160)  Bigelow D J; Squier, T. C. Biochim. Biophys. Acta 2005, 1703, 121–134. 
(161)  Hoffman, R. M. BBA-Rev. Cancer 1984, 738, 49–87. 
(162)  Birben, E.; Sahiner, U. M.; Sackesen, C.; Erzurum, S.; Kalayci, O. World Allergy 
Organ. J. 2012, 5 (1), 9–19. 
(163)  van der Westhuyzen, J. Nutr. Cancer 1985, 7 (3), 179–183. 
(164)  Patra, R. .; Swarup, D.; Dwivedi, S. . Toxicology 2001, 162 (2), 81–88. 
(165)  Jori, G.; Galiazzo, G.; Marzotto, A.; Scoffone, E. BBA-Protein Struct. M. 1968, 154 
(1), 1–9. 
(166)  Jori, G.; Galiazzo, G.; Marzotto, A.; Scoffone, E. J. Biol. Chem. 1968, 243, 4272–
4278. 
(167)  Misani, F.; Fair, T. W.; Reiner, L. J. Am. Chem. Soc. 1951, 73 (1), 459–461. 
(168)  Whitehead, J. K.; Bentley, H. R. J. Chem. Soc. 1952, 0 (0), 1572. 
(169)  Brill, A. S.; Weinryb, I. Biochemistry 1967, 6 (11), 3528–3535. 
(170)  Toennies, G. J. Biol. Chem. 1940, 132, 455–455. 
(171)  Link, T. P.; Stark, G. R. J. Biol. Chem. 1968, 243, 1082–1088. 
(172)  Toennies, G.; Kolb, J. J. J. Am. Chem. Soc. 1945, 67 (5), 849–851. 
(173)  Gerd Gundlach, H.; Moore, S.; Stein, W. H. J. Biol. Chem. 1959, 234 (7), 1761–1764. 
(174)  Mondal, J.; Tiwary, P.; Berne, B. J. J. Am. Chem. Soc. 2016, 138 (13), 4608–4615. 
(175)  Gundlach, H. G.; Steip, W. H.; Moore, S. J. Biol. Chem. 1959, 234 (7), 1754–1760. 
(176)  Bradshaw, R. A.; Robinson, G. W.; Hass, G. M.; Hill, R. L. J. Biol. Chem. 1969, 244, 
1755–1763. 
(177)  Lawson, W. B.; Schramm, H. J. J. Am. Chem. Soc. 1962, 84 (10), 2017–2018. 
(178)  Lawson, W. B.; Schramm, H.-J. Biochemistry 1965, 4 (3), 377–385. 
(179)  Jones, J. B.; Hysert, D. W. Can. J. Chem. 1971, 49, 3012–3019. 
References   
 224 
(180)  Naider, F.; Bohak, Z. Biochemistry 1972, 11 (17), 3208–3211. 
(181)  Naider, F.; Bohak, Z.; Yariv, J. Biochemistry 1972, 11 (17), 3202–3207. 
(182)  Doi, J. T.; Luehr, G. W. Tetrahedron Lett. 1985, 26 (50), 6143–6146. 
(183)  Vithayathil, P. J.; Richards, F. M. J. Biol. Chem. 1960, 235 (8), 2343–2351. 
(184)  Gorent, H. J.; Barnard, E. A. Biochemistry 1970, 9 (4), 959–973. 
(185)  Landis, B. H.; Berliner, L. J. J. Am. Chem. Soc. 1980, 102 (16), 5350–5354. 
(186)  Kramer, J. R.; Deming, T. J. Biomacromolecules 2012, 13, 1719–1723. 
(187)  Kramer, J. R.; Deming, T. J. Chem. Commun. 2013, 49 (49), 5144–5146. 
(188)  Gharakhanian, E. G.; Deming, T. J. Chem. Commun 2016, 52, 5336–5339. 
(189)  Gross, E.; Witkop, B. J. Am. Chem. Soc. 1961, 83 (6), 1510–1511. 
(190)  Gross, E.; Witkop, B. J. Biol. Chem. 1962, 237 (6), 1856–1860. 
(191)  Andreev, Y. A.; Kozlov, S. A.; Vassilevski, A. A.; Grishin, E. V. Anal. Biochem. 2010, 
407 (1), 144–146. 
(192)  Lin, S.; Yang, X.; Jia, S.; Weeks, A. M.; Hornsby, M.; Lee, P. S.; Nichiporuk, R. V; 
Iavarone, A. T.; Wells, J. A.; Toste, F. D.; Chang, C. J. Science 2017, 355, 597–602. 
(193)  Kramer, J. R.; Schmidt, N. W.; Mayle, K. M.; Kamei, D. T.; Wong, G. C. L.; Deming, 
T. J. ACS Cent. Sci. 2015, 1, 83–88. 
(194)  Maaskant, R. V.; Roelfes, G. ChemBioChem 2019, 20 (1), 57–61. 
(195)  Zhdankin, V. V; Stang, P. J. Chem. Rev. 2008, 108, 5299–5368. 
(196)  Merritt, E.; Olofsson, B. Angew. Chem. Int. Ed. 2009, 48 (48), 9052–9070. 
(197)  Perkins, C. W.; Martin, J. C.; Arduengo, A. J.; Lau, W.; Alegria, A.; Kochi, J. K. J. 
Am. Chem. Soc 1980, 102 (26), 7753–7759. 
(198)  Malmgren, J.; Santoro, S.; Jalalian, N.; Himo, F.; Olofsson, B. Chem. Eur. J. 2013, 19 
(31), 10334–10342. 
(199)  Stang, P. J.; Zhdankin, V. V. Chem. Rev. 1996, 96, 1123–1178. 
(200)  Yoshimura, A.; Zhdankin, V. V. Chem. Rev. 2016, 116, 3328–3435. 
(201)  Zhdankin, V. V.; Stang, P. J. Chem. Rev. 2002, 102 (7), 2523–2584. 
References  
 225 
(202)  Okuyama, T.; Takino, T.; Sueda, T.; Ochiai, M. J. Am. Chem. Soc. 1995, 117 (12), 
3360–3367. 
(203)  R Crowder, B. J.; Glover, E. E.; Grundon, M. F.; Kaempfen, H. X. J. Chem. Soc. 1963, 
4578–4585. 
(204)  Chan, L.; Mcnally, A.; Toh, Q. Y.; Mendoza, A.; Gaunt, M. J. Chem. Sci. 2015, 6, 
1277–1281. 
(205)  Carroll, M. A.; Nairne, J.; Woodcraft, J. L. J. Labelled Compd. Rad. 2007, 50 (5–6), 
452–454. 
(206)  Martín-Santamaría, S.; Carroll, M. A.; Carroll, C. M.; Carter, C. D.; Pike, V. W.; 
Rzepa, H. S.; Widdowson, D. A. Chem. Commun.  2000, 649–650. 
(207)  Yan, J.; Hu, W.; Rao, G. Synthesis 2006, 6, 943–945. 
(208)  Yan, J.; Hu, W.; Zhou, W. Synth. Commun. 2006, 36, 2097–2102. 
(209)  Yan, J.; Zhu, M.; Zhou, Z. Eur. J. Org. Chem. 2006, 2006 (9), 2060–2062. 
(210)  Carroll, M. A.; Wood, R. A. Tetrahedron 2007, 63, 11349–11354. 
(211)  Krief, A.; Dumont, W.; Robert, M. Chem. Commun. 2005, 2167–2168. 
(212)  Krief, A.; Dumont, W.; Robert, M.; Professor Atta-ur-Rahman, T. Synlett 2006, 16, 
2601–2604. 
(213)  Krief, A.; Dumont, W.; Robert, M. Synlett 2006, 3, 484–486. 
(214)  Matoušek, V.; Václavík, J.; Hájek, P.; Charpentier, J.; Blastik, Z. E.; Pietrasiak, E.; 
Budinská, A.; Togni, A.; Beier, P. Chem. Eur. J. 2016, 22 (1), 417–424. 
(215)  Václavík, J.; Zschoche, R.; Klimánková, I.; Matoušek, V.; Beier, P.; Hilvert, D.; Togni, 
A. Chem. Eur. J. 2017, 23 (27), 6490–6494. 
(216)  Frei, R.; Jérô Me Waser, J. J. Am. Chem. Soc 2013, 135, 9620–9623. 
(217)  Abegg, D.; Frei, R.; Cerato, L.; Prasad Hari, D.; Wang, C.; Waser, J.; Adibekian, A. 
Angew. Chem. Int. Ed. 2015, 54 (37), 10852–10857. 
(218)  Tolnai, G. L.; Brand, J. P.; Waser, J. Beilstein J. Org. Chem 2016, 12, 745–749. 
(219)  Hansen, M. B.; Hubálek, F.; Skrydstrup, T.; Hoeg-Jensen, T. Chem. Eur. J. 2016, 22 
(5), 1572–1576. 
References   
 226 
(220)  Weiss, R.; Seubert, J.; Hampel, F. Angew. Chem. Int. Ed. 1994, 33 (19), 1952–1953. 
(221)  Sahu, S.; Sahoo, R.; Patel, S.; Mishra, B. K. J. Sulfur Chem. 2011, 32 (2), 171–197. 
(222)  Vogler, T.; Studer, A. Synthesis 2008, 2008 (13), 1979–1993. 
(223)  Cvetkovic, R. S.; Plosker, G. L. Drugs 2007, 67 (6), 935–954. 
(224)  Leuchte, H. H.; Baezner, C.; Baumgartner, R. A.; Bevec, D.; Bacher, G.; Neurohr, C.; 
Behr, J. Eur. Respir. J. 2008, 32, 1289–1294. 
(225)  Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Drug Discov. Today 2010, 
15, 40–56. 
(226)  Saag, K. G.; Shane, E.; Boonen, S.; Marín, F.; Donley, D. W.; Taylor, K. A.; Dalsky, 
G. P.; Marcus, R. N. Engl. J. Med. 2007, 357, 2028–2067. 
(227)  Cottrell, J. S. J. Proteomics 2011, 74, 1842–1851. 
(228)  Matthiesen, R.; Bunkenborg, J. In Mass Spectrometry Data Analysis in Proteomics; 
Matthiesen, R., Ed.; Methods in Molecular Biology; Humana Press: Totowa, NJ, 2013; 
Vol. 1007, pp 1–45. 
(229)  Greenfield, N. J. Nat. Protoc. 2006, 1 (6), 2876–2890. 
(230)  Baldwin, A. D.; Kiick, K. L. Bioconjugate Chem. 2011, 22 (10), 1946–1953. 
(231)  Lewis, M. R.; Shively, J. E. Bioconjugate Chem. 1998, 9 (1), 72–86. 
(232)  Lapko, V. N.; Smith, D. L.; Smith, J. B. J. Mass Spectrom. 2000, 35 (4), 572–575. 
(233)  Reid, G. E.; Roberts, K. D.; Simpson, R. J.; O’Hair, R. A. J. J. Am. Soc. Mass Spectr. 
2005, 16 (7), 1131–1150. 
(234)  Schneider, C.; LaFortune, J. H. W.; Melen, R. L.; Stephan, D. W. Dalt. Trans. 2018, 47 
(36), 12742–12749. 
(235)  Doyle, M. P.; Duffy, R.; Ratnikov, M.; Zhou, L. Chem. Rev. 2010, 110, 704–724. 
(236)  Ciszewski, Ł. W.; Rybicka-Jasińska, K.; Gryko, D. Org. Biomol. Chem. 2019, 17 (3), 
432–448. 
(237)  Dang, H.-S.; Roberts, B. P. J. Chem. Soc. Perk. T. 1 1996, 769–775. 
(238)  Horner, L.; Schwarz, H. Liebigs Ann. Chem. 1971, 747 (1), 1–13. 
(239)  Banga, A. K.; Chien, Y. W. Int. J. Pharm. 1988, 48, 15–50. 
References  
 227 
(240)  Szychowski, J.; Mahdavi, A.; Hodas, J. J. L.; Bagert, J. D.; Ngo, J. T.; Landgraf, P.; 
Dieterich, D. C.; Schuman, E. M.; Tirrell, D. A. J. Am. Chem. Soc. 2010, 132 (51), 
18351–18360. 
(241)  Connon, S. J. Org. Biomol. Chem. 2007, 5, 3407–3417. 
(242)  Buckler, S. A.; Doll, L.; Lind, F. K.; Epstein, M. J. Org. Chem. 1962, 27 (3), 794–798. 
(243)  Takagaki, Y.; Gupta, C. M.; Khorana, H. G. Biochem. Bioph. Res. Co. 1980, 95 (2), 
589–595. 
(244)  Prier, C. K.; Rankic, D. A.; Macmillan, D. W. C. Chem. Rev. 2013, 113, 5322–5363. 
(245)  Walton, J. C.; Portela-Cubillo, F. In Encyclopedia of Reagents for Organic Synthesis; 
John Wiley & Sons, Ltd: Chichester, UK, 2007. 
(246)  Hedstrand, D. M.; Kruizinga, W. H.; Kellogg, R. M. Tetrahedron Lett. 1978, 19 (14), 
1255–1258. 
(247)  Zhu, X.-Q.; Liu, Y.-C.; Cheng, J.-P. J. Org. Chem. 1999, 64, 8980–8981. 
(248)  Huang, W.; Cheng, X. Synlett 2017, 28, 148–158. 
(249)  Li, G.; Chen, R.; Wu, L.; Fu, Q.; Zhang, X.; Tang, Z. Angew. Chem. Int. Ed. 2013, 52 
(32), 8432–8436. 
(250)  Chen, W.; Liu, Z.; Tian, J.; Li, J.; Ma, J.; Cheng, X.; Li, G. J. Am. Chem. Soc. 2016, 
138 (38), 12312–12315. 
(251)  Goldmann, S.; Born, L.; Kazda, S.; Pittel, B.; Schramm, M. J. Med. Chem. 1990, 33 
(5), 1413–1418. 
(252)  Zempleni, J.; Wijeratne, S. S. K.; Hassan, Y. I. BioFactors 2009, 35 (1), 36–46. 
(253)  Van Bergen, T. J.; Hedstrand, D. M.; Kruizinga, W. H.; Kellogg, R. M. J. Org. Chem. 
1979, 44 (26), 4953–4962. 
(254)  Taylor, M. T.; Nelson, J. E.; Suero, M. G.; Gaunt, M. J. Nature 2018, 562 (7728), 563–
568. 
(255)  Maruani, A.; Richards, D. A.; Chudasama, V. Org. Biomol. Chem 2016, 14, 6165–
6178. 
(256)  Banerjee, D.; Liu, A. P.; Voss, N. R.; Schmid, S. L.; Finn, M. G. ChemBioChem 2010, 
11 (9), 1273–1279. 
References   
 228 
(257)  Stephanopoulos, N.; Tong, G. J.; Hsiao, S. C.; Francis, M. B. ACS Nano 2010, 4 (10), 
6014–6020. 
(258)  Maruani, A.; Smith, M. E. B.; Miranda, E.; Chester, K. A.; Chudasama, V.; Caddick, S. 
Nat. Commun. 2015, 6 (6645), 1–9. 
(259)  Joo, C.; Balci, H.; Ishitsuka, Y.; Buranachai, C.; Ha, T. Annu. Rev. Biochem. 2008, 77, 
51–76. 
(260)  Cecconi, C.; Shank, E. A.; Bustamante, C.; Marqusee, S. Science 2005, 309 (5743), 
2057–2060. 
(261)  Temming, R. P.; Eggermont, L.; van Eldijk, M. B.; van Hest, J. C. M.; van Delft, F. L. 
Org. Biomol. Chem. 2013, 11 (17), 2772–2779. 
(262)  Yamaguchi, A.; Matsuda, T.; Ohtake, K.; Yanagisawa, T.; Yokoyama, S.; Fujiwara, 
Y.; Watanabe, T.; Hohsaka, T.; Sakamoto, K. Bioconjugate Chem. 2016, 27 (1), 198–
206. 
(263)  Ratner, V.; Kahana, E.; Eichler, M.; Haas, E. Bioconjugate Chem. 2002, 13 (5), 1163–
1170. 
(264)  Sonntag, M. H.; Ibach, J.; Nieto, L.; Verveer, P. J.; Brunsveld, L. Chem. Eur. J. 2014, 
20 (20), 6019–6026. 
(265)  Nathani, R. I.; Moody, P.; Chudasama, V.; Smith, M. E. B.; Fitzmaurice, R. J.; 
Caddick, S. Chem. Sci. 2013, 4, 3455–3458. 
(266)  Puthenveetil, S.; Musto, S.; Loganzo, F.; Tumey, L. N.; O’Donnell, C. J.; Graziani, E. 
Bioconjugate Chem. 2016, 27 (4), 1030–1039. 
(267)  Crochet, A. P.; Mohiuddin, M. K.; Francis, M. B.; Paavolam C. D. Biosens. 
Bioelectron. 2010, 26, 55–61. 
(268)  Neumann, H.; Wang, K.; Davis, L.; Garcia-Alai, M.; Chin, J. W. Nature 2010, 464 
(7287), 441–444. 
(269)  Wan, W.; Huang, Y.; Wang, Z.; Russell, W. K.; Pai, P.-J.; Russell, D. H.; Liu, W. R. 
Angew. Chem. Int. Ed. 2010, 49 (18), 3211–3214. 
(270)  Johnson, D. B. F.; Xu, J.; Shen, Z.; Takimoto, J. K.; Schultz, M. D.; Schmitz, R. J.; 




(271)  Park, H.-S.; Hohn, M. J.; Umehara, T.; Guo, L.-T.; Osborne, E. M.; Benner, J.; Noren, 
C. J.; Rinehart, J.; Soll, D.; Reppas, N. B.; Emig, C. J.; Bang, D.; Hwang, S. J.; Jewett, 
M. C.; Jacobson, J. M.; Church, G. M. Science 2011, 333 (6046), 1151–1154. 
(272)  van Kasteren, S. I.; Kramer, H. B.; Jensen, H. H.; Campbell, S. J.; Kirkpatrick, J.; 
Oldham, N. J.; Anthony, D. C.; Davis, B. G. Nature 2007, 446 (7139), 1105–1109. 
(273)  Brustad, E. M.; Lemke, E. A.; Schultz, P. G.; Deniz, A. A. J. Am. Chem. Soc. 2008, 
130 (52), 17664–17665. 
(274)  Simon, M.; Zangemeister-Wittke, U.; Plückthun, A. Bioconjugate Chem. 2012, 23 (2), 
279–286. 
(275)  Moroder, L. J. Pept. Sci. 2005, 11 (4), 187–214. 
(276)  Kim, J.; Seo, M.-H.; Lee, S.; Cho, K.; Yang, A.; Woo, K.; Kim, H.-S.; Park, H.-S. 
Anal. Chem. 2013, 85, 1468–1474. 
(277)  Strohalm, M.; Hassman, M.; Košata, B.; Kodíček, M. Rapid Commun. Mass Sp. 2008, 
22 (6), 905–908. 
(278)  Ideue, E.; Toma, T.; Shimokawa, J.; Fukuyama, T. Org. Synth. 2012, 89, 501–509. 
(279)  Suero, M. G.; Bayle, E. D.; Collins, B. S. L.; Gaunt, M. J. J. Am. Chem. Soc. 2013, 135 
(14), 5332–5335. 
(280)  Glunz, P. W.; Mueller, L.; Cheney, D. L.; Ladziata, V.; Zou, Y.; Wurtz, N. R.; Wei, A.; 
Wong, P. C.; Wexler, R. R.; Priestley, E. S. J. Med. Chem. 2016, 59 (8), 4007–4018. 
(281)  Lauber, M. B.; Stahl, S. S. ACS Catal. 2013, 3 (11), 2612–2616. 
(282)  Kim, Y.-W.; Grossmann, T. N.; Verdine, G. L. Nat. Protoc. 2011, 6 (6), 761–771. 








































































* * * 






















































































































* * * 




































































































































































































Appendix II – Published work  
 256 






A protein functionalization platform based on 
selective reactions at methionine residues
Michael T. Taylor1, Jennifer E. Nelson1, Marcos G. Suero1 & Matthew J. Gaunt1*
Nature has a remarkable ability to carry out site-selective post-
translational modification of proteins, therefore enabling a marked 
increase in their functional diversity1. Inspired by this, chemical 
tools have been developed for the synthetic manipulation of 
protein structure and function, and have become essential to the 
continued advancement of chemical biology, molecular biology 
and medicine. However, the number of chemical transformations 
that are suitable for effective protein functionalization is limited, 
because the stringent demands inherent to biological systems 
preclude the applicability of many potential processes2. These 
chemical transformations often need to be selective at a single site 
on a protein, proceed with very fast reaction rates, operate under 
biologically ambient conditions and should provide homogeneous 
products with near-perfect conversion2–7. Although many 
bioconjugation methods exist at cysteine, lysine and tyrosine, 
a method targeting a less-explored amino acid would considerably 
expand the protein functionalization toolbox. Here we report the 
development of a multifaceted approach to protein functionalization 
based on chemoselective labelling at methionine residues. By 
exploiting the electrophilic reactivity of a bespoke hypervalent 
iodine reagent, the S-Me group in the side chain of methionine can 
be targeted. The bioconjugation reaction is fast, selective, operates 
at low-micromolar concentrations and is complementary to existing 
bioconjugation strategies. Moreover, it produces a protein conjugate 
that is itself a high-energy intermediate with reactive properties and 
can serve as a platform for the development of secondary, visible-
light-mediated bioorthogonal protein functionalization processes. 
The merger of these approaches provides a versatile platform for the 
development of distinct transformations that deliver information-
rich protein conjugates directly from the native biomacromolecules.
The sheer structural diversity of the proteome in any single organism 
means that no one protein functionalization method is likely to pro-
vide a universal solution for the preparation of protein constructs8–11 
(Fig. 1a). Although encoded by the AUG start codon at the beginning 
of protein synthesis, methionine is often post-translationally excised 
and thus has a low abundance in proteins (around 2%). It is also 
frequently used as a replacement for hydrocarbon-containing 
residues12. The limited function of methionine, being mainly 
responsible for protection against oxidative stress, compared to other 
residues means that its functionalization is less likely to impair protein 
function13. Targeting methionine would not only provide a distinct 
bioconjugation approach but also, using our strategy, the resulting 
methionine conjugates would provide exploitable intrinsic reactivity 
such that they could lead to the rapid synthesis of diverse, functional 
protein constructs from native proteins.
So far, there has been only one effective method reported for bio-
conjugation at methionine, in which the oxidation of thioethers with 
oxaziridine reagents provided the basis for an elegant bio-inspired 
strategy to form stable protein-bound sulfoximines14. We aimed to 
target the polarizable thioether on the methionine side chain with a 
suitable electrophile to form a cationic sulfonium species, selectively 
installing a versatile payload and distinct functionality at a methionine 
residue, thereby providing a fundamentally different bioconjugation 
approach8–11 (Fig. 1a). Methionine residues react with cyanogen 
bromide (CNBr); however, such a process cannot function as a 
bioconjugation method because the instability of the resulting cyano- 
substituted sulfonium cation triggers cleavage of the protein 
backbone15. Conversely, methionine residues undergo slow S-alkylation 
reactions with iodoacetamide or with other benzyl-derived electrophiles 
to form relatively stable trialkyl sulfonium cations16–19. The need to 
strike a balance between the stability of the protein-bound sulfonium 
cations, the compatibility of the reaction conditions, and the reaction 
rate of the thioether with suitable electrophiles has, so far, 
precluded the development of an effective alkylation-based method for 
bioconjugation at methionine. Guided by these limitations, we posited 
that a distinct class of electrophile, based on the hypervalent iodine 
scaffold of λ3-iodanes20, could make for a functioning bioconjugation 
process at methionine. Tailoring the substituents and counteranion 
on the I(iii) atom should enable us to tune both the reactivity of 
the polarizable I(iii) nodal centre, to dovetail with the electron lone 
pair of the thioether, and also the stability of the resulting sulfonium 
conjugate, through modulation of the electronic features of the groups 
directly attached to the cationic sulfur motif. We noted that a struc-
turally remarkable iodonium salt (1 in Fig. 1, R = Et and X = OTf 
(trifluoromethanesulfonate, also known as triflate)) reacts rapidly with 
dimethylsulfide (the simplest possible mimic of the thioether motif in 
methionine) to form a sulfonium adduct21,22. Successful reaction of 
this iodonium salt with methionine would not only represent a distinct 
method for bioconjugation, but also deliver a high-energy conjugate 
equipped with reactive ‘on-protein’ groups that could serve as a basis 
for designing new transformations towards protein constructs with 
diverse functionality (Fig. 1b).
We first examined the reaction between dipeptide 2a and iodonium 
triflate 1a (Fig. 2a). We observed the formation of the desired sulfonium 
conjugate 3a, although it was clear from the low yield (27%) 
that the iodonium salt was poorly stable in aqueous solution. By 
tailoring the aryl group of the iodonium salt (to the electron-deficient 
2,4-difluorobenzene) and replacing the triflate counteranion with 
tetrafluoroborate, we found that a readily prepared reagent 1b displayed 
superior physical properties (half-life in water is >50 h). Treatment 
of reagent 1b with dipeptide 2a gave 72% of the desired product 3b 
accompanied by the corresponding sulfoxide (not shown) after reaction 
for 30 min.
Moving to a more complex substrate, the GLP-1 receptor agonist 
exenatide (Byetta, 2b, a 39-residue helical polypeptide containing 
a single mid-chain methionine, Fig. 2b), we found that treatment 
of a 100 µM aqueous solution with 1b led to decomposition of the 
polypeptide. A key breakthrough revealed that the addition of a 
low concentration of thiourea (20 mM) resulted in a substantial 
improvement of the reaction, such that sulfonium conjugate 4a was 
formed with 68% conversion in less than 2 min, accompanied by 
non-specific oxidation and labelling. Further improvements could 
be made by performing the reaction in the presence of TEMPO 
((2,2,6,6-tetramethylpiperidin-1-yl)oxyl, 10 mM), which minimized 
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the formation of oxidative by-products, and adding aqueous formic 
acid solution (5 mM, approximately pH 3), which reduced the forma-
tion of non-specifically labelled by-products to trace levels. Finally, we 
found that the labelling process proceeded effectively when conducted 
in distilled water. Routine analysis of electrospray ionization mass 
spectrometry (ESI-MS) and tandem mass spectrometry (MS/MS) 
fragmentation data confirmed selective reaction at methionine and, 
although the concentration of thiourea is well below the levels needed 
for protein denaturation, it was confirmed by circular dichroism 
spectra of exenatide conjugate 4a that the characteristic helical structure 
was retained (see Supplementary Fig. 10). Although we are not yet 
certain of the role of thiourea, it is important to note that its presence 
appears to be fundamental in providing a bioconjugation process at 
reaction rates needed for transformation on complex biomolecules. 
With these refined conditions, the thiourea-accelerated bioconjugation 
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Fig. 1 | The development of a methionine-selective protein 
functionalization strategy. a, Existing protein functionalization strategy, 
and the potential for methionine-selective bioconjugation. R = peptide or 
protein; R1 = various organic groups; R2 = aryl or ester group.  
b, Functionalized hypervalent iodine reagents enable methionine-selective 
protein modification, leading to methionine-based bioorthogonal protein 
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Fig. 2 | Evolution of a methionine-selective bioconjugation strategy. a, Initial results for functionalization at methionine with hypervalent iodine 
reagents. b, Optimal process for the thiourea-accelerated methionine-selective bioconjugation of exenatide.
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5–500 µM without compromising the conversion, and a larger, 
milligram-scale reaction enabled the purification of conjugate 4a by 
semi-preparative high-performance liquid chromatography to give a 
79% yield of isolated product. Given the similarity of the exenatide 
conjugate to the intermediate that would arise from reaction of the 
polypeptide with cyanogen bromide (leading to peptide cleavage), 
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Fig. 3 | Scope of the methionine-selective bioconjugation strategy. a, Range of polypeptide or protein substrates. b, Functionalized iodonium reagents 
compatible with the bioconjugation. c, A stimuli-responsive strategy for reversing methionine bioconjugation.
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it is remarkable that 4a has a half-life in water of over 100 h. We believe 
that the observed stability of 4a is a result of the ethyl diazoacetate 
motif imparting a lesser electron-withdrawing effect (than the cyano 
group) on the sulfonium salt, which in turn leads to a species that is 
less reactive to attack by the proximal carbonyl group and is, therefore, 
a more stable conjugate.
The optimized conditions, using 1b, were used to evaluate the 
substrate scope (Fig. 3a). Random coil polypeptides that contain 
methionine, such as aviptadil and tetracosactide, are efficiently 
converted to the sulfonium conjugates 5 and 6 respectively. GTP-
binding protein fragment Gα, which contains a free sulfhydryl group 
in an N-terminal cysteine residue, underwent smooth methionine 
labelling to 7 with concomitant oxidative disulfide formation. 
Teriparatide, a polypeptide containing two methionines, formed 
bis-sulfonium conjugate (8) with good conversions. α-Lactalbumin, 














































































































































































Fig. 4 | Exploiting the multi-faceted reactivity of the protein–sulfonium 
conjugate. a, A photocatalytic design plan for secondary protein 
diversification. SET, single-electron transfer. b, A system for photoredox-
mediated reduction of the sulfonium conjugate and examples of the 
substrate scope. Notably, the reduction of 3c proceeds in light, without the 
iridium photocatalyst, but the yield is greatly reduced. c, Secondary protein 
functionalization via photoredox radical cross-coupling between the diazo 
sulfonium–protein conjugate and the C-4 substituted Hantzsch ester.
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undergoes bioconjugation to 9 with minimal competitive oxida-
tion. Aprotinin (Trasylol) also forms the corresponding sulfonium 
conjugate 10 in good conversion to product. Particularly notable 
is the observation that two cysteine disulfide linkages within the 
structure of aprotinin (and the labelling to 7) are not affected by 
1b, with a single methionine-derived conjugate obtained in high 
conversion. When the methionine residues are buried within the 
tertiary structure of the protein, for example with RNA-ase B, the 
bioconjugation does not occur, highlighting the inherent selec-
tivity of the labelling process for exposed rather than inaccessible 
thioether groups. This feature is highlighted by the case of ubiquitin: 
the N-terminal methionine residue has only moderate surface expo-
sure and can slow down the rate of functionalization to the point 
where oxidation becomes competitive. Accordingly, reaction under 
deoxygenated conditions enabled efficient conversion to the labelled 
product (84%), with a 10:1 label:oxidation ratio (11). The methio-
nine-selective bioconjugation strategy effectively functionalizes a 
range of polypeptides and proteins in high conversion at micromolar 
concentrations and in very short reaction times. Given that 1b is a 
carbon electrophile with two of the best leaving groups known to 
organic chemists, it would be thought to be very reactive; it is there-
fore remarkable that this species selectively engages the moderately 
nucleophilic methionine residue in the presence of competitively 
nucleophilic and oxidizable amino acid residues. Bioconjugation 
strategies that target other amino acids should, therefore, be compat-
ible with, and complementary to, our methionine-functionalization 
process. To exemplify this, we showed that the GTP-binding protein 
fragment Gα could be first labelled at cysteine, using a maleimide 
derivative23, and then conjugated at methionine using iodonium salt 
1b to form 12. The methionine-selective process does not interfere 
with the cysteine–maleimide motif, which itself contains a thioether 
linkage, thereby highlighting possible applications towards multi-site 
heterolabelling of proteins24.
The modular synthesis of the hypervalent iodine reagents enables 
facile incorporation of different acyl groups attached to the diazo 
motif, allowing the transfer of a range of functional payloads to 
proteins (Fig. 3b). Functional groups relevant to other bioorthogonal 
reactions are readily tolerated in both the reagent synthesis and the 
methionine labelling, smoothly affording sulfonium conjugates 4b and 
4c with 95% and 85% conversion to product, respectively. Biochemical 
reporter groups, such as myristyl- and fluorescein-derived esters 4d 
and 4e, are also readily transferred to exenatide. Notably, we found that 
sulfonium conjugates of exenatide (such as 4f) underwent reaction 
with the tertiary phosphine TCEP (tris(2-carboxyethyl)phosphine), a 
standard biochemical reagent, resulting in the cleavage of the labelling 
group and return of the parent exenatide 2b in >90% conversion25 
(Fig. 3c); the cleavage reaction also works for conjugates 5, 6 and 8 in 
comparable conversions and provides a stimulus-responsive means of 
removing the methionine label.
Next, we turned our attention to exploring the multifaceted reactivity 
that we anticipated would be intrinsic to the high-energy methionine- 
derived conjugate. The electrophilicity of the diazo sulfonium conju-
gate 4 prompted us to investigate the single-electron transfer chemistry 
of this reactive motif enabled by visible-light photocatalysis26,27. 
The addition of a single electron to the diazo sulfonium conjugate 4 
could result in intermediate 15, which, upon cleavage of the C–N2 bond, 
would form a putative radical ylide synthon 15ʹ (Fig. 4a). We visualized 
two pathways through which we could exploit the reactivity of the 
previously unexplored radical ylide. First, combining the radical ylide 
with Hantzsch ester 13* (from 13) may lead to a reduction process 
resulting in the generation of a trialkylsulfonium motif, which 
would impart enhanced chemical stability to the protein conjugate. 
Furthermore, the use of a C-4 benzylated Hantzsch ester derivative 
(14, an established precursor for a benzyl radical)28 to intercept the 
radical ylide species would lead to a C-benzylation product that could 
be used to introduce functional diversity to the protein conjugate. We 
screened a range of photocatalysts under visible-light conditions. When 
3c was irradiated with a 30 W lamp in the presence of fac-Ir(ppy)3 (ppy, 
2-phenylpyridinato) and the Hantzsch ester 1329,30, we observed the 
formation of the reduced trialkylsulfonium product 17a in 95% yield 
(determined by 1H NMR, Fig. 4b). Using these conditions, we showed 
that a range of sulfonium–protein conjugates, including exenatide, 
glucagon and thioredoxin derivatives, are reduced to stable trialkylsul-
fonium species with excellent conversions (17b–e, see Supplementary 
Information). Notably, reduction of a thioredoxin derivative31 to its 
trialkylsulfonium–protein congener 17e proceeds in high conversion 
without affecting its labile disulfide linkage, which serves to highlight 
the mild nature of this protocol. Additionally, the methionine 
bioconjugation and photoreduction steps can be carried out in a one-pot 
operation, which considerably simplifies the overall process without 
compromising the yield or purity of the trialkylsulfonium product.
In testing the viability of the proposed C-benzylation using a 
modified Hantzsch ester derivative28, we found that treatment of the 
exenatide–sulfonium conjugate 4b with o-tolyl Hantzsch ester deriv-
ative 14a, under slightly modified photocatalytic conditions, led to 
cross-coupling and the formation of the C-ligation product 18a in 
high conversion. This unique bioorthogonal protein functionalization 
reaction not only represents a synthetic radical–radical cross-coupling 
using a polypeptide scaffold, but also provides a platform for bioortho-
gonal protein diversification wherein two distinct functionalities could 
be introduced sequentially at the same amino acid residue.
In summary, through the merger of methionine-selective 
bioconjugation and a new visible-light-mediated photocatalytic 
reaction platform, information-rich synthetic constructs can be rapidly 
assembled by a two-step protocol directly from native proteins. The 
reactivity inherent to the methionine conjugate distinguishes the 
bioconjugation process from other methods. Moreover, the capacity 
for functional diversification, by tailoring the hypervalent iodine 
reagent and modified Hantzsch-ester derivative, means that highly 
functional protein conjugates could be made readily available directly 
from native proteins.
Data availability
The data that support the findings of this study are available within the paper and 
its Supplementary Information. Raw data are available from the corresponding 
author on reasonable request.
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